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Throughout human existence a large variety of plants and their extracts are being used 
for medicinal purposes. Possibly the oldest plant with known strong medicinal powers 
is the opium poppy, Papaver somniferum, with evidence of its use dating back to the 
prehistoric era.1 Its powerful analgesic properties and euphoric pleasures were known 
to many ancient civilizations. Not only the beneficial effects were described but the 
poisonous natures of the sap from the opium poppy were known as well. In the early 
1800s, the German pharmacist and chemist Sertürner took a major step forward towards 
modern pharmacotherapy with the isolation of the alkaloid morphine from opium sap. 
Morphine turned out to be a potent analgesic that was used to treat severe pain as 
well as other ailments such as diarrhea and persistent coughing. Until today, morphine 
remains the gold standard for treatment of moderate to severe pain.2
Another plant extract with analgesic properties is capsaicin, which is derived from the 
chili pepper, Capsicum, and was first isolated in the early 1800s.3 Capsaicin produces a 
burning sensation when it comes into contract with the skin (at high concentrations) or 
mucous membranes (at low concentrations). Paradoxically, capsaicin is used as analgesic 
ointment in patients with neuropathic pain such as postherpetic neuralgia (PHN) and 
diabetic polyneuropathy (DPN). When applied as a patch, capsaicin (QutenzaTM, Astellas 
Pharma Inc.) diffuses through the skin (or mucous membrane) and acts at the heat-
sensitive transient receptor potential cation-channel subfamily V member 1 (TRPV1), 
also known as the capsaicin receptor or vanilloid receptor 1 (VR1).4 Apart from capsaicin, 
the TRPV1 receptor is activated by heat (> 43° C), acids and the pungent constituents of 
mustard and wasabi. The TRPV1 receptor is expressed on small afferent nerve C and Aδ 
(nociceptive) fiber endings. While capsaicin initially causes a severe burning sensation, 
prolonged exposure causes peripheral nerve desensitization, which results in analgesia. 
Additionally, activation of the TRPV1 receptor causes the inhibition of Piezo proteins (a 
family of mammalian cation-selective ion channels that respond to mechanical stretch) 
found in somatosensory neurons of the dorsal root ganglion.5 By inhibition of the Piezo 
proteins, capsaicin might significantly reduce neuropathic pain-related mechanical 
hypersensitivity.
In the Western world, pain is the most common reason for individuals to seek medical 
care.2 Hence it is not surprising that apart from morphine and capsaicin, in contemporary 
medicine a large number of drugs are available to treat mild to severe pain with a large 
variety in mechanisms of action (about half of the currently used pain medication acts at 
G-protein coupled receptors, which includes the opioid receptor family). A new analgesic 




designer drug that targets the μ-opioid receptor (MOR), alike morphine, but additionally 
interacts with (e.g. inhibits) neuronal noradrenaline reuptake mechanism.6 As such it 
generates two signals:
(1) at the MOR, albeit at a 50-fold lower affinity compared to morphine; and
(2) by increasing extraneuronal noradrenaline concentrations at analgesic α2-adrenergic 
receptors in the spinal cord dorsal horn (through noradrenaline reuptake inhibition or 
NRI).
The two signals produce synergistic analgesia. Activation of the spinal α2-adrenergic 
receptors is a crucial part of the endogenous pain modulatory system.
The ongoing search for new analgesics, new administration techniques (e.g. 
transcutaneous, transmucosal, intranasal, inhalational, orodispersible) and the regular 
but sparse introduction of new drugs indicates an apparent dissatisfaction with current 
pain pharmacotherapies.7 The “dissatisfaction” relates to the often-restricted efficacy 
of analgesic medication frequently combined with the occurrence of side effects that 
reduces patient compliance. Introduction of new analgesics is a complex, time consuming 
and costly process. Prior to registration multiple placebo-controlled efficacy trials in large 
patient populations are performed and similar studies are executed after the drugs have 
been registered for marketing purposes. Large trials are needed, as the placebo effect 
in analgesia trials is substantial. In these trials treatment of chronic pain conditions is 
commonly assessed at preset times during and after treatment by analysis of the total 
study population (e.g. at 12 weeks of treatment). However, these often high-quality 
trials are “easily” analyzed by novel approaches.7,8 For example, an alternative approach 
is the identification of specific patient subgroups characterized by differential response 
patterns in their analgesic response and to determine the presence of significant 
predictors of effect (Chapters 3 and 4 of this thesis). At the basis of such approach are 
population (pharmacokinetic and) pharmacodynamic analyses of the data allowing a 
clear understanding of the temporal profile of treatment in individual patients as well of 
the within- and between-subject variability (Chapters 2 and 5 of this thesis).
Another relatively new approach is the application of dynamic psychophysical tests as 
predictor of drug efficacy (Chapter 6 of this thesis). One such test is Conditioned Pain 
Modulation (CPM), a test designed to engage top-down inhibitory pain pathways. 
Yarnitsky et al.9 and Niesters et al.10 showed that chronic pain patients who are unable 
to activate CPM benefit most from medication that interacts with the endogenous pain 
modulatory system such as duloxetine and tapentadol and vice versa patients that have 
an active CPM have little analgesic benefit from these drugs (Figure 1, which further 
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highlights the importance of subgroup analysis). New tests and analyses techniques, 
such as suggested here, will eventually allow optimization of individual pain therapy 
with specific predictors linked to specific pharmacotherapies. An individual treatment 
approach based on prediction of effect to specific drugs is needed as some patients 
(i) respond to certain treatments but are intolerant to others (in fact, this is true for 
individual opioids as well), (ii) require an adaptation to their dosing scheme, (iii) need 
a combination of analgesic agents, or (iv) will benefit more from non-pharmacological 
interventions. Additionally, clinical data are showing that this is true for the analgesic 
efficacy and the adverse events that pain treatment invariably causes. For example, 
opioid switching results in improvement of symptoms and side effects in more than 50% 
of patients.2
Thesis outline
In this thesis novel techniques are described which are developed to analyze or predict 
the efficacy of pharmacotherapy for pain.
In Chapter 2 an overview is presented on recent pharmacokinetic pharmacodynamic 
(PKPD) modeling in acute (in volunteers and postoperative patients) and chronic pain. 
Novel observations on opioids, NSAIDs, acetaminophen, epidural analgesia, ketamine 
and GABAergic drugs are described. Additionally, PKPD models of naloxone reversal of 
opioid-induced respiratory depression are discussed.
Chapter 3 describes the analgesic effect of a capsaicin patch in DPN pain patients. A 
longitudinal population PD analysis is performed. In addition, a mixture model is applied 
to match patters in pain-associated behavior and to identify subgroups that responded 
differently to treatment. 
In Chapter 4 a subgroup analysis is performed on pooled data from 4 multicenter trials 
on the effect of capsaicin 8% patch (versus an active control, capsaicin 0.04% patch) in 
PHN. Apart from longitudinal and mixture analyses, covariates are examined to identify 
predictors of efficacy. 
In Chapter 5 the analgesic effect of orodispersible oxycodone versus an active comparator 
(orodispersible paracetamol) for the management of breakthrough pain is quantified. 
A novel pharmacodynamic model is used that describes the analgesic effect over 





Finally, Chapter 6 describes the effect of tapentadol versus morphine on CPM in healthy 
volunteers. A difference in CPM engagement between these two “opioids” might proof 
the difference in mechanisms of action between the classical MOR agonist and the 
combined MOR-NRI compound.
Figure 1  Chronic pain patients with DPN treated with tapentadol or placebo that initially have a 
diminished ability to engage CPM (negative or small %CPM values) gain the most from treatment 
with the lowest pain scores after 4 weeks of treatment. This graph further shows the presence of 
two responder subgroups with an identical relationship between pretreatment CPM and pain relief. 
In the high responder group 5 of 6 patients received tapentadol; in the low responder group 5 of 
13 patients received tapentadol. Data are a reanalysis of Niesters et al.,10 CPM is conditioned pain 
modulation, VAS is visual analogue score.
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INTRODUCTION
The objective of pharmacokinetic–pharmacodynamic (PKPD) modeling is the 
development and application of mathematical models to describe and/or predict the 
time course of dose-to-concentration (pharmacokinetics [PK]) and concentration-to-
effect (pharmacodynamics [PD]) of pharmacological active agents in health and disease.1,2 
The PK model part of PKPD models describes the macrodistribution of the drug (drug 
distribution kinetics). Effect-compartment PKPD models add a hypothetical (infinitely 
small) effect compartment to describe the delay in effect (i.e., quantification of drug 
effect in terms of drug concentration at the target or effect site [CE] vs measured effect). 
In compartmental models, the concentration–time profiles are described/explained by 
drug transfer between interconnected hypothetical compartments, mimicking drug 
absorption, distribution and elimination. Drug distribution towards the target site is 
described by the plasma effect-site equilibration constant (ke0; or its half-life [t1/2ke0] = 
ln2/ke0), whereas the concentration–effect relationship is often described by a sigmoid 
maximum effect (Emax) model of the form:
Effect=Aγ/(1+Aγ)
where A = CE/C50 (with C50 as the measure of drug potency or the effect-site or steady-
state concentration causing 50% of the effect, and γ as the Hill-factor). The first to 
propose a first-order rate constant between plasma and an effect-compartment was 
the Italian, Segre, in a pivotal article published in 1968.3 Segre described the transfer 
function of norepinephrine’s effect on the circulatory system and estimated a delay of 
15 s between changes in plasma epinephrine concentration and blood pressure in a cat, 
showing that epinephrine’s target site (i.e., the ‘biophase’) is not in plasma. This concept 
was later further developed by Hull and Sheiner et al., in two separate studies, both 
in 1979.4,5 Effect-compartment models are empirical models that do not describe the 
physiological or mechanistic pathway of the drug from its concentration in plasma to 
effect. Recently, novel mechanism-based biophase distribution models were developed.1 
For example, mechanism-based PKPD models may incorporate concepts from receptor 
theory describing the drug–receptor interaction (receptor kinetics) in terms of drug-
association and -dissociation kinetics and enable the quantification of the rate-limiting 
factor in drug effect owing to drug distribution versus receptor kinetics.6
Rather than analyzing individual PKPD data, population PKPD analyses (i.e., performing 
a simultaneous analysis on the whole population dataset) has become the acceptable 
approach in current PKPD modeling studies. A population analysis will lead to an 
19
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Chapterestimate of the population PK and PD estimates, identify the sources of variability that 
influence PK and PD, estimate the magnitude of between-subject variability, as well as 
intrasubject variability, and allow for the estimate of random residual variability (random 
effects).7 To separate random (i.e., variability parameters) from fixed effects (i.e., the PK 
and PD parameter estimates), nonlinear mixed-effects modeling is required.8 Various 
statistical packages are available to perform nonlinear mixed-effects modeling, of which 
NONMEM® is considered the most state-of-the-art.7-10 NONMEM was developed by Lewis 
Sheiner and Stuart Beal at the University of California in San Francisco (CA, USA) and was 
initially developed to analyze PK data but is currently applied to model PK, PD and PKPD 
datasets.9,10 Particularly in studies on the pharmacology of analgesics and anesthetics, 
drug–drug interactions, population PK, PD and PKPD analyses using NONMEM is 
currently the gold standard.8,10
In this article, we will discuss population effect-compartment and mechanism-based 
PKPD and PD modeling studies published in the last 5 years on the effects of various 
analgesic agents in acute (in volunteers and postoperative patients) and chronic pain 
patients. End points covered are the relief of experimental and surgery- and disease-
induced pain (i.e., antinociception and analgesia). In addition, we will discuss PKPD 
models of naloxone reversal of opioid-induced respiratory depression, the most life-
threatening side effect of potent opioids.
PKPD MODELING OF ACUTE ANTINOCICEPTION & PAIN
Morphine & its metabolites
Morphine, first extracted from opium in 1806, is still considered the gold standard in the 
treatment of severe acute and chronic pain, although it has no clear superiority in efficacy 
or tolerability over other opioids.11 In 2005, Lötsch listed six PKPD studies on morphine.12 
Studies were performed either on a surrogate measure of opioid effect, pupil size, or on 
electrical noxious cutaneous stimulation. One of the studies discussed demonstrated that 
sex was a significant covariate on pain relief responses, with greater morphine potency 
in women (C50 = 250 nM in men vs 150 nM in women) (Table 1) but with a slower onset/
offset time (blood effect-site equilibration t1/2ke0 for pain relief response [pain tolerance] 
was 1.6 h in men vs 4.8 h in women), without any sex differences in morphine’s PK.13 
These data were later confirmed in a systematic review and meta-analysis and account 
for the difference in opioid consumption between men and women in postoperative 
patient-controlled analgesia morphine studies.14 Interestingly, while studies on pupil size 
had similar estimates for t1/2ke0 as observed in pain studies, the potency of morphine 
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Table 1  Population pharmacodynamic model estimates for various analgesic agents andnaloxone using 
pain relief or respiration as effect parameter; studies performed in healthy volunteers or patients
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a: t1/2koff is calculated as ln2/koff;
b: no hysteresis observed between plasma concentration and effect;
c: C50 varied depending on the nociceptive assay employed (see text);
d: The values of 11-days represent a rate-constant form disease modulation (t1/2k) unrelated to the blood-effect-
site equilibration half-life.
C50 = Steady-state concentration causing 50% of the effect; CRPS = Complex regional pain syndrome; Kd = Equilibrium 
dissociation constant; ke0 = Effect-site equilibration constant; 
Koff = Receptor dissociation constant; Kon = Receptor-association constant; P = Patients; t1/2= Half-life; V = Volunteers.
Table 1  Population pharmacodynamic model estimates for various analgesic agents andnaloxone using 
pain relief or respiration as effect parameter; studies performed in healthy volunteers or patients
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a: t1/2koff is calculated as ln2/koff;
b: no hysteresis observed between plasma concentration and effect;
c: C50 varied depending on the nociceptive assay employed (see text);
d: The values of 11-days represent a rate-constant form disease modulation (t1/2k) unrelated to the blood-effect-
site equilibration half-life.
C50 = Steady-state concentration causing 50% of the effect; CRPS = Complex regional pain syndrome; Kd = Equilibrium 
dissociation constant; ke0 = Effect-site equilibration constant; 
Koff = Receptor dissociation constant; Kon = Receptor-association constant; P = Patients; t1/2= Half-life; V = Volunteers.
Table 1  Population pharmacodynamic model estimates for various analgesic agents andnaloxone using 
pain relief or respiration as effect parameter; studies performed in healthy volunteers or patients
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a: t1/2koff is calculated as ln2/koff;
b: no hysteresis observed between plasma concentration and effect;
c: C50 varied depending on the nociceptive assay employed (see text);
d: The values of 11-days represent a rate-constant form disease modulation (t1/2k) unrelated to the blood-effect-
site equilibration half-life.
C50 = Steady-state concentration causing 50% of the effect; CRPS = Complex regional pain syndrome; Kd = Equilibrium 
dissociation constant; ke0 = Effect-site equilibration constant; 
Koff = Receptor dissociation constant; Kon = Receptor-association constant; P = Patients; t1/2= Half-life; V = Volunteers.
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Table 1  Population pharmacodynamic model estimates for various analgesic agents andnaloxone using 
pain relief or respiration as effect parameter; studies performed in healthy volunteers or patients
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a: t1/2koff is calculated as ln2/koff;
b: no hysteresis observed between plasma concentration and effect;
c: C50 varied depending on the nociceptive assay employed (see text);
d: The values of 11-days represent a rate-constant form disease modulation (t1/2k) unrelated to the blood-effect-
site equilibration half-life.
C50 = Steady-state concentration causing 50% of the effect; CRPS = Complex regional pain syndrome; Kd = Equilibrium 
dissociation constant; ke0 = Effect-site equilibration constant; 
Koff = Receptor dissociation constant; Kon = Receptor-association constant; P = Patients; t1/2= Half-life; V = Volunteers.
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pain relief or respiration as effect parameter; studies performed in healthy volunteers or patients
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a: t1/2koff is calculated as ln2/koff;
b: no hysteresis observed between plasma concentration and effect;
c: C50 varied depending on the nociceptive assay employed (see text);
d: The values of 11-days represent a rate-constant form disease modulation (t1/2k) unrelated to the blood-effect-
site equilibration half-life.
C50 = Steady-state concentration causing 50% of the effect; CRPS = Complex regional pain syndrome; Kd = Equilibrium 
dissociation constant; ke0 = Effect-site equilibration constant; 
Koff = Receptor dissociation constant; Kon = Receptor-association constant; P = Patients; t1/2= Half-life; V = Volunteers.
Table 1  Population pharmacodynamic model estimates for various analgesic agents andnaloxone using 
pain relief or respiration as effect parameter; studies performed in healthy volunteers or patients
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a: t1/2koff is calculated as ln2/koff;
b: no hysteresis observed between plasma concentration and effect;
c: C50 varied depending on the nociceptive assay employed (see text);
d: The values of 11-days represent a rate-constant form disease modulation (t1/2k) unrelated to the blood-effect-
site equilibration half-life.
C50 = Steady-state concentration causing 50% of the effect; CRPS = Complex regional pain syndrome; Kd = Equilibrium 
dissociation constant; ke0 = Effect-site equilibration constant; 
Koff = Receptor dissociation constant; Kon = Receptor-association constant; P = Patients; t1/2= Half-life; V = Volunteers.
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a: t1/2koff is calculated as ln2/koff;
b: no hysteresis observed between plasma concentration and effect;
c: C50 varied depending on the nociceptive assay employed (see text);
d: The values of 11-days represent a rate-constant form disease modulation (t1/2k) unrelated to the blood-effect-
site equilibration half-life.
C50 = Steady-state concentration causing 50% of the effect; CRPS = Complex regional pain syndrome; Kd = Equilibrium 
dissociation constant; ke0 = Effect-site equilibration constant; 
Koff = Receptor dissociation constant; Kon = Receptor-association constant; P = Patients; t1/2= Half-life; V = Volunteers.
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a: t1/2koff is calculated as ln2/koff;
b: no hysteresis observed between plasma concentration and effect;
c: C50 varied depending on the nociceptive assay employed (see text);
d: The values of 11-days represent a rate-constant form disease modulation (t1/2k) unrelated to the blood-effect-
site equilibration half-life.
C50 = Steady-state concentration causing 50% of the effect; CRPS = Complex regional pain syndrome; Kd = Equilibrium 
dissociation constant; ke0 = Effect-site equilibration constant; 
Koff = Receptor dissociation constant; Kon = Receptor-association constant; P = Patients; t1/2= Half-life; V = Volunteers.
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pain relief or respiration as effect parameter; studies performed in healthy volunteers or patients
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a: t1/2koff is calculated as ln2/koff;
b: no hysteresis observed between plasma concentration and effect;
c: C50 varied depending on the nociceptive assay employed (see text);
d: The values of 11-days represent a rate-constant form disease modulation (t1/2k) unrelated to the blood-effect-
site equilibration half-life.
C50 = Steady-state concentration causing 50% of the effect; CRPS = Complex regional pain syndrome; Kd = Equilibrium 
dissociation constant; ke0 = Effect-site equilibration constant; 
Koff = Receptor dissociation constant; Kon = Receptor-association constant; P = Patients; t1/2= Half-life; V = Volunteers.
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a: t1/2koff is calculated as ln2/koff;
b: no hysteresis observed between plasma concentration and effect;
c: C50 varied depending on the nociceptive assay employed (see text);
d: The values of 11-days represent a rate-constant form disease modulation (t1/2k) unrelated to the blood-effect-
site equilibration half-life.
C50 = Steady-state concentration causing 50% of the effect; CRPS = Complex regional pain syndrome; Kd = Equilibrium 
dissociation constant; ke0 = Effect-site equilibration constant; 
Koff = Receptor dissociation constant; Kon = Receptor-association constant; P = Patients; t1/2= Half-life; V = Volunteers.
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a: t1/2koff is calculated as ln2/koff;
b: no hysteresis observed between plasma concentration and effect;
c: C50 varied depending on the nociceptive assay employed (see text);
d: The values of 11-days represent a rate-constant form disease modulation (t1/2k) unrelated to the blood-effect-
site equilibration half-life.
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a: t1/2koff is calculated as ln2/koff;
b: no hysteresis observed between plasma concentration and effect;
c: C50 varied depending on the nociceptive assay employed (see text);
d: The values of 11-days represent a rate-constant form disease modulation (t1/2k) unrelated to the blood-effect-
site equilibration half-life.
C50 = Steady-state concentration causing 50% of the effect; CRPS = Complex regional pain syndrome; Kd = Equilibrium 
dissociation constant; ke0 = Effect-site equilibration constant; 
Koff = Receptor dissociation constant; Kon = Receptor-association constant; P = Patients; t1/2= Half-life; V = Volunteers.
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was much greater for miosis (C50 ranging from 17 to 24 nM, without occurrence of any 
sex differences). Collectively, these data indicate that morphine has an onset time that 
is much smaller than observed in any of the other opioids currently in clinical use.12-14 In 
comparison, t1/2ke0 (derived from yet another surrogate end point of opioid effect: changes 
in EEG power spectrum) is 5–6 min for fentanyl and sufentanil, 1–2 min for alfentanil and 
remifentanil, 8–19 min for methadone and 17 min for piritramide.12 This makes morphine 
a relatively slow and consequently difficult to control opioid analgesic. Note, however, 
that currently no comparable data on morphine’s effect on EEG-related parameters are 
available.
Morphine is rapidly metabolized in the liver into the (presumably) inactive morphine-
3-glucuronide (M3G) and the active morphine-6-glucuronide (M6G). Animal studies 
indicate that M6G is a μ-opioid receptor agonist with greater potency than morphine 
and rapidly crosses the blood–brain barrier (BBB).15 By contrast, PKPD studies in humans 
revealed a three- to five-fold lower potency than observed in animals after intravenous 
M6G administration coupled with a slow transfer of the drug across the BBB (C50 = 750 
nM and t1/2ke0 6–8 h).12 Using data obtained from healthy volunteers that were injected 
with either intravenous morphine or intravenous M6G, we were able to construct a 
population PKPD model of morphine’s metabolism into M6G and determine M6G’s 
contribution to morphine analgesia.16 The fraction of morphine metabolized into M6G 
was 6.0 ± 0.2% (median value ± standard error); M6G formation was sex independent. 
Simulation studies demonstrated that repetitive morphine infusions (0.1 mg/kg at 8-h 
intervals) resulted in stable M6G effect-site (‘brain’) concentrations of 10–20 nM that 
contributed approximately 8 (women) and 15% (men) to the analgesic response. Under 
conditions of renal impairment, the effect-site M6G concentration rose by a factor of 
ten and its estimated contribution to effect increased by a factor of two. These findings 
derived from modeling studies and simulations are important as they tempered 
the initial aspirations of M6G as the replacement of morphine in the treatment of 
severe acute pain and exemplify the strength of population PKPD modeling studies 
in the development of new (analgesic) drugs.12,15,16 The aspirations were based on early 
observations in animals and later in humans that M6G causes less respiratory depression 
and possibly less nausea and vomiting compared with the parent compound.15 However, 
its low potency but especially its slow passage across the BBB and accumulation in renal 
impairment make it an analgesic that is even more difficult to control than morphine in 
perioperative patients and should be avoided in patients with reduced renal function.
Previously discussed studies used effect-site PKPD modeling and consequently remained 
uninformed on receptor kinetics. Using a mechanism-based PKPD approach, Olofsen et 
al. described naloxone reversal of morphine- and M6G-induced respiratory depression.17 
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ChapterThey estimated the following pharmacokinetic parameters: ke0 or the biophase 
distribution constant, kon or the receptor association constant, koff or the receptor 
dissociation constant of morphine and M6G, and ke0 of naloxone. Naloxone is a μ-opioid 
receptor antagonist used both in clinical practice to reverse opioid-induced respiratory 
depression and in the treatment of opioid addiction. Since it was first synthesized in 1960 
by Jack Fishman and further developed through the early 1970s by Harold Blumberg,18 
little progress has been made on the policies required to administer appropriate doses of 
naloxone that cause rapid reversal with a limited chance of renarcotization. The study by 
Olofsen et al.17 and especially the additional model simulations are insightful and enable 
the development of specific guidelines on the reversal of the toxic effects of morphine and 
its active metabolite M6G in clinical practice. The parameter estimates of the study are 
given in Table 1. Morphine and M6G both display slow receptor association/dissociation 
kinetics with an apparent potency (Kd = koff/kon) similar to C50 values obtained in previous 
studies (see earlier). Naloxone had rapid receptor kinetics with t1/2ke0 of approximately 
5 min on average, while its apparent estimated potency was greater for M6G reversal 
than for morphine reversal. The latter observation is hard to explain as naloxone is a 
competitive antagonist at the opioid receptors (i.e., its effect is described by a single 
equilibrium dissociation constant). Possibly, the differences in potency may be related 
to the ability of M6G to increase the affinity of naloxone for the μ-receptor.17 Since the 
elimination t1/2 of naloxone is between 15 and 30 min, naloxone is a limiting factor in 
the reversal of (long-acting) opioids. However, in addition, the slow receptor kinetics of 
morphine (and M6G) limits naloxone’s ability to disperse the opioid agonist from the 
receptor rapidly. This has clinical consequences as increasing the naloxone dose will 
not increase the speed of morphine reversal (i.e., the increase in ventilation over time), 
although the magnitude and duration of reversal will increase (Figure 1). Taken together, 
a sufficient high dose of naloxone is required, preferably administered as continuous 
infusion, to reverse morphine-induced respiratory depression with a reduced chance of 
renarcotization; the speed of reversal is not affected by the naloxone dose. Note that 
these observations regard only opioid agonists that have slow receptor association/ 
dissociation kinetics (such as morphine, M6G and buprenorphine, see later) but are not 
valid for opioids with rapid kinetics such as fentanyl or any of the other fenylpiperidines 
(with the exception of remifentanil; if the remifentanil infusion is stopped, breathing 
resumes within minutes).19 A more rapid reversal of fentanyl just requires a greater dose 
of naloxone, as naloxone reversal is not dictated by receptor kinetics of the agonist 
(fentanyl).
Chapter 2  |  Pharmacokinetic–pharmacodynamic modeling in acute and chronic pain: an overview of the recent literature
24
Two recent studies analyzed the effect of morphine on acute postoperative pain using a 
population PKPD analysis in NONMEM. Mazoit et al. modeled morphine’s effect taking 
the potential effects of M3G and M6G into account in patients in acute pain following 
a variety of surgical interventions with a mean age of 51 years.20 They assumed additive 
agonistic effects from morphine and M6G and an antagonistic effect from M3G. Using a 
sigmoid Emax model with pain (as determined from a visual analogue scale [VAS] scoring 
system) as effect variable, they estimated a tenfold greater potency of M6G compared 
with morphine (C50 = 124 [morphine] vs 13 nM [M6G]) and an inhibitory effect from M3G 
with C50 of 880 nM. The analgesic effect of M6G was delayed significantly relative to 
morphine (t1/2ke0: 1.7 [morphine], 3 [M6G] and 3 h [M3G]). Age, sex and weight did not 
improve the PD model. The M6G potency is much greater than observed in earlier studies 
in volunteers12,16,17 and, although one may argue that in the Mazoit study measurements 
were made for 24–48 h (compared with 6–10 h in previous studies), the M6G potency is an 
indirect estimate derived from a study where morphine, but not M6G, was administered. 
Figure 1  Effect of nalaxone on opioid-induced respiratory depression. A. Mechanism-based PKPD 
modeling of the ability of different doses of an opioid antagonist (naloxone, given at t = 55 min, 
low dose = 0.1 mg, high dose 0.4 mg) to reverse the opioid-induced respiratory depression from 
an opioid agonist with relatively lowkoff-value (opioid agonist injected at t = 0 min). The speed of 
reversal is independent of the antagonist dose and is determined by the agonist opioid receptor 
koff-value. B. Effect of variations in the koff-value of an opioid agonist (injected at t = 0 min over 90 s) 
on the effect of a fixed dose of an opioid receptor antagonist (naloxone, given at t = 55 min over 90 
s) on reversal of opioid-induced respiratory depression. Koff-values are relative with 0.2 min-1 = 0.2 × 
typical value, 1 = typical value, 5 = 5 × typical value. Here the typical value = 0.03 min-1. Koff : Receptor 
dissociation constant. Data adapted from Olofsen et al.17
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ChapterConsequently, the true potency of M6G remains unknown, in comparison with previous 
studies where only M6G was administered. Of further interest is the observation of 
an antagonistic or hyperalgesic effect of M3G with a relatively slow distribution into 
the biophase. This suggests that reduced morphine efficacy may coincide with M3G’s 
hyperalgesic effect, requiring the switch to other opioid analgesics in some patients.
Abbou Hammoud et al. modeled the effect of morphine titration in the first postoperative 
hours on pain relief (using VAS) in patients (mean age of 62 years) following orthopedic 
surgery.21 They used an indirect response Emax model with variations in pain expressed by 
the equilibrium of Kin (a zero-order rate constant of the appearance of pain) and Kout (a 
first-order rate constant of the disappearance of pain) with morphine inhibiting Kin. They 
added a virtual kinetic compartment, as no PK data were available. They estimated a 
value for ED50 (dose of morphine causing 50% pain relief) of 10.2 ± 0.8 mg with significant 
covariates including initial VAS (direct postoperative VAS just before dosing), and the use 
of additional pain medication (but not age, sex or weight). The model is of interest as it 
predicts that greater titration doses are associated with a significant reduction in time to 
achieve analgesia (especially in patients with a greater initial VAS), albeit at the expense 
of increased toxicity (sedation in their study).
Buprenorphine
There is a renewed and increasing interest in this 30-year-old semisynthetic opiate 
derived from the morphine precursor, thebaine. Currently, buprenorphine is applied 
in the treatment of chronic pain using a relatively novel patch formulation and in the 
treatment of addiction (SubutexTM or in combination with naloxone Subutex [Reckitt 
Benckiser, Slough, UK]). Buprenorphine is a partial agonist at the μ-opioid receptor and 
displays typical opioid behavior (analgesia, sedation, nausea, delayed gastric emptying 
and respiratory depression). Yassen et al. performed a series of experiments in men using 
a mechanism-based population PKPD approach.6,22-24 The most important observations 
from these studies are:
•  In the clinically relevant intravenous dose range of 0.05–0.6 mg/kg, buprenorphine 
displayed a lack of ceiling effect for antinociception (related to the absence of saturation 
of receptor occupancy);24
•  Rate-limiting factors in the onset and offset of antinociceptive effect are biophase 
distribution and slow receptor association–dissociation (Table 1);24
•  In contrast to antinociception, ceiling was observed for respiratory depression at high 
buprenorphine concentrations (the intrinsic activity of buprenorphine is 56%);23
•  Reversal of buprenorphine-induced respiratory depression with naloxone is possible, 
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however, owing to the slow receptor kinetics of buprenorphine, in combination with 
the fast elimination kinetics of naloxone, naloxone is best administered as a continuous 
infusion rather than a single bolus injection (optimal dosage is 2–4 mg naloxone per 
h).6
Naloxone reversal is slow, however, and cannot be accelerated by giving higher naloxone 
doses (see earlier). The findings from these modeling studies indicate that buprenorphine 
is an opioid analgesic that provides long-term analgesia without ceiling over the clinical 
dose-range and has a limited effect on the respiratory systems. In case life-threatening 
respiratory depression does occur, it can be antagonized but requires high doses and 
continuous infusions of naloxone. These data demystify some of the old beliefs around 
buprenorphine that can still be found in older textbooks, including the existence of a 
ceiling in analgesic effect and inability to reverse buprenorphine-induced respiratory 
depression.
Ketamine
The third ‘senior’ analgesic that we discuss is the 50-year-old N-methyl-d-aspartate 
receptor (NMDAR) antagonist ketamine. Initially developed as an anesthetic, multiple 
studies show that at low (subanesthetic) doses, ketamine is a potent analgesic in the 
treatment of both acute and chronic pain.25 In the last few years, a series of investigations 
on population PKPD modeling in children and adults has been published. The studies in 
children were aimed at the anesthetic properties of ketamine and will not be discussed 
here.26,27 In healthy volunteers, Sigtermans et al. tested the effect of increasing doses of 
the S(+)-enantiomer of ketamine (S-ketamine) on antinociception using two different 
nociceptive assays: heat pain (a fixed-heat stimulus was applied to the arm giving 
a baseline [i.e., predrug] VAS of 6 cm or greater) and tolerance to electrical pain (a 10-
Hz stimulus train increasing at 0.5 mA/s).28 Using an effect-compartment population 
PKPD analysis yielded a significant difference in ketamine’s potency in the two assays 
(Table 1) with a sixfold greater potency for pain relief of heat pain. Of further interest 
is the observation of hyperalgesic responses following S-ketamine withdrawal that 
was modeled with a linear trend term. This phenomenon has recently been described 
in experimental and clinical studies. A delay between concentration and effect (that is 
hysteresis) was not observed for any of the antinociceptive end points. This indicates 
an almost immediate passage of S-ketamine across the BBB and rapid receptor kinetics. 
Similar observations were made previously on the effect of ketamine racemic mixture on 





Kowalski et al. constructed PKPD models to describe the effect of the experimental 
COX-2 inhibitor SC-75416 (Pfizer, MI, USA) and performed trial simulations to enhance 
the further development of this analgesic.29 SC-75416 is a selective COX-2 inhibitor that 
has anti-inflammatory and analgesic activity. They studied postoral surgery patients 
and performed comparisons with placebo, ibuprofen, rofecoxib and valdecoxib. In an 
initial study, an oral solution of SC-75416 was followed by a capsule formulation. They 
constructed logistic effects models in NONMEM with three main components: placebo 
effect (modeled by an exponential function) and drug effect (modeled by a sigmoid Emax 
function); random effect; and investigating pain relief. The estimated EC50 values for SC-
7541, rofecoxib, valdecoxib and ibuprofen were 5.5, 0.3, 0.07 and 6.8 μg/ml, respectively. 
The most important results of the study were: the study and trial simulations prompted 
further study developments (pursuing a high-dose strategy) that otherwise might not 
have been considered; the approach resulted in time and cost savings by not having to 
repeat the postoral surgery study and formulation rework was carried out to optimize 
drug delivery.
Li et al. performed a PKPD analysis of dental pain relief by ibuprofen.30 Their aim was to 
assess the efficacy of a novel effervescent formulation in comparison with the standard 
tablets of NSAIDs. In a group of patients following third-molar extraction surgery, the 
effect of the two formulations and placebo were modeled using an Emax pain relief 
model and hazard models to analyze time to pain relief and remedication. The data 
show differences in PK parameters between the two formulations with a greater oral 
absorption rate for the effervescent ibuprofen and greater effect-site concentrations 
between t = 0 and 2.5 h following dosing. This caused more rapid pain relief and less 
remedication for the effervescent formulation compared with standard ibuprofen. 
The authors constructed nomograms to correlate time to pain relief with PK profiles. 
Overall, these data indicate the usefulness of PKPD modeling in the development of new 
formulations of analgesic drugs (see later).
Acetaminophen
Another example where model-based analysis was used to aid the development of a new 
formulation is the study by Green et al.31 They performed PKPD analysis on pain relief data 
following administration of four different acetaminophen (paracetamol) formulations 
(Tylenol®, Panadol® Rapid and two that used new formulation technologies from Imaginot 
Pty, Ltd., Brisbane, Australia) to explore possible differences in PD outcomes. The authors 
used the PKPD data from Anderson et al. to do a simulation on the effects of the new 
formulation.32 PK data were obtained from volunteers that received a single dose of 1 g of 
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the four formulations; PD data were obtained from simulations on an earlier published 
PD model that quantified pain relief following tonsillectomy. Interestingly, their data 
indicate that the placebo effect was appreciable and there was a potential difference 
between acetaminophen and placebo at t = 0 and 30 min post dosing only. With respect 
to the comparison between formulations, the authors conclude that their analysis 
suggests a significant reduction in time to onset of effect with the newer formulations. 
The current approach of learning drug behavior from already published datasets was 
used ‘because running a confirmatory clinical trial was prohibitively expensive’.31
Epidural anesthesia/analgesia
Epidural anesthesia and analgesia is obtained by an injection of a local anesthetic, an 
opioid or their combination into the epidural space. The injected drugs spread over the 
epidural space, diffuse towards the intrathecal space (where the drugs diffuse into and 
bind to neuronal tissue) and into blood vessels of the epidural space. Depending on the 
concentration used and type of drug injected, motor and sensory blockade develops and 
dissipates. Onset/offset times and spread of the effect across the spinal segments vary 
and depend on the kinetic and dynamic properties of the injected anesthetic/opioid. 
Olofsen et al. are the first to develop a population PKPD model of epidural anesthesia and 
analgesia.33 Their analysis enables the development of predictive epidural anesthesia, 
in this case, analgesia models that may improve therapeutic outcome. An indirect 
assessment of the epidural drug concentration was made by estimation of the time 
course of systemic drug absorption from the epidural space (by measurement of the 
drug concentration after an epidural injection). Simultaneously, they assessed the level of 
sensory blockade over time. Tested drugs were the local anesthetics levobupivacaine and 
ropivacaine. The epidural segments were modeled by central and peripheral absorption 
compartment- and effect-sites. Differences were observed in the onset/offset half-lives 
between the two drugs (15 min for levobupivacaine and 25 min for ropivacaine). Age was a 
significant modifier with respect to onset/offset half-lives (increasing age reduced t1/2 for 
levobupivacaine at all segments) and anesthetic potency (increasing age increased the 
potency at segments Th12 and higher for ropivacaine). The model enables individualized 
dosing depending on age, sex and drug, and gives a predictive indication of the time 




PKPD MODELING IN CHRONIC PAIN
Ketamine
In a reanalysis of a study on the long-term (12 week) effects of a 100-h S-ketamine infusion 
on pain relief in chronic pain patients owing to complex regional pain syndrome type 1, 
Dahan et al. used an inhibitory sigmoid effect-compartment model of the form: PAIN 
score = BASELINE PAIN/(1 + [CE/C50] γ), and onset/offset rate constant k.34 This very simple 
model satisfactorily described the 12-week pain relief data with a value for C50 of 10 ng/
ml and t1/2k of 10.9 days (95% CI: 5–21 days). The C50 for relief of chronic (neuropathic) pain 
is approximately 50-times lower than that observed for the relief of acute nociceptive 
pain (in volunteers) and suggests a different mode of action of S-ketamine in these 
two distinct pain states. This an example derived from chronic pain data of the power 
of PKPD modeling in understanding the complex behavior of analgesic agents. The 
parameter t1/2k is not synonymous to the blood effect-site equilibration parameter 
t1/2ke0. While the later parameter described the passage of the drug to the postulated 
receptor site, parameter k reflects the dynamics of disease modulation by S-ketamine. 
The plasma concentration of S-ketamine drops rapidly below detection values (within 
Figure 2  Population PKPD modeling of epidural analgesia. A. Blockade probabilities after an epidural 
injection of 125 mg ropivacaine in a 50 year old patient. The size of the dots is proportional to the 
probability of blockade with 90% (solid line), 75% (broken line), and 50% (dotted line) isoeffect lines. 
Time is expressed on the x-axis and the dermatone level on the y-axis. B. Probability of blockade, 
P(block), for dermatomes S5 (broken line), Th11 (solid line) and Th7 (dotted line) versus time. Data 
adapted from Olofsen et al.33
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hours) following the withdrawal from ketamine, while its analgesic effect persists for 
weeks, probably owing to the initiation of a complex cascade of events of which NMDAR 
desensitization is the first step of this disease-modulatory process.
Assuming that PK of S-ketamine is irrelevant in describing its prolonged analgesic effect 
in chronic pain, in addition a (population-based) time-series analysis was performed 
using a mixture model and autoregressive (Kalman) filter constructed in NONMEM. 
The model assumes an exponential return of pain values towards baseline pain with 
autoregressive factor F, which is comparable to parameter k. Indeed, the observed value 
of t1/2F corresponded well with the range observed for k: 15–41 days. The mixture model 
allows the estimation of the chance of an analgesic effect to ketamine (or placebo) 
by objectively subdividing the patient population into four subgroups: two types of 
nonresponders and two types of responders (Figure 3). This type of analysis is attractive 
as it rapidly allows a subdivision of analgesic responses into various subgroups that 
may be defined a priori without the need for PK data. Mixture models using time-series 
analysis may be especially advantageous when quantifying the analgesic efficacy of 
drugs in terms of onset/offset time, division into subgroups, magnitude of variability 
and placebo effect, or when quantifying the effect of drugs that act locally, such as local 
applications of lidocaine or capsaicine.
Pregabalin
Pregabalin is an analog of GABA and acts at the α2δ protein associated with voltage-
gated calcium channels. It has anxiolytic, antiepileptic and analgesic properties. Byon 
et al. performed a pregabalin exposure-response analysis in fibromyalgia chronic pain 
patients.35 They modeled the probability of an observed specific daily pain score (on 
an 11-point categorical scale) using a proportional odds logistic regression model in 
NONMEM with additive components: baseline pain, placebo response (exponential 
function) and drug effect (Emax and linear models were tested). The logistic regression 
approach is used when pain or pain relief is scored with an ordered categorical scale and 
was first introduced by Sheiner in 1994.36 Byon et al. incorporated data from four separate 
randomized, placebo-controlled studies including 2758 patients with daily dosing for 8–14 
weeks in the dose range of 150–600 mg two- to three-times per day.35 The average drug 
concentration was estimated from the pregabalin dose and renal function. The Emax drug 
effect model gave the best results and they estimated an EC50 of 1.4 μg/ml (equivalent to 
174 mg/ day in a patient with creatinine clearance of 100 ml/min), the delay in drug effect 
had a t1/2 of 11 h. Sex and age were significant covariates, with increasing values for Emax 




Expert commentary & five-year view
In the last 5–6 years, only a limited number of studies have been published on population 
PKPD modeling of analgesic agents used in acute and/or chronic pain. The majority of 
studies focused on older analgesics, including morphine, buprenorphine and ketamine, 
while studies on newer agents were scarce and limited to morphine’s metabolite 
M6G, the experimental NSAID SC-75416 and pregabalin. We believe that population 
PKPD modeling is an important tool, not only in the description of the time course of 
drug effect (which enables the appropriate use of the drug), but equally important 
Figure 3  Mixture analyses of the effect of a 1-week ketamine treatment (dashed box) on pain scored 
in patients with chronic pain. The analysis objectively divided the total population response into 
4 categories, with A = no response to treatment, B = a response in the treatment week only, C = a 
long-term response with a slow return towards pre-treatment baseline, and D = full recovery. Data 
adapted from Dahan et al.34
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to understand the interaction of a specific pharmacological agent within the often 
complex disease processes and possibly even understand the complexities of the disease 
itself. Furthermore, model-based analysis using a population PKPD approach is useful in 
the development of new formulations of older drugs such as was shown for ibuprofen 
29,30 and acetaminophen.31 Simulation-based PKPD modeling may be a cheap but valid 
alternative to expensive large clinical trials.31
In the upcoming 5 years, we foresee various advances in the use of population PKPD 
models in acute and chronic pain, most importantly in the development of new 
analgesic agents, in the development of new formulations or the switch towards new 
indications of already registered analgesics. Particularly in the development of new 
analgesic agents, population PKPD modeling enables simultaneous assessment of the 
various properties of analgesics by calculation of utility or safety functions. There are 
various possible calculations of the therapeutic utility functions possible such as the 
probability of analgesic effect minus the probability of side effect. In an animal study, 
Yassen et al. performed a logistic regression analysis to characterize the relationship 
between drug exposure and two effects of buprenorphine and fentanyl: antinociception 
and respiratory depression.37 Odds ratios for both end points were calculated and were, 
for buprenorphine, 29 and 2 for antinociception and respiratory depression, respectively, 
while for fentanyl these values were 3 and 2.5. The safety index, calculated as the odds 
ratio for analgesia divided by the odds ratio for a side effect of 1.2 for fentanyl and 14 
for buprenorphine, suggests a distinct margin of safety for these two opioids, with 
greater safety for buprenorphine compared with fentanyl. Respiratory depression, as 
a complication of potent opioid analgesics, is seldom studied, while respiratory events 
are potentially life-threatening side effects of these agents.38 Hence, we encourage the 
industry to determine the safety index in the development of new analgesic agents. 
Particularly when developing potent analgesic agents or new formulations (such as 
for fentanyl and sufentanil), PKPD studies on opioid side effects (including respiratory 
depression, nausea/vomiting, delayed gastric emptying and sedation) should be part of 
the preregistration study process.
Another advancement would be the use of PD mixture models in NONMEM to predefine 
response groups into responders and nonresponders. Both responders and nonresponders 
require further a priori descriptions with patients that experience at least 50% pain relief 
throughout the treatment period as most clinically relevant. Apart from drug effect per 
se, the variability within the different groups is an important marker of drug efficacy. 
Moreover, patients in the different response groups may be further examined to link 
specific patient characteristics (such as parameters derived from quantitative sensory 
testing, duration of disease, severity of pain symptoms and variability in painsymptoms) 
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Chapterto drug efficacy, eventually allowing prediction of drug response based entirely on these 
pretreatment assessments.39 We predict an important place for mixture modeling in 
NONMEM in the development of new drugs or new indications of already registered 
drugs. 
The chronification of pain is complex and poorly understood. Both peripheral and 
central processes play important roles, although the specifics vary per disease. To fully 
understand the effect of analgesics on these processes, disease-modulatory PKPD 
models are required that describe the effects of specific analgesics within the various 
pain pathways.31 These models need to be dynamic as processes vary over time. For 
example, it may well be that chronic pain in its initial phase has predominant peripheral 
inflammatory components, while over time structural plastic changes within the spinal 
cord or at supraspinal sites develop. Abandanes et al. use PET to predict brain target 
occupancy of duloxetine, a serotonin-reuptake inhibitor with analgesic properties, with 
various dosing regimens, using a mechanism-based PK brain target occupancy models.40 
They define 50% receptor occupation (OC50) as the drug plasma concentration that 
achieves 50% receptor occupation with OC50 = koff/kon. Applying these techniques to 
specific pharmacological targets of chronic pain within the different timeframes of the 
lifecycle of the disease and linking receptor occupation to pain relief is an example of 
the building of disease-modulatory PKPD models. Such models will increase our insight 
into the disease process (such as the process of chronification of pain) and will improve 
treatment development.
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The development of painful diabetic peripheral neuropathy (DPN) is a common longterm 
complication in diabetic patients. It is relatively more common in older patients and 
patients with suboptimal glycemic control.1 Although the exact pathophysiologic 
mechanism is unknown, several contributing factors have been proposed, such as 
microvascular insufficiency, oxidative stress, nitrosative stress, defective neurotrophism, 
and autoimmune-mediated nerve destruction.2,3 Patients with DPN exhibit a variety of 
pain symptoms and sensory qualities. Approximately 20%–24% of patients experience 
onset of insidious pain (or dysesthesias) and present with varying degrees of numbness, 
tingling, burning pain, loss of sensations, paresthesias and loss of balance or coordination. 
Of the 60% of diabetics who develop neuropathy, about 30%–40% have no symptoms.4
Attempts to treat DPN can be divided into those directed at modification of the underlying 
disease process and those directed toward symptom suppression.5 No consensus on the 
optimal management of neuropathic pain exists and consequently the treatment of pain 
is largely empirical and diverse, relying primarily on antidepressants, anticonvulsants and 
narcotic analgesics.6 This study focuses on the local application of a high concentration 
(8%) capsaicin patch, NGX-4010 (QutenzaTM) for treatment of painful DPN. Capsaicin 
is the pungent ingredient in chili peppers and it is believed that exaggerated activity 
of capsaicin-sensitive nerve fibers is involved in the pain of peripheral neuropathies 
like DPN and postherpetic neuralgia.7 Capsaicin is a highly selective activating ligand 
for transient receptor potential vanilloid 1 (TRPV1), which is a ligand-gated nonselective 
cation channel highly expressed in small diameter primary afferent neurons (C- and Aδ-
fibers), especially those nerve fibers that specialize in the detection of painful or noxious 
sensations,8–10 Activation of this receptor by capsaicin results in a burning sensation, 
hyperalgesia, allodynia, and erythema (due to release of vasoactive neuropeptides 
from small-diameter sensory axons).9 After prolonged exposure to capsaicin, the small 
diameter sensory axons become less sensitive to a variety of stimuli, including capsaicin 
itself or thermal stimuli, resulting in a reduced pain response.8 These later stage effects 
of capsaicin are frequently referred to as “defunctionalization” and serve as the rationale 
for the development of capsaicin formulations for the treatment of various neuropathic 
pain syndromes.7 Studies have shown that such alterations from prolonged low-
concentration capsaicin exposure are reversible, at which point normal function (the 
detection of noxious sensations) returns.11,12
In this study, patients received a single treatment with the high concentration capsaicin 
patch (NGX-4010). While a (limited) descriptive analysis of the data has been published 




modeling in NONMEM considering the whole time course of effect (0–12 weeks).14 The 
aims of the study were (i) to get an indication of the variability in responses and attempt 
to identify subgroups in response to capsaicin treatment using a pharmacodynamic 
mixture model; (ii) to describe the magnitude of effect and time courses of onset and 
offset of effect of 8% capsaicin patch in the observed subgroups.
METHODS
The study was registered in the Clinical Trial register (www. clinicaltrials.gov) under 
number NCT00082316.
Patient population and study design
After approval of the protocol by the local ethics committee patients with moderate to 
severe pain (numerical pain rating score [NPRS] of 3 or greater on a scale from 0 [no 
pain] to 10 [worst possible pain]), secondary to DPN were enrolled in the study. DPN was 
defined as neuropathic pain (related to type I or II diabetes mellitus) in both feet for at 
least 3 months prior to the study.
Inclusion criteria were: men and women aged at least 18 years, absence of pain from other 
causes (eg, from fibromyalgia, arthritis, mononeuritis multiplex, hereditary neuropathy), 
intact skin around the treatment area, absence of significant medical problems of the 
heart, kidneys, liver, or lungs. Chronic pain medication was allowed with the exception 
of any topical medication in the affected areas of the body, including nonsteroidal anti-
inflammatory drugs, menthol, methyl salicylate, local anesthetics, steroids, or capsaicin. 
After the screening visit, no pain medication changes were allowed. Exclusion criteria 
included a history of substance abuse, pregnancy or lactation, the presence of cancer, 
opioid medication use, unless orally or transdermally administered and not exceeding a 
total daily dose of morphine 60 mg/day, chronic alcohol abuse, uncorrected vitamin B12 
deficiency, or treatment with any drugs that may have contributed to the neuropathy 
during the 90 days prior to the study, hypersensitivity to capsaicin (ie, chili peppers or 
over-the-counter capsaicin products), local anesthetics or adhesives.
This multicenter study had a randomized, open-label design and was aimed at the 
evaluation of the tolerability and efficacy of the application of 1–4 high-concentration 
capsaicin (640 g/cm2) patches, preceded by the topical application of lidocaine 4%. Prior 
to treatment with NGX-4010, the lidocaine cream was applied over and extending 1–2 
cm beyond the perimeter of the marked painful area(s) for 60 minutes. After removal 
of the topical anesthetic, up to four 20 x 14 cm capsaicin patches were applied for 60–
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90 minutes. The patch(es) were then removed and a cleansing gel was used to remove 
excess capsaicin from the skin, after which the treated area was gently washed with 
soap followed by water. The patients were monitored for at least 2 hours following 
treatment before being discharged. For discomfort, the patients were permitted to use 
analgesic medications during (oxycodone oral solution 1 mg/mL) and after treatment 
(hydrocodone/acetaminophen tablets, 5/500 mg, two tablets every 8 hours, for a 
maximum of 5 days).
The primary study parameter was the average NPRS for the past 24 hours obtained at 
24-hour intervals at 0900 PM. Average weekly NPRSs were used in the analysis, without 
imputation for missing scores. Pain scores were obtained for 12 weeks following the 
application of the capsaicin patch.
Pharmacodynamic data analysis
Model fitting was performed using a nonlinear mixed effects modeling approach 
using nonlinear mixed effect modeling software (NONMEM version VII level 1; ICON 
Development Solutions, Ellicott City, MD).14 The first-order conditional estimation (FOCE) 
with interaction algorithm was used for model development. The performance of the 
analysis was evaluated by various selection criteria, including visual inspection of the 
goodness-of-fit plot, changes in the objective function value and parameter estimates 
and their respective standard errors. Using the likelihood ratio test, the significance level 
was set at α = 0.01, which corresponds to a reduction of 6.6 units in objective function 
value (χ2 distribution) to discriminate between two nested structural models after 
inclusion of one additional parameter. Model diagnostic checks of the final model were 
conducted using R (R-project, version 2.12.0).
Pharmacodynamic model
The effect of capsaicin 8% on NPRS was characterized using a Bateman function with the 
following structure:
        konset
Effect =   ____________ . (e-koffset . time – e–konset . time)    (1)
 konset – koffset
The Bateman function characterizes the time course of NPRS pain score from week 0 
(baseline) to week 12 in terms of two first-order rate constants describing the onset (konset) 
and offset (koffset) of the effect following the application of capsaicin 8%. The change in 




NPRS(t) = NPRS0 . (1 – α . Effect )      (2)
where NPRS0 is the NPRS pain score at baseline and α is the magnitude of effect.
Random effects were included in the pharmacodynamic model provided that 
the parameters are either normally or log-normally distributed. For example, the 
pharmacodynamic parameter α was modeled assuming a normal distribution allowing 
for the estimation of negative values of the parameter α (increase in NPRS pain score):
αj = θα + ηj         (3)
where αj is the estimate of α for the jth individual and θα represents the population 
estimate for the pharmacodynamic parameter α. ηj describes the inter-individual 
variability on α, which is assumed to be a normally distributed random effect variable 
with mean zero and variance ω2. Similarly, the inter-individual random effect variables for 
NPRS0 and konset were assumed to be normally distributed. The inter-individual variability 
random effect variable for koffset was assumed to be log-normally distributed.
Residual variability, which is a measure of the unexplained variability (including error 
associated with reporting of chronic pain outcome), was described using an additive 
error model:
NPRSobs,ij = NPRSpred,ij + εij,        (4)
where the residual variability, εij, at time point i for individual j, is a normally distributed 
random effect variable with mean zero and variance σ2.
Mixture model
Aside from the advantage of the use of the population approach in simultaneously 
analyzing individual data, the nonlinear mixed effects modeling approach also enables 
the definition of a mixture model, in which the existence of subgroup of patients that may 
respond differently to capsaicin 8% patch treatment can be explored. For this analysis, it 
is assumed that the structural model is the same for subgroups, but that patients may 
differ in their onset and offset of response and also may respond differently to capsaicin 
8% patch in terms of magnitude of response. To this end, the pharmacodynamic 
parameters, konset, koffset and α are assumed to be distributed multimodally and therefore 
the mixture feature in NONMEM is used to differentiate between subgroups of patients 
on the basis of the distribution of the pharmacodynamic parameter estimates. Initially, 
based on visual inspection of the individual data, the mixture model was defined to 
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separate four sub-groups of patients, including patients that show (1) worsening of 
response, (2) no response, (3) maximum response with trend to return to baseline after 12 
weeks and (4) maximum response which is maintained during 12 weeks.
RESULTS
The data from 91 patients were included in the analysis. Data of patients with early 
termination from the study were included in the analysis (n = 13). Early termination was 
most often related to unsatisfactory therapeutic response and occurred most often in 
week 6 of the study. An overview of the demographic patient data (of patients included 
in the analysis) is provided in Table 1. The mean time course profiles of the numerical pain 
rating score for the total population are shown in Figure 1A. The mean percentage of pain 
reduction from baseline at week 12 for the total population was 30.5% (95% confidence 
interval [CI]: 21.1%–39.9%). The proportion of patients that show at least 30% reduction in 
NPRS from baseline at week 12 was 46.8%; the 50% responder rate at week 12 was 33.8%.
Description of the four subgroups
The mixture model analysis clearly showed that the dataset can be separated into 
subgroups (Tables 2–4). These subgroups have different shapes of the time versus 
response profile, indicating that patients differ in their response to capsaicin 8% 
treatment. The mean time course profiles of NPRS pain score for the different subgroups 
are shown in Figure 1B–E. The standard errors shown serve to illustrate that the average 
NPRS score in each subgroup (except for subgroup 1) is estimated with a high degree of 




Patients in subgroup 1 (n = 3) displayed a worsening of response (increase in NPRS score) 
following capsaicin 8% treatment that was maintained during the 12 weeks of the 
study (Figure 1B). The mean increase in NPRS from baseline at week 12 was 28.0%. Note, 
however, that this subgroup contains just three subjects.
Subgroup 2 contains 28 patients that showed no or minimal response to capsaicin 8% 
treatment (Figure 1C). On average, a slight increase in NPRS pain score from baseline of 
5.62% was observed (Table 2), while none of the patients n that subgroup showed at 
least 30% reduction in NPRS from baseline at week 12.
Table 1  Demographics of patients involved in the analysis
Characteristic % of population




Age ± SD (years) 58.7 ± 11.21
Age distribution (n)
< 65 years 63 (69.2%)
≥ 65 years 28 (30.8%)
Weight ± SD (kg) 97.7  ± 22.86
Height± SD (cm) 172.5 ± 9.81
Race distribution (n)
White 69 (75.8%)
African American 10 (11.0%)
Hispanic 9 (9.9%)
Other 3 (3.3%)
SD = standard deviation
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Figure 1  (A) Mean response of the total population (n = 91). (B) Mean response of patients belonging to 
group 1 (patients with a deterioration of their pain) as determined from the mixture model analysis. 
(C) Mean response of patients belonging to group 2 (patients with no response to treatment). (D) 
Mean response of patients belonging to group 3 (patients with an initial drop in NPRS followed by a 
slow decline towards baseline NPRS). (E) Mean response of patients belonging to group 4 (patients 
with a reduction in NRPS which is maintained throughout the study period). Values are mean ± SEM. 




Table 2  Pharmacodynamic parameter estimates
Subgroup Typical estimate ± SE
1 2 3 4
Fixed effect parameters (θ)
NPRS0 6.0 ± 0.1 6.0 ± 0.2 6.0 ± 0.2 6.0 ± 0.2
konset (week-1) 0.76 ± 0.12 0 ± NE 0.76 ± 0.12 0.76 ± 0.12
koffset (week-1) 0 ± NE 0 ± NE 0.09 ± 0.04 0 ± NE
α -0.2 ± 0.08 0 ± NE 0.79 ± 0.06 0.79 ± 0.06
Inter-individual random effect parameters
NPRS0 (%CV) 2.04 ± 0.323 (24%)
0.20 ± 0.08 (58%)
1.30 ± 0.75 (114%)




Residual random effect parameter
Additive residual error                              0.51 ± 0.082
NPRS0 = numerical pain rating score at baseline;
konset = the response-onset rate constant;
koffset = the response-offset rate constant;
α = magnitude of effect. 
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Subgroup 3 and 4 do show a clear analgesic response to capsaicin 8% treatment. On 
average, the 29 patients in subgroup 3 had a quick reduction in NRPS with a nadir of 
42.6% reduction in NPRS occurring between weeks 3 and 4, followed by a slow increase 
NPRS towards baseline (Figure 1D). At the end of the study the mean NPRS reduction was 
15.6%, while the proportion of patients that showed at least 30% reduction in NPRS pain 
score was 34.8%; the 50% responder rate was 13.0%.
Patients in subgroup 4 show a sharp reduction in NPRS that was maintained during the 
12 weeks of the study (Figure 1E). The mean percentage reduction in NPRS from baseline 
is 69.7% at week 12% and 90.3% of the patients showed at least 30% reduction in NPRS 
pain score from baseline at week 12, while 74.2% of the patients showed at least 50% 
reduction in NPRS pain score from baseline.
To get an indication of the adequacy of the model, best, median and worst data fits of 
NPRS obtained in groups 3 and 4 are given in Figure 2. The goodness-of-fit plots given 
in Figure 3 do not show any systemic deviation of the model predicted versus observed 
NPRS.
Table 3  Percentage reduction in numerical pain rating score from baseline at week 
4 and 12
% of total 
population
Week 4
% (mean ± SE)
Week 12
% (mean ± SE)
Total population 100 33.7 ± 3.99 30.5 ± 4.84
Subgroups
Worsening of response 
(Group 1)
3.3 –34.7 ± 10.3 –28.0 ± 1.84
No response (Group 2) 30.8 0.01 ± 2.12 –5.62 ± 3.7
Maximum response with 
trend to return to baseline 
(Group 3)
31.9 42.5 ± 5.94 15.6 ± 6.30
Maximum response which is 
maintained during 12 weeks 
(Group 4)
34.1 61.7 ± 5.24 69.7 ± 5.11







These distinct profiles are translated into quantitative estimates of pharmacodynamic 
parameters, which may differ across the different subgroups. For subgroups 1, 3, and 4, 
the rate of onset was estimated at 0.76 week–1 (Table 2), corresponding to a half-life 
(t1/2,onset) of 0.91 weeks, indicating that every 0.91 weeks the NPRS is reduced or increased 
(in case of subgroup 1) by 50% relative to the NPRS obtained in the previous week. 
Differences in onset of effect between the subgroups has been formally tested for during 
the analysis, but did not result in a further improvement of the model fit at the level 
of α = 0.01, indicating that the rate of onset of response is similar for the subgroups. 
For subgroup 2, the patients that showed no or minimal response to capsaicin 8% 
treatment, the rate constant for onset of effect was assumed to be 0 and was based 
on the reasonable assumption that this subgroup has no kinetics of action. In total 28 
patients of 91 patients (30.8%) showed no effect to capsaicin 8% treatment.
Figure 2  Examples of the data fits of Groups 3 and 4. Best, median and worst fits of NPRS responses 
belonging to Groups 3 (A, B, and C) and 4 (D, E, and F) are given.
NPRS = numerical pain rating score.




The offset of effect was quite different between the subgroups. Patients in subgroup 
3 (n = 29, 31.9%) showed a response to capsaicin 8% patch treatment, which gradually 
returned toward baseline. The estimate of the rate constant of offset for subgroup 3 was 
0.09 week–1 (Table 2), corresponding to a half-life (t1/2,offset) of 7.8 weeks (based on the 12-
week treatment period). This indicates that every 7.8 weeks the NPRS is increased by 50% 
relative to the NPRS of the previous week. Subgroups 1, 2 and 4 did not have an offset 
of effect. For subgroup 4 (n = 31, 34.1% of patients) this is shown in Figure 1E by a well-
preserved maintenance of the maximum response during the 12 study weeks, showing 
no offset of effect. For subgroup 1 (n = 3, 3.3% of patients), NPRS pain scores go up and 
remain at higher scores after treatment with capsaicin 8%.
Figure 3  Goodness-of-fit plots of the final pharmacodynamic model. Observed versus population 
predicted (A) and individual predicted NPRS pain score (B). The black lines are the lines of identity. In 
the lower panel the conditional weighted residuals versus population predicted NPRS score (C) and 





The development of effective and safe treatments for chronic neuropathic pain indications 
remains challenging. The heterogeneity (eg, ethnicity, age, sex) and complexity (eg, 
disease processes, underlying mechanisms) of the chronic pain population, including DPN 
patients, is well recognized and may partly explain the large variability in the response to 
pharmacological treatment.15,16 In the current study a mathematical pharmacodynamic 
model was developed, considering the time course of response, to quantify the magnitude 
and onset/offset times of the effect of capsaicin 8% patch in the treatment of DPN. In 
addition, a mixture model was applied to objectively match patterns in pain-associated 
behavior (NPRS). The main findings of the study are: (i) on average, a single application of 
capsaicin 8% patch produced a variable analgesic response with an average 30.5% pain 
reduction (95% CI: 21.1%–39.9%) from baseline NPRS at week 12 in DPN patients; and (ii) 
using the pharmacodynamic mixture model, four distinct subgroups could be identified 
that respond differently to capsaicin 8% treatment. Subjects allocated to group 1 (3.3% 
of patients) showed worsening of pain; group 2 (31%) showed no change in NPRS from 
baseline pain; group 3 (32%) had a quick drop in NPRS with a nadir between weeks 3 and 
4, followed by a slow return towards baseline; group 4 (34%) had a quick reduction in 
NPRS that was maintained throughout the 12 weeks of the study (Figure 1; Table 2). With 
the exclusion of group 1, each of the groups displayed a significant reduction in response 
variability separating a heterogeneous population into homogenous subgroups in terms 
of response to treatment. This further underlines the relevance of collecting time course 
data during and after the treatment period and provides confidence that the developed 
pharmacodynamic model adequately described the time course of response in individual 
patients.
The division into the four subgroups was based on characterization of the time course 
of the response in terms of onset/offset times and magnitude of response. The onset 
of response had a half-life of about 1 week that was similar for groups 3 and 4 and also 
group 1. In the latter group the response was algesic rather than analgesic. This indicates 
that the onset of efficacy is relatively fast and within 3–4 weeks maximum reduction 
in NPRS was achieved (3–4 x t1/2,onset). Group 1 includes just three patients and cannot be 
considered a robust response group compared to groups 2, 3, and 4. It is not possible to 
understand the algesic behavior in this small group. Possible causes include the presence 
of unpredictable and varying pain in these patients with spontaneous worsening of 
symptoms irrespective of treatment, or the presence of mood-related disorders with a 
poor or erratic response to any medication.
In group 3, NPRS was reduced by 42.6% from baseline at week 4 after treatment (30% and 
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50% responder rates were 60.7% and 42.9%, respectively, Table 3). In group 4, reduction 
in NPRS from baseline was 61.7% at week 4 after treatment (30% and 50% responder 
rate were 83.9% and 64.5%, respectively, Table 4). The response to capsaicin 8% patch 
treatment was further maintained or even increased from week 5 to at least week 12 in 
this subgroup, indicating long-lasting pain relief from a single patch application. Only in 
group 3 a response–offset rate constant could be estimated with a half-life of 7.8 weeks. 
This indicates that in group 3 the NPRS increased slowly (≈50% increase every 7.8 weeks 
from week 4 on), suggesting that patients in group 3 would need retreatment after 10 
to 12 weeks (at that time the reduction in NPRS is less than 20%). Furthermore, a design 
in which retreatment is applied would enable assessment of stable treatment reactions. 
We previously assessed the effect of a 1-week ketamine intravenous treatment on 
neuropathic pain in patients with complex regional pain syndrome type 1 (CRPS1).17,18 At 
the end of the 12-week follow-up, about 20% of the subjects had significant pain relief 
(ie, relief 30% of baseline pain score versus 47% in the current study, Table 4). While this 
suggests a rather poor efficacy of ketamine in the treatment of CRPS1 pain a subsequent 
subgroup analysis using a pharmacodynamic mixture model showed that 37% (11/30) 
of patients were unresponsive to ketamine treatment following the treatment week (cf, 
our groups 1 and 2), 56% (17/30) of patients had an initial analgesic response (>50% of 
baseline pain) that slowly returned towards baseline levels (cf, our current group 3) and 
just 7% (2/30) patients had persistent pain relief (cf, group 4).7 Evidently, patients that 
were unresponsive to ketamine are not suitable for retreatment. In contrast, patients 
in the ketamine group 3 were given the opportunity for retreatment with ketamine. 
Similarly, in our current study, patients in group 3 would be well served by retreatment.
The current and previous analyses indicate that subdividing patients into specific 
subgroups provides additional information of the effect of pharmacological treatment 
on pain responses over time by identifying homogenous subgroups with two classes of 
responders (ie, group 3 and 4 responders). This approach is superior to the dichotomous 
classification of patients into responders versus nonresponders made at a specific 
time-point following treatment (eg, at an arbitrary week following treatment). Also 
in our study, conclusions drawn form a dichotomous study outcome at week 12 would 
significantly differ from those obtained using the current approach and would have 
missed the earlier but transient robust analgesic effects and would have suggested the 
need for retreatment at week 12 in most patients. Retreatment of patients in subgroups 1 
and 2 is not warranted, as discomfort will predominate without any therapeutic benefit. 
Retreatment in subgroup 4 is not needed since the analgesic response to the patch 
application was maintained during the observation period.




We did not take side effects into account, as serious adverse events did not occur (side 
effects were transient capsaicin-application related, and included local erythema, pain, 
and itching).13 Still, for other types of systemic medication that show similar large 
variability in response efficacy (eg, NMDA receptor antagonists, GABAergic, antiepileptic 
and antidepressant medications) nontransient central side effects (sedation/nausea/
dysphoria/hallucinations) may occur in patients that experience analgesia as well as 
those that do not.17,18 Especially for these medications with a narrow therapeutic index 
the characterization of subgroups is important as it allows a more accurate description 
of the efficacy–safety balance. Concomitant modeling of analgesia and side effects 
will allow the development of so-called utility functions in which the balance between 
safety and efficacy is quantified over time.19,20 For example patients that do not respond 
to medication (cf, our groups 1 and 2) are especially vulnerable to a potential imbalance 
between efficacy and safety as they lack any treatment advantage.
A limitation to our analysis is that in case of small response groups (subgroup 1 with 
just three patients), changes observed in effect could easily be due to random variation 
without any relationship to treatment. Furthermore, while our classification into four 
response groups is an important enrichment tool (eg, for assessment of treatment 
efficacy or an indicator for the need for treatment switch) it remains a post-hoc 
analysis. A useful addition to our analysis would be to incorporate a priori functional or 
neurosensory testing allowing response prediction. To the best of our knowledge, so far, 
no useful link has been made between any functional testing and drug response outcome. 
A first approach could be the use of quantitative sensory testing (QST) or brain-evoked 
potentials using electrical (SEP) or laser stimulation (LEP) of the skin prior to treatment. 
For example, specific QST, SEP, or LEP patterns detected may be linked to specific response 
groups. Our model-based approach can be seen as a complementary tool to functional 
tests like QST, combining mechanistic insights in chronic pain conditions with patient 
outcome measures. An additional approach could be to link response groups to patient 
covariates (including patient characteristics, genetic factors (e.g., variations in the TRPV1 
gene), disease severity/state. While this initially requires post-hoc testing, subsequent 
studies may be designed to address the prognostic value of these covariates in predicting 
the response to treatment. The developed pharmacodynamic model can be used as a 
basis for identification of covariates that have potential prognostic value for prediction 
of treatment outcome, our patient population, however, was too small to allow for such 
covariate analysis.
In conclusion, we showed that characterization of the time course of the analgesic 
response is essential to further understand the heterogeneity in treatment effect (and 
study population). In the current study in a relatively small population of neuropathic 
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pain patients, about two-thirds of the patients showed significant reduction in pain 
following a single application of capsaicin 8% patch. In one subpopulation (34%) the 30% 
and 50% responder rate was around 90% and 70% at week 12. These results indicate that 
the single topical application of capsaicin 8% patch provides an effective and long-lasting 
treatment in DPN pain, although the efficacy should be viewed in light of the open-label 
study design. Finally, we and others,17,18 have shown that the model-based approach may 
have added value in analyzing longitudinal data from chronic pain trials and may provide 
insights into the nature of drug response and allows the optimization of treatment 
algorithms for patients suffering from chronic pain conditions. We applied the mixture 
model analysis to a small population of DPN patients treated with a single capsaicin 8% 
patch, but it may be a valuable tool for all therapies with similar large response variability 
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INTRODUCTION
Postherpetic neuralgia (PHN) is a chronic neuropathic pain condition caused by the 
varicella zoster virus.1,2 The virus is usually contracted in childhood (causing chicken 
pox) but remains dormant in the nervous system. Reactivation in later life (causing 
acute herpes zoster) may be complicated with longterm neuropathic pain confined to 
the affected dermatomes. PHN develops in 8–19% of patients following acute herpes 
zoster, although prevalence increases with age.2 Recent trials on the efficacy of topical 
treatment with capsaicin 8% versus an active control patch (capsaicin 0.04%) in PHN 
patients3-6 reported favourably on the safety and efficacy of capsaicin 8% with significant 
pain relief at week 12 after patch application. However, an appreciable effect from the 
active control patch was observed, although responses were smaller compared to the 
test treatment (difference in effect <10%).
Capsaicin is a highly selective ligand of the vanilloid 1 receptor (TRPV1) or capsaicin 
receptor.7,8 This ligand-gated receptor is expressed on small primary afferent peripheral 
nerve endings, particularly of those fibres that detect painful and noxious sensations 
(C and Ad-fibres).9,10 Acute activation of the receptor causes burning pain, allodynia, 
hyperalgesia and erythema, while more prolonged exposure causes desensitization of 
the afferent fibres, resulting in a reduced response to noxious and thermal stimuli.11 
These later effects are at the basis of the use of capsaicin topical formulations in the 
treatment of various neuropathic pain syndromes, including PHN, diabetic neuropathic 
pain and HIV-related neuropathy.12
In this study, we pooled data from four double-blind, randomized controlled trials on the 
efficacy of capsaicin 8% versus 0.04% patches in patients with PHN.3-6 Our analysis has 
three parts: (1) we characterized the longitudinal responses of each patient; (2) collected 
them in one of five specific response groups; and (3) performed a covariate analysis. 
Our methodology is distinct from more common and traditional approaches, in which 
the responder rate at fixed time points during or following treatment are quantified. 
Our approach allows for a more descriptive examination of specific patient populations 
with links to a variety of effect predictors. We argue that application of this analytical 
approach improves insight in the cause of treatment success or failure in individual 
chronic pain patients.
The study aims were as follows: description of the time course of effect of a topical 
application of capsaicin 8% and 0.04% in patients with PHN; identification of 
subpopulations in analgesic response patterns; and determination of covariates that 






Data from four double-blind, randomized controlled trials on the efficacy of the 
capsaicin 8% patch versus capsaicin 0.04% patch in patients suffering from PHN were 
pooled and analysed.3-6 In all four trials, PHN patients were included when they had a 
pain score of 3–9 on a numerical pain rating scale (NPRS) ranging from 0 (no pain) to 10 
(worst imaginable pain). PHN was defined as persistent or recurrent neuropathic pain 
for at least 3–6 months after vesicle crusting due to acute herpes zoster infection. As 
spontaneous improvement of PHN during the first 6 months may occur, only subjects 
with at least 6 months of pain since vesicle crusting were included. All subjects were 
at least 18 years old, of both sexes, did not have significant pain due to other causes, 
had intact skin at the treatment area, had no history or current problem with substance 
abuse, were not pregnant during screening and follow-up period, and had no significant 
internal medical problems. Subjects could be on stable chronic oral pain medication 
regimens, but could not use any topical pain medications on the affected areas, such 
as non-steroidal anti-inflammatory drugs, menthol, methyl salicylate, local anaesthetics 
including 5% lidocaine patch, steroids or capsaicin. After inclusion, no pain medication 
changes were allowed.
Exclusion criteria were (1) concomitant opioid medication use, unless orally or 
transdermally administered and not exceeding a total daily dose of morphine 60 mg/
day, or equivalent; (2) evidence of another contributing or immunologic cause for the 
sensory neuropathy, such as chronic alcohol abuse, hereditary neuropathy, uncorrected 
vitamin B12 deficiency, or treatment with any drug(s) that may have contributed to the 
neuropathy during the 90 days prior to the first treatment visit; (3) significant ongoing 
or recurrent pain of another aetiology, including fibromyalgia, arthritis and mononeuritis 
multiplex; (4) any implanted medical device (spinal cord stimulator, intrathecal pump or 
peripheral nerve stimulator) for the treatment of neuropathic pain; 5) hypersensitivity to 
capsaicin (i.e., chilli peppers or over-the-counter capsaicin products), local anaesthetics 
or their components, oxycodone hydrochloride, hydrocodone bitartrate or adhesives; (6) 
painful PHN areas located on the face, above the hairline of the scalp and/or in proximity 
to mucous membranes; and (7) evidence of cognitive impairment, which may interfere 
with subject’s ability to complete daily pain diaries (which requires the subject’s recall of 
average PHN pain level in the past 24 h).
Chapter 4  |   A novel approach to identify responder subgroups and predictors of response to low- and high-dose capsaicin  
patches in postherpetic neuralgia
62
The studies were approved by the Institutional Review Boards/Human Ethics Committees 
at the participating sites, and conducted according to regulatory requirements (e.g., Good 
Clinical Practice guidelines) and the ethical principles as written down in the Declaration 
of Helsinki. Written consent was obtained from all patients before inclusion in the study.
Study design
All studies were randomized, double-blind, controlled, multicentre evaluations of the 
efficacy of the high-concentration capsaicin patch (640 mg/cm2, Qutenza®, NeurogesX, 
San Mateo, CA, USA), for the treatment of PHN compared to an identically formulated 
control patch (0.04% capsaicin, 3.2 mg/cm2). After a 14-day period of baseline pain 
assessment, patients were treated with a capsaicin patch. First, they received a local 
anaesthetic cream (lidocaine 4%) on the affected areas prior to placement of one or 
more patches containing study drug. This local anaesthetic was used for the prevention 
of pain associated with the placement of the capsaicin patch. After removal of the local 
anaesthetic, subjects received a single 30-, 60- or 90-min treatment with the 8% or 
0.04% capsaicin patches (maximum area treated 1000 cm2) over the affected skin area. 
After treatment, the patch(es) were removed and the treatment area(s) were cleaned 
with a cleansing gel to remove residual capsaicin. Subjects were monitored for at least 2 
h following treatment before being discharged. In case of discomfort during application 
and the first hour thereafter, cooling could be applied or oxycodone (oral solution 1 
mg/mL) could be taken. Furthermore, rescue medication was available to the patients 
for the 3–5 day period following patch placement: two tablets of Vicodin® (5 mg 
hydrocodone/500 mg acetaminophen) (Abbott Labs, Abbott Park, IL, USA) every 8 h. The 
primary efficacy parameter was the average NPRS over the past 24 h obtained at 9 a.m. 
at 24-h intervals. Average weekly NPRS scores obtained were used in the current analysis, 
without imputation of missing scores. Pain scores were obtained for the 12-week period 
following patch application.
Analysis of longitudinal efficacy data and mixture analysis (Figure 1)
A longitudinal model using a Bateman function was developed using a non-linear mixed 
effect model to describe the time course of NPRS scores following application of the low-
or high-concentration capsaicin path [see Appendix 1 and Figure 1 (longitudinal model)].13 
Next, subgroups in the data were objectively identified using the identical structural 
model but allowing differences in magnitude of response and in onset/offset response 
times [see Appendix 1 and Figure 1 (mixture analysis)]. The procedure resulted in five 
distinct response populations: (1) a population showing worsening of response (i.e., 




Figure 1  Outline of the data analyses. The raw data are analysed using a pharmacodynamic (PD) 
model (step 1: longitudinal pharmacodynamic analysis) characterized by two first-order rate 
constants describing the onset (kONSET) and offset (kOFFSET) and a parameter that describes the 
magnitude of effect (a). See also equations (A1) and (A2) of Appendix 1. Next (step 2: mixture 
analysis), the data are grouped into 1 of 5 possible responder groups on the basis of the parameter 
(kONSET, kOFFSET and a) distributions. Finally, (step 3: covariate analysis) the relationships that exist 
between a set of covariates and the five patient responder profiles following treatment with low- or 
high-concentration capsaicin patches was explored.
a population showing a (partial or full) analgesic response with return to pretreatment 
pain levels within 12 weeks; (4) a population showing a partial analgesic response at week 
1 that remained constant during the study period; and (5) a population that showed an 
ongoing decline in pain rating during the 12 weeks of the study.
Covariate analysis
For the covariate analysis, multinomial logit models were used to investigate the 
relationships that exist between covariates and the five patient responder profiles 
following treatment with low- or high-concentration capsaicin patches. To this end, the 
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response variable is the subgroup classification number (1–5) for each patient obtained 
from the mixture analysis. The independent (predictor) variables that were collected in 
the four clinical studies and included in the covariate analysis were seven categorical 
and seven continuous variables, as shown in Table 1. The multinomial logit models 
were implemented in R (version 2.12.0; http:// www.r-project.org) using the multinom 
function in the nnet package. The stepAIC function in the MASS package was used to 
perform the stepwise backward elimination covariate model selection based on the 
Akaike information criterion (AIC).
Table 1  List of covariates 
Categorical variables
1 Concomitant use of opioids: yes/no
2 Concomitant use of antidepressants: yes/no
3 Concomitant use of anticonvulsants: yes/no
4 Concomitant use of any other pain medication: yes/no
5 Use of pain co-medication (opioids/antidepressants/anticonvulsants): yes/no
6 Sex: male/female
7 Race: Caucasian, African American, Asian American, other
Continuous variables
8 NPRS at week 0 (baseline) 
9 NPRS after lidocaine pre-treatment and before capsaicin patch application
10 NPRS after capsaicin patch removal 
11 Variance in NRPS during run-in (pre-treatment) period 
12 Age 
13 Weight
14 Duration of disease






Data from 1248 patients who had participated in one of four trials were pooled, yielding 
a total of 15,547 numerical pain rating scores. Further, 526 patients were treated with 
the low concentration capsaicin patch (i.e., the active control 0.04% capsaicin) and 
722 patients were treated with Qutenza (8% capsaicin). An overview of the population 
characteristics is provided in Table 2. The mean time course of NPRS scores of all  patients 
treated with the active control and high-concentration capsaicin patches are shown 
in Figure 2. The mean pain reduction in NPRS from baseline at week 12 for the patients 
treated with control or 8% capsaicin were 23.9% and 29.0%, respectively.
Table 2  Patient characteristics
0.04 % capsaicin patch 8 % capsaicin patch 
(Qutenza)
Number of patients 526 722
Sex distribution (n)
Men 277 (47.3 %) 340 (47.1 %)
Women 249 (52.7 %) 382 (52.9 %)
Age ± SD (years) 70.8 ± 11.9 70.8 ± 11.4
Age distribution (n)
< 65 years 134 (25.5 %) 184 (25.5 %)
≥ 65 years 392 (74.5 %) 538 (74.5 %)
Weight ± SD (kg) 78.8 ± 17.7 78.0 ± 18.2
Race distribution (n)
Caucasian 480 (91.2 %) 664 (92.0 %)
African American 19 (3.6 %) 19 (2.6 %)
Asian American 6 (1.1%) 19 (2.6 %)
Other 21 (4.0%) 27 (3.7 %)
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Description of the five subgroups
Longitudinal and mixture model analysis of the NRPS scores resulted in five well-defined 
subgroups with differences in magnitude of effect and onset/offset times (Appendix 1). 
The mean time-course profiles are given in Figure 3. The graphs indicate that the subgroup 
analysis yielded similar profiles in patients treated with high-dose capsaicin patch 
and those treated with the active control patch. Apart from subgroup 1, the standard 
deviations of the subgroup data points were all smaller compared to those of the NPRS 
scores of the total population (cf. Figure 2A and B with Figure 3), an indication that the 
Figure 2  Time course of effect of the low-dose capsaicin patch (A, capsaicin 0.04%) and Qutenza 




Figure 3  Time course of effect separated by subgroup. Top panels (A–E): treatment with active 
control (capsaicin 0.04% patch); bottom panels (F–J): treatment with capsaicin 8% patch. Values are 
mean ± SD.
subgroups constitute a more homogenous set of patients (i.e., patients responding to 
treatment with similar time profiles were correctly lumped together).
Subgroup 1
Only a small fraction of patients displayed worsening of pain during treatment (1.5% 
and 0.8% of patients treated with the high-dose capsaicin and active control patch, 
respectively; Table 3). Despite its small size, incorporation of this subgroup was an 
important addition to the mixture analysis, yielding a significant improvement in the 
goodness of fit over a four-subgroup mixture model as judged by the objective function 
value.
Subgroup 2
Subgroup 2 contained all patients that showed no response to treatment (i.e., non-
responders). The number of non-responders differed between treatments: 22.7% of 
patients treated with capsaicin 8% versus 39.1% of patient treated with the active control 
patch. The percentage change in NPRS from baseline at week 12 was comparable between 
the two treat- ment arms with an observed 8% reduction in NRPS (active control) versus 
an observed increase in NRPS of 8% (capsaicin 8%; Table 3).
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Subgroup 3
The patient fraction that showed an initial reduction in NRPS at week 1 followed by a 
slow return towards baseline was 17.6% (active control) versus 24.7% (capsaicin 8%; Table 
3). The effect at week 1 was similar between treatments: a reduction in NRPS of 43.6% 
and 40.4% in patients treated with the active control and high-dose patch, respectively. 
Return to baseline occurred faster in patients treated with the active control with NRPS 
values at week 6 within 10% of baseline. In contrast, patients treated with the high-dose 
patch showed a return to 10% of baseline at week 9.
Subgroup 4
In contrast to patients in subgroup 3, patients classified into subgroup 4 showed a 
reduction in NRPS at week 1 that was maintained throughout the time course of study. 




in NRPS at 
week 12*
30% reduction 
in NPRS at 
week 12 (%) ξ
50% reduction 
in NPRS at 
week 12 (%) ξ
Treatment with capsaicin 8% (n = 722)
1 11 (1.5) -27.1 0 0
2 164 (22.7) -0.8 0 0
3 178 (24.7) 4.5 27 (3.8) 6 (0.9)
4 105 (14.5) 24.4 31 (4.3) 2 (0.3)
5 264 (36.6) 67.4 252 (35) 198 (27.4)
Treatment with capsaicin 0.04% (n = 526)
1 4 (0.8) -84.6 0 0
2 206 (39.1) 0.8 3 (0.6) 0
3 93 (17.6) -0.3 10 (1.9) 5 (0.9)
4 75 (14.3) 30.2 40 (7.6) 2 (0.4)
5 148 (28.2) 69.6 144 (27.3) 125 (23.8)
* Negative values indicate an increase in NPRS. 
ξ Presented are the number of patients and percentage of total population.





Patients treated with the active control patch (14.3%) showed a 30.2% reduction in NRPS 
from baseline at week 12. Patients treated with the 8% capsaicin patch (14.5%) showed a 
mean 24.7% reduction in NRPS from baseline at week 12.
Subgroup 5
This subgroup included all patients that showed a large reduction in NRPS scores in week 
1, with a further progressive decrease in NRPS scores during the time course of the study. 
For patients treated with the high-dose patch, subgroup 5 was the largest subgroup 
including 36.6% of the patients. Their mean reduction in NRPS scores from baseline 
at week 12 was 67.4% (Table 3). A similar treatment effect at week 12 was observed for 
patients treated with the active control assigned to subgroup 5 (28.2% of the study 
population): a 69.6% reduction in NPRS. Differences between treatment groups were the 
different proportion of patients responding with 30% and 50% reduction in NRPS (Table 
3) and the proportion of patients allocated to this subgroup.
Covariate analysis
Significant covariates detected in the analysis of the NRPS data of patients treated with 
the high-dose capsaicin patch were age, duration of disease, concomitant opioid use, 
variability in the NRPS observed in the 14-day pre-study run-in phase, baseline NPRS and 
NPR scores after lidocaine pretreatment (before capsaicin patch application). There was 
some overlap in significant covariates between treatment groups (age, baseline NPRS 
and run-in pain score variability were significant predictors in both treatment groups). 
For the low-concentration capsaicin treatment, the following covariates were further 
identified: age, concomitant use of anticonvulsants, sex, NPRS after capsaicin patch 
removal and baseline NPRS.
Our analysis allowed a separate quantification of covariate behaviour among the five 
subgroups. As expected, covariate effects differed between subgroups. Figure 4 shows 
the probabilities of belonging to subgroups 2, 4 and 5 as a function of the significant 
predictor variables upon treatment with capsaicin 8% and active control. The covariates 
showed limited predictive effect on the other subgroups (data not shown).
Capsaicin 8% treated patients (Figure 4A–F)
In patients treated with capsaicin 8%, age affected the probabilities of belonging to 
subgroups 2 and 5 (Figure 4A): the probability of belonging to subgroup 5 decreased with 
increasing age (45% at age 50 years, 33% at 80 years); the reverse was true for belonging 
to subgroup 2, where the probability of belonging to that response profile increased with 
the patient age at the time of treatment. Duration of disease most importantly affected 
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the probability of belonging to subgroup 5, with a sharp reduction in efficacy of treatment 
with an increase in the duration of disease (in Figure 4B the disease duration range is 0.5–
25 years). A striking observation was the effect of the local anaesthetic pretreatment on 
NRPS scores as predictor of the efficacy of the capsaicin 8% patch (Figure 4C). When pain 
was completely relieved by lidocaine, the cumulative probability of falling in subgroups 4 
and 5 was 70% (subgroup 4 = 32%, subgroup 5 = 38%) and in subgroup 2, 15%. In contrast, 
when pain scores were elevated after lidocaine pretreatment (NPRS = 10), the probability 
of capsaicin 8% treatment success decreased to 5% (subgroup 4) and 20% (subgroup 5), 
and the probability of falling in subgroup 2 increased to 51%. Concomitant opioid use had 
a negative effect on treatment outcome (Figure 4D), as did high baseline pain scores (the 
probability of belonging to subgroup 5 decreased from 50% at baseline NPRS 3 to 20% at 
baseline NPRS 9; Figure 4E). Finally, the variability of pain reporting in the 14 days prior to 
treatment also had a significant impact on treatment efficacy. When variability was high, 
the probability of being in subgroup 5 was almost 80% and in subgroup 2 0%. In contrast, 
Figure 4  Influence of significant covariates on the probability of belonging to specific sub- groups. 
(A–F) Patients treated with capsaicin 8%; (G–L) patients treated with active control. Note that panel 
F has a different y-axis. Values are median probabilities. The covariates showed little predictive 




at low variability (i.e., pain scores were constant over time), the probability was 28% for 
belonging to either subgroup 2 and 5 or 28% (Figure 4F).
Active control treatment (Figure 4G–L)
Covariates age, baseline pain scores and variability in the NRPS observed in the 14-day 
pre-study run-in phase affected probabilities of subgroup 2 and 5 participation similar to 
those observed following capsaicin 8% treatment (Figure 4G,K,L). Further, gender effects 
(Figure 4H: men have a higher probability of falling in subgroup 2 compared to 5, while 
for women, the probabilities are similar), NRPS after control patch removal (Figure 4I) and 
the use of anticonvulsants (Figure 4J) were significant predictors of effect.
Model parameters
The parameter estimates are given in Table 4 and discussed in Appendix 1.
DISCUSSION
In the current analysis, we pooled data from four double-blind, randomized controlled 
trials of the efficacy of the capsaicin 8% transdermal patch (Qutenza) versus an active 
control (capsaicin 0.04% transdermal patch) in PHN. The current novel analysis of the 
pooled dataset consisted of three distinct parts (  1): (1) a longitudinal analysis of the 
NPRS scores, followed by (2) a mixture analysis enabling the division of the data set into 
five distinct response groups; and (3) a covariate analysis aimed at the quantification 
of the covariate-related probability of falling into one of the five subgroups. The more 
common and traditional approach of analysing pain data is by assessing the magnitude 
of change in NPRS from baseline at a predefined time following treatment (e.g., 12 
weeks following treatment) in terms of responder rate (e.g., number of patients having 
30% or 50% reduction in NPRS). This approach neglects the information inherently 
present in the temporal profile of the response data and the possibility of the presence 
of subgroups with real mechanistic between-group differences. This is important 
as therapeutic strategies may differ among different response groups. For example, 
patients in the subgroup that show no treatment response (subgroups 1 and 2 in our 
analysis) are probably better off with a different therapeutic option, while patients that 
show a transient effect (subgroup 3) may benefit from a repeated patch application. We 
recently developed two longitudinal models to characterize the time course of NPRS 
scores in patients with complex regional pain syndrome (treated with ketamine) and 
patients with diabetic polyneuropathy (treated with the capsaicin 8% patch).13,14 Based 
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on the time-course analyses, we detected four response profiles. A drawback of these 
studies was the small number of subjects included and, consequently, the inability to link 
specific predictors to effect profiles.
Response groups
The current analysis yielded five homogenous response groups. Two subgroups showed 
either an increase in pain response or no treatment effect (subgroups 1 and 2). The 
cumulative proportion of patients in these subgroups was 39.9% after treatment with 
capsaicin 0.04% and 24.3% after treatment with Qutenza. The group that showed 
the greatest analgesic efficacy (subgroup 5) contained 36.6% of the population after 
Qutenza and 28.2% after active control. These data indicate that while active control 
response profiles may be similar to those observed from treatment with the test drug, 
the proportional distribution of patients among the five response groups is in favour of 
Qutenza with, compared to the active control, 40% less patients showing no response and 
25% more patients showing a full analgesic effect. Just reviewing the analgesic data of 
the total population would have concluded that both active control and test drug cause 
effective analgesia, albeit with a small advantage of the test drug (Figure 2). The different 
subgroup treatment efficacies may be related to the differences in pain mechanisms and 
a strategy to identify these subgroups will allow mechanism rather than disease-based 
pain treatment.
Predictors of effect
The covariate analysis enabled us to identify factors that may explain why patients 
respond differently to therapy. There was overlap in covariates between treatments (age, 
baseline pain and run-in pain variability). This suggests a similar mechanism of action of 
the test drug and the control. Indeed, the small amount of capsaicin present in the control 
patch may have an analgesic effect. However, six covariates differed between treatment 
groups. This would suggest a difference in the mechanism of action of the two treatments. 
Possibly, the active control patch served as a true placebo treatment, engaging opioidergic 
and non-opioidergic placebo analgesic mechanisms, with the presence of active 
compound in the control patch causing some burning pain on application enhancing 
the placebo response.15 It may be argued that both mechanisms were activated upon 
treatment with the active control patch. An important observation in patients treated 
with the active control is that men had a greater probability of being a non-responder 
compared to women (probability of falling in subgroup 2: men 51% vs. women 29%; Figure 
4H). Previous studies on placebo responses were unable to detect a sex difference in acute 




strongly dependent on the study set-up and patient expectations.
Covariate analysis yielded a set of important predictors that in part may explain the 
efficacy of capsaicin 8% treatment. Increasing age and a longer duration of disease 
reduced the probability of falling into subgroup 5 (Figure 4A and B). These factors are 
possibly interdependent (i.e., an older patient may have a more prolonged disease process 
than a younger patient) but confirm the notion of the complexity of treating chronic pain 
in the elderly. Opioid use and high baseline pain scores reduce the probability of a full 
analgesic response (Figure 4D and E). It may possibly be that the lack of opioid efficacy 
is a symptom of (general) therapy resistance, although further study is required to 
understand this important issue. The finding that run-in pain score variability influences 
the efficacy of treatment (for test drug and active control) is an interesting and novel 
observation. Patients that show high variability in their run-in pain scores have an almost 
80% probability of a full analgesic response and almost 0% probability of falling into 
the non-responder group (Figure 4F). In contrast, low variability (a constant NPRS value 
for 14 days) results in a probability for subgroups 2 and 5 of about 30%. Possibly the low 
variability NRPSs are an indication of a rigid and fully manifested chronic pain process 
with severe central plastic changes unresponsive to therapy. The reverse may be the 
case in patients that experience variable pain scores over time. We believe that this is an 
important first observation that needs further confirmation. Finally, pain scores following 
lidocaine pretreatment over the skin where the capsaicin 8% patch will be applied 
predicted treatment efficacy. The probability of being a non-responder increases from 14% 
at a pain score of zero to 51% at a pain score of 10. The reverse was observed for subgroups 
4 and 5 (Figure 4C). While lidocaine and capsaicin have distinct mechanisms of action, the 
current finding indicates a common target, i.e., the peripheral nerves, and suggests that 
synergistic treatment effects are possible when combining the two treatments.
We restricted our covariate analysis to a set of 14 variables (Table 1). It may well be that 
other factors alone or in combination with the current set may enhance our ability to 
predict therapy efficacy; e.g., by adding functional or neurosensory testing [such as 
quantitative sensory testing (QST), responses to electrical or laser stimulation of the skin, 
conditioned pain modulation (CPM)]. Specific patterns in the QST profile may represent 
specific disease modalities with a greater or lesser probability of therapy efficacy. There 
are various examples in the literature that concur with our suggestion. Eisenberg et al. 
showed that the magnitude of heat pain thresholds predicts the magnitude of reduction 
of pain intensity in response to oxycodone treatment (the greater the heat pain threshold 
the greater the opioid effect; R2 = 0.17) in healthy volunteers.18 Yarnitsky et al. showed 
that patients with less efficient CPM have greater analgesic responses to duloxetine (R2 
= 0.39) in patients with painful diabetic neuropathy.19 We recently showed a significant 
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correlation between the magnitude of CMP and pain relief in patients with chronic 
neuropathic pain and treated with placebo, morphine and ketamine.20 Finally, also 
genetic factors, such as variations in the TRPV1 gene, may be used in predictive analyses 
of treatment effect.
Conclusions and final remarks
Pain data from 1248 patients with PHN and treated with a capsaicin 8% patch or an 
active control were successfully divided into five response groups using time-course 
and mixture analyses. Covariate analysis identified factors that enhanced prediction 
of treatment responses. The most important variables identified include age, disease 
duration, pain score following local anaesthetic pretreatment of the affected skin area, 
baseline pain and pretreatment pain score variability. Further studies should address 
whether incorporation of additional variables (TRPV1 gene-related, sensory testing-
related, symptom-related) may enhance prediction of treatment effect. Our current and 
previous analytical approach provides strong indications of the existence of specific 
subgroups and predicting variables related to treatment of chronic pain patients. This 
indicates not only that our approach may be applied across different chronic pain 
syndromes, but suggests also that our approach is a step towards individually tailored 
treatment. An example could be to treat patients with Qutenza who display a large 
variability in their pain scores at baseline or those patients that respond favourably to 
a baseline trial with topical lidocaine. This latter approach is similar to the approach of 
Campbell et al. who determined the effect of capsaicin as a predictor of topical clonidine 
treatment in painful diabetic neuropathy.21 As discussed by Sindrup and Finnerup and 
shown here, drugs have different efficacies in subgroups of patients, possibly related to 
different pain mechanisms despite a presumed common underlying disease.22
APPENDIX 1: THE LONGITUDINAL MODEL AND MIXTURE ANALYSIS
The longitudinal model was developed within the non-linear mixed effect modelling 
software (NONMEM version VII level 1, ICON Development Solutions, Ellicott City, MD) 
to describe the time course of NPRS following application of the low- (0.04%) and high-
concentration capsaicin path.23 The first-order conditional estimation (FOCE) was used for 
model development. The performance of the analysis was evaluated by various selection 
criteria, including visual inspection of the goodness of fit plot, changes in the objective 
function value and parameter estimates and their respective standard errors. Using 




to a reduction of 6.6 units in objective function value (χ2 distribution) to discriminate 
between two nested structural models after inclusion of one additional parameter. 
Model diagnostic checks of the final model were conducted using R (R-project, version 
2.12.0).
Longitudinal model
The effect of low- or high-concentration capsaicin patches on NPRS was characterized 
using a Bateman function with the following structure:13
Effect = [kONSET / (kONSET − kOFFSET)]⋅ [e−(time⋅kOFFSET) −e−(time⋅kOFFSET)]    (A1)
The Bateman function characterizes the time course of NPRS pain score from week 0 
(baseline) to week 12 in terms of two first-order rate constants describing the onset 
(kONSET) and offset (kOFFSET) of the effect following the application of capsaicin 8%. The 
change in NPRS from week 0 to week 12 was computed as follows:
NPRS(t)=NPRS0 ⋅(1−α⋅Effect)      (A2)
where NPRS0 is the NPRS pain score at baseline and α is the magnitude of effect. Random 
effects were included in the longitudinal model provided that the parameters are either 
normally or log-normally distributed. For example, the parameter a was modelled 
assuming a normal distribution allowing for the estimation of negative values of the 
parameter a (increase in NPRS pain score):
αj =θα +ηj         (A3)
where αj is the estimate of a for the j-th individual and θα represents the population 
estimate for the parameter α. η
j
 describes the interindividual variability on α, which 
is assumed to be a normally distributed random effect variable with mean zero and 
variance ω2. Similarly, the interindividual random effect variables for NPRS0 and kONSET 
were assumed to be normally distributed. The interindividual variability random effect 
variable for kOFFSET was assumed to be log-normally distributed.
Residual variability, which is a measure of the unexplained variability (including error 
associated with reporting of chronic pain outcome), was described using an additive 
error model:
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NPRSobs,ij = NPRSpred,ij + εij        (A4)
where the residual variability, eij, at time point i for individual j, is a normally distributed 
random effect variable with mean zero and variance σ2.
Mixture analysis
Aside from the advantage of analysing the longitudinal data within a mixed effect 
model framework, the NONMEM software allows for the definition of a mixture model, 
in which the existence of subgroups of patients that respond differently to the assigned 
treatment can be explored. For this analysis, it is assumed that the structural model is 
the same for subgroups, but that patients may differ in their onset and offset of response 
and also may respond differently to treatment in terms of magnitude of response. To this 
end, the parameters, kONSET, kOFFSET and α are assumed to be distributed multi-modally and 
the mixture feature in NONMEM is used to differentiate between subgroups of patients 
on the basis of the parameter distributions. Based on visual inspection of the individual 
data, the mixture model was defined to separate five distinct subgroups of patients.
Results
The data were adequately fitted to the model and a clear separation among the five 
subgroups was achieved. Among treatments, the most important differences occurred in 
the proportion of patients falling in a specific subgroup (Table 3): almost twice as many 
patients on active control were in subgroup 2 (i.e., non-responders) compared to patients 
treated with capsaicin 8% (39% vs. 22%), while more subjects on capsaicin 8% fell into 
subgroup 5 (37% vs. 28%). Table 4 gives the parameter estimates including measures of 
between-subject (ω2) and residual variability (σ2). Parameter α showed little difference 
among treatment groups, indicating that both treatments were equally effective in terms 
of magnitude of effect of the five subgroups. Values of α ranged from -0.18 (subgroup 1) 
to 0.6 (subgroups 3 and 5) for patients treated with capsaicin 8% and from -1.4 (subgroup 
1) to 0.7 (subgroups 3 and 5) for patients treated with active control. A negative value for 
α indicates that pain scores increased with treatment. Since pain scores did not change 
in subgroup 2, a value for kONSET could not be estimated for this subgroup. No offset in 
effect (return towards baseline) in subgroups 1, 2, 4 and 5 was presents (i.e., their kOFFSET 
= 0). Only for subgroup 3, a kOFFSET was detected: 0.48/week versus 0.27/week for active 
control and 8% capsaicin treatments, respectively. These rate constants are equivalent to 
half-life of 1.4 weeks (active control) and 2.6 weeks (capsaicin 8%) and indicate that every 
1.4 and 2.6 weeks the NPRS increases by 50%. The difference in values is due to the faster 





Table 4  Model parameter estimates
Subgroup 1 Subgroup 2 Subgroup 3 Subgroup 4 Subgroup 5
Treatment with capsaicin 8% (n = 722)
Parameter estimates
NPRS0 5.70 ± 0.06 5.70 ± 0.06 5.70 ± 0.06 5.70 ± 0.06 5.70 ± 0.06
KONSET (week-1) 1.31 ± 0.09 - 1.31 ± 0.09 1.31 ± 0.09 1.31 ± 0.09
KOFFSET (week-1) 0 0 0.27 ± 0.04 0 0
α -0.18 ± 0.05 0 0.61 ± 0.04 0.24 ± 0.04 0.61 ± 0.04
Between patient variability (ω2)
NPRS0 2.43 ± 0.12 2.43 ± 0.12 2.43 ± 0.12 2.43 ± 0.12 2.43 ± 0.12
α - - 0.15 ± 0.03 - 0.15 ± 0.03
KONSET (week-1) 0.70 ± 0.10 - 0.70 ± 0.10 0.70 ± 0.10 0.70 ± 0.10




Treatment with capsaicin 0.04% (n = 526)
Parameter estimates
NPRS0 5.68 ± 0.07 5.68 ± 0.07 5.68 ± 0.07 5.68 ± 0.07 5.68 ± 0.07
KONSET (week-1) 1.06 ± 0.09 - 1.06 ± 0.09 1.06 ± 0.09 1.06 ± 0.09
KOFFSET (week-1) 0 0 0.48 ± 0.08 0 0
α -1.40 ±0.82 0 0.71 ± 0.03 0.27 ± 0.01 0.71 ± 0.03
Between patient variability (ω2)
NPRS0 2.50 ± 0.14 2.50 ± 0.14 2.50 ± 0.14 2.50 ± 0.14 2.50 ± 0.14
α - - 0.17 ± 0.04 - 0.17 ± 0.04
KONSET (week-1) 0.52 ± 0.09 - 0.52 ± 0.09 0.52 ± 0.09 0.52 ± 0.09
KOFFSET (week-1) - - 1.12 ± 0.21 - -
Residual variability (σ2)
0.40 ± 0.03 0.40 ± 0.03 0.40 ± 0.03 0.40 ± 0.03 0.40 ± 0.03
NPRS0 = numerical pain rating score at baseline;
KONSET = fi rst-order rate constants describing the onset of effect;
KOFFSET = fi rst-order rate constants describing the offset of effect;
α = magnitude of analgesic effect.
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Many patients with chronic cancer and non-cancer pain experience episodes of 
breakthrough pain, which is defined as “a transitory exacerbation of pain that occurs on a 
background of otherwise stable pain while using long-term, around-the-clock analgesics 
to control chronic pain”.1,2 Breakthrough pain is usually treated with rapid onset opioid 
analgesics and a number of formulations using different administration routes are 
available, including intranasal, sublingual, oral transmucosal and transbuccal routes.2,3 
For effective treatment of breakthrough pain, or any other form of severe acute pain, a 
rapid onset of action is important. Most studies that assess the efficacy of rapidly acting 
opioids in immediate-release formulations use a fixed time-point at which superiority of 
one treatment over another is assessed (eg. 15 or 30 min following drug intake) without 
taking into account the full temporal profile of analgesic effect.2,4,5
A relatively new treatment option for breakthrough pain is the use of orodispersible 
(ie. disintegrating or melt) tablets (OT) of lipophilic opioids that are applied on or 
under the tongue and that give a rapid onset of analgesia. The OT melts in the mouth 
but is predominantly absorbed in the gut. Few studies have characterized the onset of 
analgesia of orodispersible tablets. Rauck et al.6 showed a significant reduction in pain 
intensity at 10 min following administration of sublingual orodispersible fentanyl. In 
the current study we quantified the antinociceptive effect of a 20 mg orodispersible 
oxycodone tablet (OOT) in a population of healthy volunteers. We recently showed that 
a longitudinal pharmacodynamic analysis provides important information on the onset 
and offset of action of analgesic treatment and argued that this approach is superior to 
analysis of effect at fixed time points during the course of treatment.7-9 In the current 
study we applied a modified pharmacodynamic analysis to overcome some of the 
problems of the previous analysis using two experimental pain models (electrical and 
pressure pain) over a 5-hour test period. The effect of OOT was assessed relative to an 
active placebo comparator, a 500 mg paracetamol orodispersible tablet (POT), using a 
randomized, double blind and crossover design. 
The main aim of the study was to quantify the temporal antinociceptive profile of 
administration of OOT versus POT. We hypothesize that oxycodone produces greater 
analgesia than the active comparator and meaningful analgesia, as defined by a 30% 






Healthy female volunteers were recruited to participate in the study performed at 
Leiden University Medical Center after approval of the protocol by the local Medical 
Ethics Committee. Female volunteers were chosen for reasons of availability and the 
fact that most drug trials systematically exclude females. The trial was registered 
(ISRCTN59463510) at controlled-trials.com and recruitment lasted from 1 January, 2013 - 1 
March 2013. All participants gave written informed consent and underwent a physical 
examination before enrollment in the study. Inclusion criteria were: age 18 - 65 years, 
body mass index 18 - 35 kg/m2 and body weight 50 - 100 kg. Exclusion criteria included: (a) 
a history of mental health problems; (b) a history of alcohol or substance abuse; (c) two 
or more of alcohol units/day; (d) positive pregnancy test; (e) not using oral contraceptives, 
not surgically sterilized, or not post-menopausal; (f) a history of allergic or anaphylactic 
reaction or significant intolerability to prescription or non-prescription drugs or food, 
and (g) any other condition that in the opinion of the investigator would complicate or 
compromise the study, or the well-being of the subject.
Study design
In this randomized, double blind, active-comparator, crossover study, subjects were 
randomized to receive one orodispersible oxycodone 20 mg tablet (OxyNorm Instant, 
Mundipharma Pharmaceuticals BV, Hoevelaken, The Netherlands) on one occasion 
and placebo (one paracetamol 500 mg orodispersible tablet; Roter, Hilversum, The 
Netherlands) on another occasion. One week was allowed for washout. The subjects 
were requested to fast for at least 6-hours prior to the intake of study medication. The 
tablets were placed under the tongue; the subject was not allowed to swallow until the 
drug had completely disintegrated. To assess the analgesic treatment efficacy, electrical 
and pressure nociceptive assays were applied. Prior to the study the subjects were 
familiarized with both pain tests. 
Electrical noxious stimulation
A locally designed and manufactured transcutaneous electrical stimulation device 
(TES) was used to create a constant current electrical stimulus train (stimulation at 20 
Hz, pulse duration 0.2 ms).12 The device was attached to 2 surface electrodes that were 
applied on the skin over the tibial bone of the non-dominant side. The location of the 
electrodes was chosen such that the electrical stimulation did not cause any muscle 
contraction. The current over the electrodes was increased from 0 mA at a rate of 1 mA/s, 
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with a cutoff of 128 mA. The subjects were instructed to indicate when the stimulation 
became painful (electrical pain threshold, EPTh) by pressing a button on a control box. By 
pressing a second button the subjects could end the stimulus train when the pain was 
perceived as intolerable (electrical pain tolerance, EPTol). Prior to drug administration 
baseline values were obtained. To that end, three tests were performed at 5 min intervals. 
The three currents obtained for pain threshold and tolerance were averaged and served 
as baseline values. Following treatment, TES was applied at t = 5, 10, 15, 20, 25, 35, 45, 55, 
65, 75, 85, 95, 110, 125, 140, 170 200, 230, 260 and 290 min. 
Pressure pain
An FPN 100 N Algometer (FDN 100, Wagner Instruments Inc., Greenwich, CT) was used to 
deliver pressure pain on an area of 1 cm2 between thumb and index finger.13 The FDN 100 
has a force capacity (± accuracy) of 100 ± 2 N (10 ± 0.2 kgf) and graduation of 1N (100 gf), 
respectively. A gradually increasing pressure was manually applied and the subjects were 
asked to indicate when the procedure became painful (pressure pain threshold, PPTh). 
The pressure was then released. Following treatment, the pressure test was applied at t 
= 30, 60, 90, 120, 180, 240 and 300 min.
Randomization and blinding
Randomization was performed by the local pharmacy using a computer-generated 
randomization list. The pharmacy repackaged the tablets into unmarked and identical 
containers. The repackaged tablets were allocated 1:1 on the morning of the study 
ensuring blinding of volunteers and investigators.
Conventional statistical analysis
The study was powered to detect a 25% difference in treatment effect on EPTol (SD 
25%, power 0.9). To determine the effect of treatment, a two-way analysis of variance 
was performed (factors treatment, time and treatment x time). Comparisons of time-
effects5,14 and the area-under-the time-response curves (AUC), determined from the 
linear trapezoid rule, were compared using t-tests. The statistical analysis was performed 
with the R statistical package (version 2.8, R-project; www.r-project.org); the comparisons 
were 2-sided with p-values < 0.05 considered significant.
Pharmacodynamic analysis
A longitudinal pharmacodynamic model was developed to describe the time course of 
the pain responses of primary end-points EPTol, EPTh and PPT, following administration 




effect modeling software NONMEM version VII (ICON Development Solutions, Elliott 
City, MD). The pharmacodynamic model consisted of a modified Bateman function that 
describes the time course of the response in terms of two first-order rate constants 
describing the waxing (with rate constant kON) and waning (with rate constant kOFF) of 
the response. The model is of the form: 
Effect(t) = BLN · [1 + EFF · BF(t)] + TRD/300 · t     (A1)
where t is time, BLN is the baseline value of the measured variables (EPTh, EPTol and 
PPTh), EFF the maximum observed drug effect (effect at TMAX where BF(t = TMAX) has a 
maximum possible value of 1), TRD a trend term and BF the modified Bateman Function 
with (cf. Martini et al.8):
BF =[e-kOFF · t – e-kON · t]/[(kON/ kOFF)-kOFF/(kON – kOFF) – (kON/ kOFF)-kON/(kON – kOFF)]   (A2)
In case kON = kOFF = k, the modified Bateman Function, BF(t), equals k · t · e(-k·t + 1). The time 
to maximum effect, TMAX, was calculated as follows:
TMAX = log(kON/kOFF)/(kON-kOFF), when kON ≠ kOFF     (A3)
and
TMAX = 1/k, when kON= kOFF       (A4)
Random effects were included in the model allowing for assessment of between-subject 
variability (ω2) and within-subject or residual variability (σ). Analysis was performed 
simultaneously on the complete data set allowing discrimination of drug effect on EFF, 
kON and kOFF. p-values < 0.01 were considered significant. In the analysis the responses 
to oxycodone and paracetamol were assumed to be independent, as inter-occasion 
variability of the measured pharmacodynamic responses is large, no pharmacokinetic 
data were obtained and the two drugs have different mechanisms of action. 
Bootstrap Analysis and Area-Under-The-Curve (AUC) Calculation
A bootstrap validation procedure was performed to obtain the probability distributions 
of model parameters and derived parameters, such as TMAX and AUC. One-thousand 
bootstrap data sets were simulated by including 12 random subjects to the oxycodon 
group and 12 random subjects to the paracetamol group. Model parameters and derived 
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parameters were estimated from each bootstrap data set. Quantiles of the parameter 
distributions were calculated using the statistical program R, and yielded 95% confidence 
intervals, and medians for internal validation.
As a measure of effect, AUCs were calculated as follows:
for kON = kOFF:  AUC =  EFF · e/[kON · (1-(1+ kON · TEND) · e(-kON · TEND))],    (A5)
for kON≠ kOFF:  AUC = EFF · [(1-e(-kOFF · TEND))/kOFF – (1-e(-kON · TEND))/kON] /
[(kON/kOFF)(-kOFF/(kON - kOFF) – (kON /kOFF)(-kON/(kON - kOFF))]     (A6)
where TEND is the end of study time (300 min). All AUC’s given are divided by the 300 (the 
duration in min of the study) to give an average end-point value over time. 
Side effects
Heart rate and oxygen saturation (using a finger pulse oximeter) were monitored 
throughout the studies. In case of oxygen saturation levels below 94%, oxygen could 
be administered through a facemask. All incidences of nausea, vomiting and dizziness/
lightheadedness were scored; all none expected side effects were noted as well.  
Figure 1  Mean treatment responses (± standard error of the mean) for pain tolerance (A), pain 





Twelve volunteers were enrolled and completed the study with mean age 22 (range 
18-31) years, weight 68 (53-94) kg and height 174 (160-199) cm. In none of the subjects 
respiratory issues were clinically observed. 
Conventional analysis
In Figure 1 the mean responses are given for all three pain indices. Significant treatment 
and treatment x time effects were observed for EPTol (p < 0.001), EPTh (p < 0.01) and 
PPTh (p < 0.01). For EPTol a significant difference between OOT and POT responses was 
observed from t = 45 to t = 170 min (from t = 45 to 55 min, p < 0.05; from t = 65 to 170 min, 
p < 0.01). In contrast, for EPTh a difference in effect between treatments was observed at 
t = 65 only (p=0.02). For PPTh treatments differed at t = 30 (p < 0.001), 60 (p = 0.01) and 
90 min (p = 0.02). The AUC differed only for EPTol between treatments: OOT 9.2 ± 2.2 vs. 
POT 2.1 ± 1.0 (p < 0.05). Variability in the responses was large with the greatest variability 
observed for EPTh (coefficient of variation of the AUC of the measured pain response 
data = 61-87%), followed by EPTol (60-64%) and PPT (32-51%) (Figure S1).
Pharmacodynamic analysis
As judged by the eye, the data were adequately fitted by the pharmacodynamic model, 
irrespective of end-point or treatment. For both treatments, best, median and worst 
data fits for electrical pain tolerances are given in Figures 2 (OOT) and S2 (POT) with the 
corresponding data fits for electrical pain threshold and pressure pain threshold. The 
model parameter estimates are given in Table 1. 
Transcutaneous electrical stimulation
20 mg OOT produced an increase in EPTol and EPth response currents but its effect on 
pain tolerance was more potent (parameter EFF is 2.2 greater for tolerance than threshold, 
Table 1). For both indices, the 500 mg paracetamol orodispersible tablet produced about 
14% of the analgesic efficacy of oxycodone. The response profile over time was similar for 
paracetamol and oxycodone and for threshold and tolerance with identical values for kON 
and kOFF  (paracetamol vs. oxycodone and tolerance vs. threshold, χ2-test: p > 0.05).  The 
onset and offset of the response differed significantly (p<0.01) with a more rapid onset 
(t1/2kON = 45 min) than offset (t1/2kOFF = 154 min). 
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Figure 2  Examples of oxycodone data fits. Best (A), median (C) and worst (E) data fits of electrical 
pain tolerance data (as determined by the coefficient of determination, R2) are shown, with 
corresponding fits for electrical pain threshold (A, C and E) and pain pressure threshold (B, D, F). 
Closed circles denote the measured electrical pain tolerance data, open circles the measured 
electrical pain threshold data, open squares the measured pressure pain threshold data. The lines 





The effect of OOT on pressure pain threshold was comparable to that on the electrical 
pain threshold in terms of potency (parameter EFF for both indices ≈0.4), Table 1). 
Paracetamol’s analgesic effect relative to that of oxycodone was not different from that 
observed in the electrical pain assay. In contrast to the observations in the electrical pain 
model, the rate constants for onset and offset did not differ (t1/2k = t1/2kON = t1/2kOFF = 30 
min, p > 0.05). The k-value was similar in paracetamol and oxycodone treatment groups. 
Population responses
Population pharmacodynamic responses are given in Figures 3A and B, showing the 
difference in effect of treatment on the magnitude and the temporal profile between 
(and within) electrical and pressure pain models. In panels C and D of Figure 3, the 
percentage change relative to baseline of the oxycodone responses are plotted. The time 
to an increase in baseline responses of 30% are given as an index of clinical relevant 
effect.10,11 For electrical pain, a 30% increase was observed at t = 15 and 41 min for EPTol 
and EPTh respectively; for pressure pain at t = 18 min. 
Bootstrap analysis
The results of the bootstrap validation process are given in Table S1, showing good 
correspondence with the pharmacodynamic parameter estimates (Table 1). Additional 
values were computed including TMAX (time of peak analgesic effect; 111 and 43 min in 
the electrical and pressure pain models, respectively, for both treatments) and the various 
AUCs.  
Side effects
Following oxycodone administration, five subjects experienced nausea, two of which 
vomited. Three subjects experienced dizziness/lightheadedness. In none of the subjects 
saturation levels dropped below 94%. Following paracetamol administration, one subject 
became nauseated. 
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Table 1  Parameter estimates of the longitudinal pharmacodynamic model
Estimate ± SE ω2 ± SE
Electrical pain threshold and tolerance
Baseline threshold (mA) 8.9 ±  1.3 0.46 ± 0.10
Baseline tolerance (mA) 12.6 ± 1.5 0.40 ± 0.09
KON (Electrical Pain) (min-1) 0.015 ± 0.003 0.48 ± 0.30
kON (Electrical Pain)/kOFF (Electrical Pain) 2.44 ± 1.90 3.60 ± 2.63
EFF threshold* 0.43 ± 0.15 1.20 ± 0.54
EFF tolerance* 0.96 ± 0.32 0.42 ± 0.21
σ 1.88 ± 0.31 -
Pressure pain threshold
Baseline value (gf) 422 ± 29 0.19 ± 0.05
k(Pressure Pain)/kON(Electrical pain)# 1.50 ± 0.20 -
EFF* 0.40 ± 0.09 0.49 ± 0.24
σ 57.5 ± 8.4 -
Trend term
TRD (mA/min) 0 (FIX) 0.04 ± 0.04
Paracetamol versus Oxycodone
* Relative paracetamol effect (%) 14.1 ± 4.8 -
Values are median ± SE. kON is the rate constant of the waxing response, kOFF is the rate 
constant of the waning response. # for pressure pain k = kON(Pressure Pain) = kOFF
(Pressure Pain). * EFF is the oxycodone effect with the relative paracetamol effect as % 
of the oxycodone EFF. ω2 is the between-subject variability (in the log-domain), σ is the 






The analgesic effect of orodispersible oxycodone was quantified with a mathematical 
model of analgesia evolution based on a modified Bateman function. The oxycodone 
formulation displayed analgesia greater than placebo with a faster onset than offset for 
electrical pain (t1/2kON = 45 min, t1/2kOFF = 154 min) but similar onset and offset values for 
pressure pain (both 30 min). The analgesia efficacy parameter showed that oxycodone 
produced greater analgesia as determined from EPTol (EFF = 2.2) than either EPTh or PPTh 
(EFF = 0.4). Paracetamol had little effect on any of the three end-points (analgesic effect 
14% of that of oxycodone). 
Conventional statistical analysis versus longitudinal analysis
Most clinical studies on the efficacy of acute pain medication test pain relief at fixed 
time points following the intake of study medication by comparing the effect to placebo 
using t- or comparable tests at predefined time points. For example, Schachtel et al.5 
used an onset-of-action model to assess the onset of analgesia by the flurbiprofen 
lozenge in patients with a sore throat by performing pain intensity assessments at 
2-min intervals (30 measurements per hour). They observed first significant pain relief 
by conventional analysis (ie. pain relief from treatment > placebo) at t = 26 min, while 
patients perceived reduction of throat pain already after 12 min. Our analysis allows 
assessment of the temporal profile using a sparse data sampling approach (for example, 
just 7 measurements in 5 hours were obtained using the pain pressure method). Despite 
the relatively restricted number of assessments, a reliable estimation of onset and offset 
(in terms of rate constants) of oxycodone effect could be made. Furthermore, the analysis 
allows estimation of times to a specific predefined response effects, such as a 30 or 50% 
increase in response thresholds. We present the 30% change in response thresholds 
(Figure 3) that, although somewhat arbitrary, is considered by us equivalent to a clinical 
significant effect in clinical trials, defined by a 30% reduction in pain indices.10,11 The 30% 
increase in response thresholds was observed after 15 (EPTol), 41 (EPTh) and 18 min (PPTh) 
(Figure 3). Using conventional statistics, significant differences relative to placebo were 
first observed after 45 (EPTol), 65 (EPTh) and 30 min (PPTh). Finally, our pharmacodynamic 
analysis, in contrast to conventional statistical analysis, gives a parameter for magnitude 
of effect (EFF), which allows comparison to other compounds (such as the comparison to 
the active placebo comparator in our current study or comparison among other strong 
opioids).
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Experimental versus patient studies
In contrast to others (e.g. Rauck et al.6; Schachtel et al.5), we did not assess pain relief in 
pain patients but performed our studies in healthy volunteers. Our approach is not only 
more practical but it yields data not contaminated by various patient-related factors. 
One such factor is the presence of large variability in pain over time within and among 
pain patients.8 Other factors include co-medication, underlying disease (for example, 
repetitive hypoxic events due to sleep-related breathing disorders may enhance opioid 
sensitivity)15 and past experiences with pain medication. Since the pain stimuli we 
applied are different from pathophysiological pain, the question remains whether our 
analysis also applies to patients. We argue that the temporal profile we observed may be 
be applicable to patients as well, albeit with some caution. We previously assessed the 
Figure 3  The simulated typical pharmacodynamic response to 20 mg oxycodone (blue lines) and 
500 mg paracetamol (orange lines) orodisperisble tablets. (A) Electrical pain tolerance (continuous 
lines) and electrical pain threshold (broken lines). (B) Pain pressure threshold. (C) Electrical pain 
tolerance (continuous lines) and electrical pain threshold (broken lines) as percentage of the 
baseline value. The times to an increase of 15% in tolerance and threshold responses are 6.5 and 
14.5 min, respectively. (D) Pain pressure threshold as percentage of baseline value. The time to 15% 




temporal profile of the morphine analgesia in healthy volunteers using an electrical pain 
assay and observed an effect half-life for pain threshold of 1.6 h.14 Mazoit et al. observed 
a similar value (1.7 h) in patients being treated with morphine for postoperative pain.16 
These data suggest similarities in the temporal profile of drug-induced pain relief using 
experimental and clinical pain as study end-points. Still, caution in blind extrapolation 
of our results is warranted and we will perform a patient study to validate our current 
results.   
The modified pharmacodynamic model
We previously performed a longitudinal analysis of the effect of capsaicin 8% topical 
treatment in patients with postherpetic neuralgia.8 The current analysis is a modification 
to the previous one.  This was deemed necessary since in the previous analysis both the 
AUC of the response and the maximal effect of the Bateman function (BF) depend on 
kON and kOFF. Consequently, this implies that parameter EFF, a measure of potency, is 
confounded by the onset and offset characteristics causing difficulty in its interpretation. 
The modified Bateman function is normalized in such a way that its minimum value is 0 
and its maximum value is 1, independent of kON and kOFF, so that parameter EFF indicates 
the maximum effect possible (at the dose administered).
Comparing oxycodone to paracetamol
Pain trials are commonly performed with either a placebo or active comparator. In the 
current study we applied an active comparator, the paracetamol orodispersible tablet. 
As expected, paracetamol at this low dose produced a relatively small analgesic effect 
in any of the end-points with 14% efficacy compared to oxycodone. Just 8/12 subjects in 
the electrical pain model and 3/12 in the pressure pain model showed modest analgesic 
responses following POT. Similar observations were reported previously by Moore et al. 
on paracetamol.17 Hence, taken the lack of a significant “placebo” effect, the use of the 
weak POT served as an effective method to blind the study. In future studies comparators 
such as intranasal fentanyl or orodispersible buprenorphine may be used which allows 
the same blinding but with a greater analgesic effect. 
Interestingly, we observed that two subjects did not respond to oxycodone treatment 
in both nociceptive models. We relate this to genetic factors, probably reduced activity 
of the CYP2D6 enzyme, which causes less production of oxycodone’s active metabolite 
oxymorphone (the data from both subjects were included in the analyses). Zwisler et al. 
showed in healthy volunteers that reduced CYP2D6 activity is associated with reduced 
antinociceptive responses.18
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Electrical pain versus pressure pain models
The effect of OOT on the electrical and pressure pain models differed in temporal profile 
with a more rapid analgesic onset/offset observed in the pressure pain model (Tables 1 
and S1, Figures 3A and B). To further explore possible differences among these nociceptive 
models we compared the individual potency (EFF) and residual variability (R2) estimates 
Figure 4  (A) EFF parameter values (see eq. (A1)) from the electrical pain tolerance data analysis 
(x-axis) plotted against EFF values from the electrical pain threshold data analysis (y-axis). Pearson’s 
correlation coefficient (ρ) = 0.86, p < 0.0001. (B) EFF parameter values from the electrical pain 
tolerance data analysis (x-axis) plotted against EFF values from the pressure pain threshold data 
analysis (y-axis). 
ρ = 0.13, p = 0.53. (C) The coefficient of determination from electrical pain tolerance data fits (x-axis) 
plotted against the coefficient of determination derived from electrical pain threshold data fits. ρ 
= 0.68, p < 0.01. (D) The coefficient of determination from electrical pain tolerance data fits (x-axis) 
plotted against the coefficient of determination from pressure pain threshold data fits. ρ = 0.22, p = 
0.31. (A-D) Each dot represents data from one individual. (A and C) The continuous line is the linear 




of the three indices that were measured (Figure 4). As expected we observed a close 
correlation between EPTol and EPth values for potency (Figure 4A) and variability (Figure 
4C). No correlation was present between PPT and EPTol potency and variability estimates 
(Figures 4B, 4D), a clear indication of the neurophsyiological differences between the 
electrical and pressure pain assays. While skin pressure pain elicits activation of Aδ and 
C-fibers, electrical pain stimulation of the skin bypasses the nerve endings and direct 
stimulation of the sensory and non-sensory nerves occurs, with also differentiation in 
central processing and modulation.19 It is therefore within expectation that oxycodone 
interacts differently between the two pain models. While pressure pain has the advantage 
of being more physiological, the electrical stimuli are easily controlled and consequently 
the electrical nociceptive model is widely used, especially in pharmacological trials.19
CONCLUSIONS
Orodispersible oxycodone 20 mg produced analgesic effects in two experimental pain 
models that was well described by a novel mathematical pharmacodynamic model in 
terms of onset and offset of effect and analgesic efficacy, despite sparse data sampling. 
This analytical approach has advantages over conventional statistical analyses as it, for 
example, allows the accurate estimation of the response times to specific events such 
as the time to a 30% (a measure of clinical importance) increase in response thresholds. 
For OOT, the response to a 30% increase in response threshold was rather variable and 
ranged from 15 to 41 min, depending on the end-point chosen. Future studies should 
incorporate patients and potent opioid comparators. 
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Additional Supporting Information was published in the online version of this article:
Figure S1  Influence of 20 mg oxycodone and 500 mg paracetamol orodispersible tablets on electrical 
pain threshold (A and D), electrical pain tolerance (B and E) and pressure pain threshold (C and F). 







Figure S2 Examples of paracetamol data fits. Best (A), median (C) and worst (E) data fits of 
electrical pain tolerance data (as determined by the coefficient of determination, R2) are shown, 
with corresponding fits for electrical pain threshold (A, C and E) and pain pressure threshold (B, D, 
F). Closed circles denote the measured electrical pain tolerance data, open circles the measured 
electrical pain threshold data, open squares the measured pressure pain threshold data. The lines 
are the data fits.
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Baseline threshold (mA) 6.3 9.0 11.5
Baseline tolerance (mA) 9.5 12.7 15.7
t1/2kON (min) 25 44 67
t1/2kOFF (min) 63 156 552
EFF threshold oxycodone 0.19 0.43 0.87
EFF tolerance oxycodone 0.39 0.95 1.71
EFF threshold paracetamol 0.02 0.07 0.12
EFF tolerance paracetamol 0.06 0.14 0.26
TMAX (min) 75 111 170
AUC/300 threshold oxycodone (mA/min) 0.147 0.337 0.706
AUC/300 tolerance oxycodone (mA/min) 0.322 0.732 1.400
AUC/300 threshold paracetamol (mA/min) 0.019 0.051 0.090
AUC/300 tolerance paracetamol (mA/min) 0.040 0.112 0.201
Pressure Pain Threshold
Baseline (gf) 364 421 487
t1/2k (min) * 16 30 48
EFF oxycodone 0.21 0.40 0.67
EFF paracetamol 0.03 0.06 0.10
TMAX(min) 24 43 70
AUC/300 oxycodone (gf/min) 0.093 0.218 0.408
AUC/300 paracetamol (gf/min) 0.012 0.031 0.061
Overall relative paracetamol effect
Effect (%) 7.0 14.8 30.1
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Pain perception is dependent on several modulatory mechanisms that transform 
afferent nociceptive input into the sensation of pain.1 Such endogenous pain modulatory 
mechanisms may be inhibitory or facilitatory and determine the intensity of the 
painful sensation (ranging from no pain to extremely painful) following a noxious 
event. An inhibitory mechanism that may be activated under experimental conditions 
is conditioned pain modulation or CPM; CPM is a surrogate biomarker of endogenous 
modulation of pain2-5 and is the human equivalent of diffuse noxious inhibitory controls 
or DNIC in animals. In the case of DNIC, a spinal-medullary-spinal feedback loop (without 
the involvement of higher brain centers) is engaged, causing the inhibition of a primary 
noxious stimulus by a spatially separated secondary noxious event due to inhibition of 
sensory spinal dorsal horn neurons.6 In contrast to DNIC (in animals), CPM (in humans) 
requires activation of supraspinal pathways. For example, in a recent study, Nahman-
Averbuch et al.7 show in an fMRI study that CPM is associated with reduced activity in 
nociceptive brain regions such as the thalamus, insula and secondary somatosensory 
cortex and brainstem. Alike DNIC, CPM is tested by applying a primary (test) nociceptive 
stimulus on one part of the body simultaneously with a secondary (conditioning) tonic 
nociceptive stimulus on a body part remote from the primary site.1-5 Data from healthy 
young volunteers invariably show that the conditioning stimulus inhibits the pain 
perceived from the test stimulus.4,8,9 The current notion is that CPM engages top-down 
inhibitory pathways that originate at higher sites and converge at dorsal horn neurons 
to suppress incoming afferent nociceptive information.10,11 
Apart from CPM, offset analgesia (OA) is another psychophysical paradigm, which 
enables testing of endogenous modulation of pain.7,8,12 In contrast to CPM, OA reflects 
temporal filtering of nociceptive information, and causes robust analgesia upon a slight 
decrease (offset) in noxious stimulus intensity. OA and CPM differ significantly: (1) fMRI 
studies show that OA is associated with an increase in activity in certain brain areas 
such as the anterior insula, dorsolateral prefrontal cortex and brainstem.7 (2) There is no 
correlation between OA and CPM responses;7,8 (3). When affected in chronic pain states, 
CPM but not OA is improved by pharmacotherapy.13,14 These findings indicate that OA and 
CPM engage two distinct endogenous modulatory mechanisms. 
The inability to recruit CPM-related descending inhibitory pain pathways is thought to 
play an important role in the development of chronic pain. For example, patients with a 
less efficient or absent CPM have a higher probability of chronic pain following thoracic, 
abdominal or obstetric surgery.15-17 Similarly, rodents with the genetic predisposition to 




chronic pain following peripheral nerve damage compared to animals with a lesser ability 
to do so.18 Furthermore, in a variety of painful conditions (including complex regional 
pain syndrome; diabetic-, sarcoidosis- and chemotherapy-induced polyneuropathy; 
fibromyalgia; chronic pancreatitis) impaired CPM responses have been observed.13,19-24 
The observation of a link between defects in descending pain control, as tested by CPM, 
and development and chronification of pain suggests that restoration of descending pain 
control may be a valuable analgesic tool. Several analgesics have the potential to activate 
or reinforce descending inhibition as they interact favorably with the neurotransmitter 
systems involved in descending pain pathways. Most important neurotransmitters 
include endogenous opioid peptides, noradrenaline (NA) and serotonin and it is thought 
that their release can produce pain inhibition.10,11 Tapentadol is a relatively new analgesic 
agent that is believed to activate descending inhibitory pain pathways.25 Tapentadol is 
a combined μ-opioid receptor (MOR) agonist and inhibitor of the neuronal reuptake of 
the α2-adrenergic receptor agonist NA.26 Compared to morphine it displays weak agonist 
activity at the μ-opioid receptor (MOR), however, due to synergy between the two 
mechanisms of action, tapentadol has strong antinociceptive and antihypersensitive 
effects, possibly via enhancement of descending inhibitory pathways.27 
We performed a randomized, double blind, placebo-controlled crossover study in healthy 
(pain free) volunteers to quantify the effect of tapentadol and morphine on CPM. 
Morphine, in contrast to tapentadol, is a full MOR agonist without significant effect on NA 
reuptake. Previous data suggest that morphine reduces CPM responses in volunteers.28 
We hypothesize that taken the differences in mechanisms of action of morphine and 
tapentadol and the earlier observation with morphine, these two analgesics behave 
differently in their effect on CPM with a reduction in CPM by morphine and an increase 
in CPM by tapentadol. 
MATERIALS AND METHODS
Ethics statement and trial registration 
Adult volunteers were recruited to participate in this double blind, randomized, placebo-
controlled, crossover study that was performed at Leiden University Medical Center. All 
participants gave written informed consent to participate in the trial. Approval of the 
protocol and consent procedure was obtained from the LUMC Medical Ethics Committee 
and the Central Committee on Research involving Human Subjects (CCMO, The Hague, 
The Netherlands). Trial registration was at www.trialregister.nl under number NTR2716 
(Feb 2011). The protocol and consort checklist are available for review. 




Twelve healthy Dutch-speaking (non-smoking) volunteers of either sex, aged ≥18 years 
with a body mass index < 30 kg/m2, were enrolled in the study Exclusion criteria included: 
known drug allergies, current use of legally prescribed medication; present or past illicit 
substance use; present or past alcohol abuse; history of mental illness; pregnancy and/or 
lactation; any other condition that in the opinion of the investigators would compromise 
the well-being of the subject when participating in this trial. All volunteers were 
instructed to abstain from solids and liquids during the 8 hours before dosing. 
Study Design
After arrival in the laboratory and an initial practice session, the temperatures of the test 
and conditioning stimulus were determined. Next the study medication was ingested. 
CPM responses were obtained 60-90 and 120-150 min after drug intake. 
Treatment
The subjects received placebo (cellulose; fabricated by the local pharmacy), morphine 
immediate release 40 mg (Sandoz BV, Almere, The Netherlands), and tapentadol 
immediate release 100 mg (Grünenthal BV, Breukelen, The Netherlands) tablets on 
separate occasions. The order of administration was random. At least two weeks 
was allowed between treatments for washout. The dose of tapentadol IR was based 
on the observation that in postsurgical dental pain an oral dose of 100 mg IR caused 
pain relief for 4 hours (peak effect after 1-1.5 h).29 The dose of morphine is based upon 
a 2.5-fold greater potency of morphine compared to tapentadol (data provided by the 
manufacturer and Kress et al.30). 
Test stimulus
The test stimulus was a noxious heat stimulus, administered via a calibrated 3×3 cm 
thermal probe connected to the Pathway Neurosensory Analyzer (Medoc Ltd., Ramat 
Yishai, Israel). The thermode was placed on the volar side of the lower part of the (non-
dominant) upper extremity. During noxious testing the subjects scored their pain 
intensity rating on an electronic slider, which ranged from 0 (no pain) to 100 (worst pain 
imaginable). These data on the electronic visual analogue scale (eVAS) were collected 
at 1 Hz for further analysis. To prevent sensitization of the skin, the thermal probe was 
repositioned between different zones on the forearm and ample time was allowed 
between testing. 
The temperature of the test stimulus was determined by applying a series of heat 




to a target temperature of 42 °C and kept constant for 10 seconds. If the eVAS was less 
than 50 mm a next test was performed increasing the target temperature in steps of 1 
°C. The cut-off temperature for these series was 49 °C. The lowest temperature evoking 
an eVAS of at least 50 mm was used during the remainder of the study. This procedure 
was performed, once on each experiment day, before drug administration. Consequently, 
small deviations in test stimulus intensity (but not test target temperature) due to the 
presence of the analgesic were allowed.
Conditioning stimulus (CS)
The CS was applied to the foot and lower leg of the subject (ipsilateral to the site of the 
test stimulus) and consisted of a thermal (cold water) stimulus. To generate the stimulus 
the subject’s lower extremity was immersed into an 84 L water reservoir. The water was 
produced by a rapid counter-current water-cooling system (IcyDip, IcySolutions BV, Delft, 
The Netherlands). Water temperatures in the range of 6°C to 18°C (in steps of 0.5 oC) 
were offered to the subject and the highest temperature that produced an eVAS of at 
least 30 mm was used in the remainder of the study. After the exposure to cold water, 
the subject’s extremity was warmed to normal temperature using warm water collected 
from the counter-current outlet of the IcyDip system. There was at least 1 hour between 
obtaining the optimal test and conditioning stimuli.
Conditioned pain modulation
We applied the method of King et al.19,31 to measure CPM, which was used successfully 
in previous studies from our laboratory.8,14,22 In short, the thermal probe was applied to 
the volar side of the (non-dominant) underarm and its temperature was increased from 
baseline 32 oC (temperature close to skin temperature) to the test temperature (at 1.5 
oC/s) and was kept constant for 30 s. Next, the temperature was rapidly lowered (at 6 
oC/s) to baseline. Each heat test was applied 3 times (with a 3-min rest between tests) 
after which this same sequence was repeated but now combined with the conditioning 
stimulus (immersion of foot and leg in cold water). The conditioning stimulus was applied 
25 s before the test stimulus and continued until the end of the test stimulus. During all 
tests the subjects were instructed to rate the pain intensity of the test stimulus (and not 
the conditioning stimulus) using the eVAS slider. The whole procedure lasted no longer 
than 30 min. See Figure 1 for an overview of the setup used to induce CPM.
Randomization and blinding
Non-restricted randomization and allocation (1:1:1) was performed by the local pharmacy 
using a computer-generated randomization list. To ensure blinding of both investigators 
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and participants, all tablets were recapsulated into identical capsules in form and 
taste. The capsules were dispensed to the research team on the morning of the study 
in containers marked by subject number and visit number. The investigators remained 
blinded to treatment until all data were analyzed.
Data analysis 
The study was powered to detect a difference in CPM of 20 ± 15% (mean ± SD, with α = 
0.05 and 1-β > 0.95) between active treatment (morphine or tapentadol) and placebo 
(SigmaPlot v12.0, Systat Software Inc., San Jose, CA) [8,22]. To quantify the magnitude 
of CPM, the average peak eVAS without (from 3 tests) and with CS (from 3 tests) were 
calculated. Next, CPM responses were calculated to correct for variations in peak response 
between sessions and subjects using the formula:8,14,22
[Peak eVAS (without CS) – Peak eVAS (with CS)] / 
[Peak eVAS (without CS)] × 100%       (1)
Temperatures of test and conditioning stimuli of the three treatment groups were 
compared by one-way analysis of variance. The effect of the conditioning stimulus 
on peak eVAS was tested by two-tailed t-test. To test the effect of treatment on CPM 
Figure 1  The setup used to induce Conditioned Pain Modulation (CPM). The volunteer sits on the bed 
while a thermal test stimulus is applied to the arm via a 3×3 cm thermode (insert top right). The leg 
is placed in a bucket filled with cold water (ie. the conditioning stimulus) and the subject scores the 
heat pain to the arm using an electronic visual analogue scale (insert top middle). The cold water is 




responses, a mixed effect model was applied to the data (factors: treatment, time and 
time×treatment) using package “ImerTest” of the R software package (version 2.8, 
R-project; http://www.r-project.org); post-hoc a linear mixed model was fit to the data to 
assess the significance of difference between active treatment and placebo. p-values < 
0.05 considered significant. Data are presented as mean ± SEM unless otherwise stated. 
RESULTS
Seven men and five women were enrolled from March 2011 to June 2011, aged 26 ± 1 
years and with a body mass index of 23 ± 1 kg/m2 (mean ± SD). All twelve volunteers 
were randomized and dosed and their data were fully analyzed according to protocol 
(Figure 2). None of the volunteers experienced any side effects following treatment with 
placebo, morphine and tapentadol, except for one female subject who became nauseous 
after tapentadol and morphine treatment and vomited after morphine. 
The test stimulus temperatures (heat pain) as determined prior to treatment averaged 
to 47 ± 0.5 oC, 46.6 ± 0.5 oC and 46.9 ± 0.5 oC on placebo, morphine and tapentadol 
experimental sessions (one-way anova: NS). The target conditioning stimulus 
temperatures were 7.9 ± 0.5 oC, 8.1 ± 0.6 oC and 8.3 ± 0.6 oC on placebo, morphine and 
tapentadol experimental sessions (one-way anova: NS). 
Effect of the conditioning stimulus of the eVAS of the test stimulus
In Figure 3 the mean eVAS responses to the test stimulus before (blue dots) and after 
(orange dots) application of the conditioning stimulus are given obtained at 60-90 min 
after drug intake. At that time period, a significant decrease in peak eVAS for placebo 
(peak eVAS without CS = 53 ± 4 mm vs. peak eVAS with CS = 43 ± 5 mm, p < 0.001) and 
tapentadol (45 ± 5 mm vs. 36 ± 5 mm with CS, p < 0.001) was observed, but not for 
morphine (48 ± 5 mm vs. 46 ± 6 mm, p = 0.48). Similarly, at 120-150 min after drug intake, 
a significant decrease in peak eVAS for placebo (peak eVAS without CS = 51 ± 5 mm vs. 
peak eVAS with CS = 40 ± 5 mm, p < 0.001) and tapentadol (46 ± 5 mm vs. 33 ± 4 mm with 
CS, p = 0.03) was observed, but not for morphine (51 ± 5 mm vs. 46 ± 6 mm, p = 0.12). See 
also Figure 4A and C.
CPM responses
CPM responses were 22.7 ± 6.5% (placebo), 4.5 ± 8.0% (morphine) and 21.2 ± 8.9% 
(tapentadol) after 60-90 min and 24.4 ±6.0% (placebo), 5.0 ± 2.8% (morphine) and 23.0 
± 8.1% (tapentadol) after 120-150 min. A significant treatment effect was observed (F2,55 
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= 6.2, p = 0.004), but there was no time effect (F1,55 = 0.24, p = 0.62) or time×treatment 
effect (F2,55 = 0.072, p = 0.93). Treatment effects relative for placebo were -18.8% (95% 
confidence interval -29.8 to -7.8%, p = 0.001) for morphine and -2.9% (95% confidence 
interval -13.9 to 8.1%, p = 0.60) for tapentadol. See Figure 4B and D.
Figure 2  Consort flow diagram.
Figure 3  Mean eVAS responses following treatment with placebo (A), oral morphine immediate 
release 40 mg (B) and oral tapentadol immediate release 100 mg (C) at 60-90 min after drug intake. 
The blue dots are the responses to the test stimulus without conditioning stimulus, the orange 
dots the responses to the test stimulus with conditioning stimulus. The broken line is the mean 





The effect of two opioid analgesics, morphine and tapentadol, on conditioned pain 
modulation was tested in a single population of healthy young volunteers under identical 
experimental and placebo-controlled conditions. The main findings of our study are: (1) In 
agreement with our hypothesis, a single oral dose of morphine reduces CPM responses 
relative to placebo by 80%; (2) In contrast to our hypothesis, a single dose of tapentadol 
has no effect on CPM responses compared to placebo treatment. 
Tapentadol is a combined μ-opioid receptor (MOR) agonist and inhibitor of the neuronal 
reuptake of the α2-adrenergic receptor agonist NA.26 Noradrenaline, together with other 
monoamines, plays an important role in mediation of analgesia via activation of the α2-
adrenergic receptor at supraspinal and pre- and postsynaptic spinal sites.10,11 Animal data 
indicate that the combined effect of MOR agonism and NA reuptake inhibition (the so 
Figure 4  eVAS and CPM responses at 60-90 min (A and B) and 120-150 min (C and D) after drug 
intake. A and C. Mean peak eVAS responses without (–) and with (+) conditioning stimulus for 
placebo (green), morphine (blue) and tapentadol (orange). B and D. CPM responses observed 
following placebo, morphine and tapentadol treatment. Individual data and the mean ± SEM are 
presented. é p < 0.001, * p = 0.001, + p = 0.03.?
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called MOR-NRI concept) of tapentadol produces synergistic analgesia.27 In contrast to 
tapentadol, morphine has no effect on NA reuptake. In vivo animal data of microdialysis 
in the ventral hippocampus show that tapentadol but not morphine produces a dose-
dependent increase in extracellular levels of NA.26 In mice lacking the MOR, tapentadol’s 
analgesic effect is reduced by about 50% in a model of acute thermal pain and by about 
20% in a model of neuropathic pain.32 In contrast, morphine is without any antinociceptive 
effect in this MOR knockout mouse strain. 
In the current study, we tested a single dose of tapentadol (100 mg) and a single dose 
of morphine (40 mg). The doses chosen were based on equianalgesia data from animal 
and human studies. For example, in mice the ED50 in the hot plate assay is 11.8 and 4.7 
mg/kg for tapentadol and morphine, respectively26 and in the treatment of patients with 
cancer pain the equianalgesic tapentadol/morphine dose ratio is 2.5.30 Although our data 
indicate analgesia from morphine and tapentadol (see Figures 3 and 4), our study was 
not designed to assess (equi)analgesia between treatments and the phasic heat pain 
may not be the best experimental model to evaluate potency of opioids.33
The reduction of CPM with morphine is in agreement with an earlier observation of 
Le Bars et al. from 1992 in healthy volunteers.28 To the best of our knowledge our study 
is the first to re-assess the effect of morphine on CPM in volunteers. After 0.05 mg/kg 
morphine, Le Bars et al. observed a complete loss of depression of the spinal nociceptive 
RIII-reflex (elicited by electrical stimulation of the sural nerve) by a contralateral 
conditioning temperature stimulus. The inhibition returned upon administration of 
the opioid antagonist naloxone. Animal data, showing similar effects on DNIC, suggest 
that the effect of morphine on DNIC originates at supraspinal sites.34 The data from Le 
Bars et al. and ours provide robust proof for an inhibitory effect of morphine on CPM in 
volunteers without pain. 
It is of interest to speculate on the mechanism through which morphine reduces CPM. A 
specific role form activation of the μ-opioid receptor would be expected in this respect. 
However, other opioids that have an effect on the μ-opioid receptor (such as oxycodone9) 
do not affect the CPM response as tested within 1-3 hours after the administration of the 
opioid. Furthermore, three of six human studies on the effect of naloxone or naltrexone 
on CPM found no effect of opioid receptor blockade on CPM,35-37 while three others 
showed a reduction of CPM.31,38,39 This suggests a limited role for the opioid-receptor 
system in the reduction of CPM. Alternatively, the loss of CPM by morphine may be 
related to a morphine-specific property such as due to an effect of the pronociceptive 
metabolite morphine-3-glucuronide. This metabolite appears rapidly in plasma upon 
the administration of morphine.40 Overall, the data on morphine are confusing and 




the development of descending (inhibitory or facilitatory) controls in humans. 
We did not observe an increase in CPM by tapentadol. Since monoaminergic receptors 
play an important role in descending pain inhibition,10,11 we expected an increase in 
CPM. Multiple, nonexclusive mechanisms may have played a role in our finding: (i) In 
the population of pain-free volunteers, the single administration of tapentadol was 
insufficient to have a clinical significant effect on neuronal NA reuptake and/or the dose 
was too low. However, after this single dose we did observe an analgesic effect on peak 
eVAS (Figures 2 and 3), which we relate to the synergistic effect of MOR activation and 
NA reuptake inhibition; (ii) Possibly the CPM responses of our healthy volunteers were 
at their (near) physiological maximum, and a further increase is difficult to attain. In 
contrast to healthy volunteers, in a recent protocol we observed that in neuropathic pain 
patients with absent CPM responses, a single treatment with 100 mg immediate release 
tapentadol treatment did activate CPM to values of similar magnitude as observed in the 
current study after placebo and tapentadol treatment, while intravenous morphine was 
without effect in this similar patient population;22 (iii) We cannot exclude that morphine’s 
negative impact on CPM is an opioid receptor-related effect. If so, the apparent absence of 
effect of tapentadol on CPM may be related to two opposing effects on CPM, one negative 
(related to an opioidergic effect) and one positive (due to spinal adrenergic stimulation) 
with a net zero effect. This seems an attractive explanation of our findings and is in 
agreement with animal data.26,27,32,34 Still, further studies are needed to understand the 
mechanism of tapentadol’s absence of effect on CPM in healthy volunteers. For example, 
specific α2-adrenergic and opioid receptor blockers (eg. yohimbine and naloxone) may be 
used to separate MOR and adrenergic effect on CPM during tapentadol treatment. 
Just few earlier studies addressed the effect of opioids on CPM responses in human 
volunteers.8,28,41 Comparison with our study is difficult due to differences in dosage, 
administration route, and dissimilarities in methods to induce CPM. Hence, a significant 
part of the variability observed in study outcomes may be related to methodological 
issues. An interesting example is the study by Arendt-Nielsen et al, who studied the effect 
of fentanyl (25 μg/h) and buprenorphine (20 μg/h), administered by a transdermal patch 
formulation, on CPM responses after 24, 48 h and 72 h of treatment.41 They observed 
an increase in CPM at all time points. Differences with our study include the route of 
administration (transdermal vs. oral), dose, duration of administration (continuous vs. 
single delivery), and CPM protocol. Arendt-Nielsen et al. used pressure pain tolerance 
threshold (test stimulus) applied to the left arm before, during and after immersion of 
the left hand into a fixed 3 oC water bath (conditioning stimulus). Setting the difference 
in study CPM protocol aside, these data suggest that sustained but not single deliveries 
enhance CPM responses in human volunteers. Possibly, the secondary effect of these 
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opioids on descending control via activation of off-cells in the medulla and release of 
noradrenaline in the spinal cord takes time to develop,10,11,22 and days rather than hours 
of treatment are required before the CPM increases above baseline levels. Whether 
this is also true for morphine requires further study. In order to overcome the issue of 
differences in CPM protocol, which is a general observation that relates to all studies on 
CPM, adoption of a standardized CPM protocol is required.42
One caveat of our study is that we did not collect plasma levels of morphine and 
tapentadol. We refrained from blood sampling as this could have affected the study 
outcome and blood sampling per se is not a good marker of drug effect taken the 
sometimes relatively long and variable blood-effect-site equilibration half-life (ie. passage 
of the drug to central sites) of opioids such as morphine and tapentadol.40 By performing 
CPM tests at multiple times in the first three hours following drug intake, we contend 
that we captured the peak drug effect on CPM for both morphine and tapentadol.
CONCLUSIONS
Our data show that, in agreement with earlier findings, a single oral administration of 
morphine has a negative impact on the endogenous modulation of nociceptive stimuli 
in healthy young adult volunteers. In contrast, a single oral administration of tapentadol 
was without effect on CPM despite the fact that studies were performed under similar 
controlled conditions in the same study population. These data confirm that tapentadol’s 
main mechanism of action is distinct from that of morphine and likely related to the 





1. Niesters M. Evolution of endogenous analgesia. PhD thesis, Leiden University; 2014. 
Available: https://openaccess.leidenuniv.nl/bitstream/handle/1887/29585/front.
pdf?sequence=14 or https://thesisapps.com/evolution/
2. Pud D, Granovsky Y, Yarnitsky D. The methodology of experimentally induced diffuse 
noxious inhibitory control (DNIC)-like effect in humans. Pain 2009; 144: 16–19.
3. van Wijk G. Veldhuijzen DS. Perspective on diffuse noxious inhibitory controls as a 
model of endogenous modulation in clinical pain syndromes. J Pain 2010; 11: 408–419.
4. Yarnitsky D, Arendt-Nielsen L, Bouhassira D, Edwards RR, Fillingim RB, Granot M, et al. 
Recommendations on terminology and practice of psychophysical DNIC testing. Eur 
J Pain 2010; 14: 339.
5. Yarnitsky D, Granot M, Granovsky Y. Pain modulation profile and pain therapy: 
between pro- and antinociception. Pain 2014; 155: 663–665.
6. Le Bars D, Villanueva L, Bouhassira D, Willer JC. Diffuse noxious inhibitory controls 
(DNIC) in animals and in man. Patol Fiziol Eksp Ter 1992; 4: 55-65.
7. Nahman-Averbuch H, Martucci KT, Granovsky Y, Weissman-Fogel I, Yarnitsky D, Coghill 
RC. Distinct brain mechanisms support spatial vs temporal filtering of nociceptive 
information. Pain 2014; 155: 2491-2501.
8. Niesters M, Dahan A, Swartjes M, Noppers I, Fillingim RB, Aarts L, et al. Effect of 
ketamine on endogenous pain modulation in healthy volunteers. Pain 2011; 152: 656–
663.
9. Suzan E, Midbari A, Treister R, Haddad M, Pud D, Eisenberg E. Oxycodone alters 
temporal summation but not conditioned pain modulation: preclinical findings and 
possible relations to mechanisms of opioid analgesia. Pain 2013; 154: 1413–1418.
10. Milan MJ. Descending control of pain. Prog Neurobiol 2002; 66: 355–374.
11. Ossipov MH, Dussor GO, Porreca F. Central modulation of pain. J Clin Invest 2010; 120: 
3779–3787. 
12. Grill JD, Coghill RC. Transient analgesia evoked by noxious stimulation effect. J 
Neurophysiol 2001; 87: 2205-2208.
13. Niesters M, Hoitsma E, Sarton E, Aarts L, Dahan A. Offset analgesia in neuropathic 
pain patients and effect of treatment with morphine and ketamine. Anesthesiology 
2011; 115: 1063-1071.
14. Niesters M, Proto PL, Aarts L, Sarton EY, Drewes AM, Dahan A. Tapentadol potentates 
descending pain inhibition in chronic pain patients with diabetic polyneuropathy. Br 
J Anaesth 2014; 113: 148–156.
15. Landau R, Kraft JC, Flint LY, Carvalho B, Richebé P, Cardoso M, et al. An experimental 
Chapter 6  |  Arandomizedcontrolledtrialontheeffectoftapentadolandmorphineonconditionedpainmodulation(CPM)in
healthyvolunteers
116
paradigm for the prediction of post-operative pain (PPOP). J Vis Exp 2010; pii: 1671.
16. Wilder-Smith OH, Schreyer T, Scheffer GJ, Arendt-Nielsen L. Patients with chronic pain 
after abdominal surgery show less preoperative endogenous pain inhibition and 
more postoperative hyperalgesia: a pilot study. J Pain Palliat Care Pharmacother 2010; 
24: 119–128.
17. Yarnitsky D, Crispel Y, Eisenberg E, Granovsky Y, Ben-Nun A, Sprecher E, et al. Prediction 
of chronic post-operative pain: pre-operative DNIC testing identifies patients at risk. 
Pain 2008; 138: 22–28. 
18. De Felice M, Sanoja R, Wang R, Veca-Portocarrero, Oyarzo J, King T, et al. Engagement 
of descending inhibition from the rostral ventromedial medulla protects against 
chronic neuropathic pain. Pain 2011; 152: 2701–2709. 
19. King CD, Wong F, Currie T, Mauderli AP, Fillingim RB, Riley JL 3rd. Deficiency in 
endogenous modulation of prolonged heat pain in patients with Irritable Bowel 
Syndrome and Temporomandibular Disorder. Pain 2009; 143: 172–178.
20. Lautenbacher S, Rollman GB. Possible deficiencies of pain modulation in fibromyalgia. 
Clin J Pain 1997; 13: 189–196. 
21. Nahman-Averbuch H, Yarnitsky D, Granovsky Y, Sprecher E, Steiner M, et al. 
Pronociceptive pain modulation in patients with painful chemotherapy-induced 
polyneuropathy. J Pain Sympt Mang 2011; 42: 229–238.
22. Niesters M, Aarts L, Sarton E, Dahan A. Influence of ketamine and morphine on 
descending pain modulation in chronic pain patients: a randomized placebo-
controlled cross-over proof-of-concept study. Br J Anaesth 2013; 110: 1010–1016.
23. Olesen SS, Brock C, Krarup AL, Funch-Jensen P, Arendt-Nielsen L, Wilder-Smith OH, 
et al. Descending inhibitory pain modulation is impaired in patients with chronic 
pancreatitis. Clin Gastroenterol Hepatol 2010; 8: 724-730.
24. Seifert F, Kiefer G, DeCol R, Schmelz M, Maihofner C. Differential endogenous pain 
modulation in complex-regional pain syndrome. Brain 2009; 132:788–800.
25. Steigerwald I, Muller M, Kujawa J, Balblanc JC, Calvo-Alen J. Effectiveness and safety of 
tapentadol prolonged release with tapentadol immediate release on-demand for the 
management of severe, chronic osteoarthritis-related knee pain: results of an open-
label, phase 3b study. J Pain Res 2012; 5:121–138. 
26. Tzschentke TM, Christoph T, Kögel B, Schiene K, Hennies HH, Englberger W, et al. (1R,2R)-
3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): 
a novel μ-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-
spectrum analgesic properties. J Pharmacol Exp Ther 2007; 323:265–276.
27. Schröder W. Tszschentke TM, Terlinden R, De Vry J, Jahnel T, Christoph T, et al. Synergistic 




Pharmacol Exp Ther 2011; 337:312–320.
28. Le Bars D, Willer JC, De Broucker T. Morphine blocks descending pain inhibitory 
controls in humans. Pain 1992; 48: 13–20.
29. Kleinert R, Lange C, Steup A, Black P, Goldberg J, Desjardins P. Single dose efficacy of 
Tapentadol in postsurgical dental pain: the result of a randomized, double-blind, 
placebo controlled study. Anesth Analg 2008; 107: 2048-2055.
30. Kress HG, Koch ED, Hosturski H, Steup A, Karcher K, Etropolski M, et al. Efficacy and 
safety of oral tapentadol extended rleases (ER) for the managemebnt of moderate to 
severe, chronic malignant tumar-related pain. ASRA meeting 2012, Abstract #A020. 
Available: http://www.asra.com/cme-events-past-fall-meetings-abstracts-2012.php).
31. King CD, Goodin B, Kindler LL, Caudle RM, Edwards RR, Gravenstein N, et al. Reduction 
of conditioned pain modulation in humans by naltrexone: an exploratory study of 
the effecst of pain catastrophizing. J Behav Med 2013; 36: 315–327.
32. Kögel B, De Vry J, Tzschentke T, Christoph T. The antinociceptive and antihyperalgesic 
effect of tapentadol is partially retained in OPRM1 (μ-opioid receptor) knockout mice. 
Neurosci Lett 2011; 491: 104–107.
33. Olesen AE, Andresen T, Staahl C, Drewes AM. Human experimental models for 
assessing the therapeutic efficacy of analgesic drugs. Pharmacol Rev 2012; 64: 722–
779.
34. Dickenson AH, Le Bars D. Supraspinal morphine and descending inhibitions acting on 
the dorsal horn in the rat. J Phsyiol (Lond) 1987; 384: 81–107.
35. Peters ML, Schmidt AJ, van der Hout MA, Koopmans R, Sluijter ME. Chronic back pain, 
acute postoperative pain and the activation of diffuse noxious inhibitory controls 
(DNIC). Pain 1992; 50: 177–187.
36. Edwards R, Ness TJ, Fillingim RB. Endogenous opioids, blood pressure, and diffuse 
noxious inhibitory controls: a preliminary study. Percept Motor Skills 2004; 99: 679–
687.
37. Sprenger C, Bingel U, Buchel C. Treating pain with pain: supraspinal mechanisms of 
endogenous analgesia elicited by heterotopic noxious conditioning stimulations. 
Pain 2011; 152: 428–439. 
38. Petrovaara A, Kemppainen A, Johansson P, Karonen SL. Ischemic pain non-segmentally 
produces a predominant reduction of pain and thermal sensitivity in man – a selective 
role for endogenous opioids. Brain Res 1982; 251:83–92.
39. Willer JC, Le Bars D, De Boucker T. Diffuse noxious inhibitory controls in man: 
inolvement of opioidergic link. Eur J Pharmacol 1990; 182: 347–355.
40. Sarton E, Olofsen E, Romberg R, den Hartigh J, Kest B, Nieuwenhuis D, et al. Sex 
differences in morphine analgesia: an experimental study in healthy volunteers. 
Chapter 6  |  Arandomizedcontrolledtrialontheeffectoftapentadolandmorphineonconditionedpainmodulation(CPM)in
healthyvolunteers
118
Anesthesiology 2000; 93: 1245–1254.
41. Arendt-Nielsen L, Andresen T, Malver LP, Oksche A, Mansikka H, Drewes AM. A double-
blind, placebo-controlled study on the effect of buprenorphine and fentanyl on 
descending modulation: a human experimental study. Clin J Pain 2012; 28: 623–627.
42. Yarnitsky D, Bouhassira D, Drewes AM, Fillingim RB, Granot M, et al. Recommendations 






7 General Discussion, Summary  and Conclusions
Chapter 7  |  GeneralDiscussion,SummaryandConclusions
122
The development of new effective and safe analgesics for the treatment of chronic pain 
is a challenging, time consuming and costly process. Large multicenter trials are needed, 
as the heterogeneity in pharmacological treatment response is significant, with large 
within- and between-subject variability in treatment response, which in magnitude may 
differ among trial centers. This regards not only the effect of the active compound but 
also the placebo response. Consequently many phase III trials, even the larger ones, of 
new analgesic medication do fail because of the magnitude of the placebo response. 
An example is a recent trial that was performed in our institution and one other center 
(unpublished observation). The effect of a novel compound with analgesic properties 
was tested in chronic pain patients using a placebo-controlled double-blind randomized 
design. On average, the novel compound had certainly analgesic effects but the effects 
were no greater than the placebo-induced analgesic response. Interestingly, the set-
up of the trial allows comparison of the effect of the active and placebo treatments 
between centers. The differences in the outcome between the two recruitment centers 
were remarkable. One center had low-placebo responses and high-treatment effects 
(i.e. the informative center), while the reverse was true for the other center (i.e. the 
non-informative center). Certainly this relates to differences in experience and training 
between centers, but one additional observation regarding the patients is of importance 
as well. The patients recruited in the two centers differed significantly in their body mass 
index, with severely obese patients almost exclusively recruited in the center with high 
placebo and low active treatment responses, i.e. the non-informative center. The fact that 
predominantly obese patients were recruited may be mechanistically related to the fact 
that the outcome of this trial center was negative. The pharmacokinetics of the drug 
will differ in obese versus non-obese patients. And possibly also the pharmacodynamics 
might differ although this evidently depends on the mechanisms of action of the active 
treatment (e.g. obese patients differ in their metabolic, hormonal and inflammatory 
status). Furthermore, we have indications that small peripheral nerves in obese patients 
are less active compared to normal individuals with higher cutaneous stimulus detection 
and pain thresholds. This will impact trials that rely on intact peripheral nerves when 
assessing treatment effects through quantitative sensory testing (QST), a test battery 
consisting of 7 tests measuring 13 variables. Additionally, we recently observed that 
obese patients have difficulty in rating pain possibly due to a problem with number 
sensing. Irrespective of the underlying causes for the observed outcome, this trial serves 
as an example of the difficulties that may arise when performing pain treatment studies, 
especially when multiple trials centers are involved. We will need to further analyze the 
data but we are convinced that apart from patient-related factors, the quality of trial 




(i.e. using patients with predefined weights), application of enrichment trials (in which 
placebo responders are excluded) or the use of only “informative” or “high quality” trial 
centers seem possible solutions. If such restrictions are applied in phase III trials, they 
will certainly influence outcome in a positive fashion. Still, in real life such exclusions do 
not exist. Physicians and patients outside the trial setting will not benefit from such an 
approach as it remains unknown which patient will respond to treatment and which will 
not. Hence it is more important to use these often-large phase III trials to improve our 
understanding of predictors of effective treatment and/or of the placebo response.  This 
was the goal of the research described in this thesis, in which novel analysis techniques 
are described to quantify and most importantly predict the efficacy of pharmacotherapy 
for acute and chronic pain. We made use of existing data sets of large multicenter 
trials (Chapters 3 and 4) or performed experiments in our pain laboratory on healthy 
volunteers exposed to opioid treatment and experimental nociceptive assays (Chapters 
5 and 6).  Three important findings of my thesis are that (i) there are multiple responder 
subgroups to analgesic treatment rather than just “responders” versus “non-responders”, 
(ii) it is important to collect multiple data points over time rather than to collect one end-
point at the end of study (e.g. after 12 weeks) and (iii) predictors of analgesic (and placebo) 
effect differ among response subgroups (and are possibly dependent on the recruitment 
centers, see above). These findings alone should lead to an “enriched” analysis approach 
of future phase III trials. And indeed, the approach presented in Chapter 4 has already 
been proposed by some international regulatory offices. 
In this final chapter, I will give a summary of the observations made in the different 
studies that are presented. Next, I will discuss response (sub)group analyses, the leading 
theme of this thesis, and the placebo response. Finally, future perspectives and the 
conclusions of the thesis are presented. 
SUMMARY
In Chapter 2 an overview of the recent literature on pharmacokinetic (PK) and 
pharmacodynamic (PD) modeling in acute and chronic pain is presented. In this review, 
novel observations on opioids, NSAIDs, epidural analgesia, ketamine and GABAergic 
drugs are highlighted. Several mathematical models are discussed that describe and/or 
predict the time course of analgesic agents and link PK to PD. Population PKPD modeling 
allows, apart from the estimation of fixed effects (the PK and PD model estimates), the 
quantification of random effects: the within- and between-subject variability. Effect-
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compartment and mechanism-based biophase distribution models incorporate drug 
association and dissociation kinetics and enable the quantification of the rate-limiting 
factors in drug effect due to drug distribution versus receptor kinetics. It is a useful 
technique in understanding the complex behavior of specific compounds, especially 
with respect to the occurrence and management of side effects. A somewhat different 
approach in chronic pain studies is the application of mixture models. Mixture models 
allow the identification of specific response subgroups. Combining mixture analysis and 
(PK)PD modeling or time series analysis leads to the improvement of current therapeutics 
with respect to dose design, outcome, and understanding the interaction of analgesics 
within complex chronic pain disease processes and may play an important role in new 
drug development. For example, the effect of a 100 h intravenous ketamine and placebo 
infusion on pain in patients with Complex Regional Pain Syndrome type 1 is discussed. 
Mixture modeling identified 4 treatment-independent response groups, ranging from 
non- to super-responders. This is an important finding and emphasizes the importance 
of subgroup analysis and the often large effect of placebo, as is further discussed in 
Chapters 4 and 5.
In Chapter 3 a pharmacodynamic model was developed to quantify the magnitude and 
onset/offset times of a single capsaicin 8% patch in the treatment of painful diabetic 
peripheral neuropathy in 91 patients. In addition, a mixture model was applied to 
objectively match patterns in pain-associated behavior. The analysis allowed separation 
of a heterogeneous neuropathic pain population into homogenous subgroups with 
distinct behaviors in response to treatment with capsaicin. Four distinct subgroups were 
identified: (1) 3.3% of patients showed worsening of pain; (2) 31% showed no change in 
pain; (3) 32% showed a quick reduction in pain that reached a nadir in week-3, followed 
by a slow return towards baseline (16 ± 6% pain reduction in week-12); and finally (4) 
34% showed a quick reduction in pain that persisted (70 ± 5% reduction in week-12). The 
response-onset half-life was such that every week the pain score reduced by 50% relative 
to the score of the previous week (t1/2~1 week). In contrast, the response-offset half-life 
was about 8 weeks (estimated from subjects in groups 2-4). It is argued that this model-
based approach may have added value in analyzing longitudinal chronic pain data 
and allows optimization of treatment algorithms for patients suffering from chronic 
pain conditions. The small sample size of this study prevented association of specific 
predictors to the observed distinct responses. The detection of predictors would further 




In Chapter 4 subgroup analysis (a combination of pharmacodynamic and mixture 
analyses) was followed by the estimation of significant predictors of response. 
Longitudinal data from 4 double-blind randomized controlled trials on the efficacy of 
topical capsaicin 8% (Qutenza, n = 722) versus an active control (capsaicin 0.04%, n = 
526) were collected yielding a data set consisting of 1,248 subjects that provided 15,547 
numeric pain rating scores (NPRS) over 12 weeks. Five distinct response subgroups were 
detected with different treatment efficacies: (1) a group with increase in pain response 
(1.5% Qutenza, 0,8% active control); (2) a group of non-responders (22.7% Qutenza, 39.1% 
active control); (3) a group showing an initial reduction in pain response with slow return 
towards baseline (24.7% Qutenza, 17.6% active control); (4) a group showing partial 
analgesic effect with a reduction in NPRS of 25-30% at week 12 (14.5% Qutenza, 14.3% 
active control) and finally (5) a group of super-responders showing large analgesic effect 
with a reduction in NPRS of 67-70% at week 12 (36.6% Qutenza showing 28,2% active 
control). Active control and Qutenza had similar response profiles but the proportional 
distribution of patients among the 5 response groups was in favor of Qutenza with 40% 
less non-responders and 25% more super-responders. For Qutenza important predictors 
of a super-response were age, duration of disease, concomitant opioid use, pretreatment 
pain score variability, baseline NPRS, and efficacy of lidocaine pretreatment. These 
analyses are a major advancement over previous analyses that yield predictors of 
response per se (versus non-response) whereas the current analysis allows specification 
of predictors of distinct response groups. Additionally our results (in terms of treatment 
effect and predictors) obtained from one treatment (Qutenza) in one disease (post-
herpetic neuralgia) with presumably one underlying disease process suggest that pain 
mechanisms may differ among patients, that possibly require dissimilar treatment 
approaches. Finally, we observed a large placebo effect, part of which must be also 
inherent to the active treatment group. 
Chapters 5 and 6 present data obtained from our laboratory on the effect of opioids 
on experimental pain models applied to healthy volunteers. Chapter 5 deals with the 
antinociceptive profile of an orodispersible oxycodone tablet (OOT) compared to an 
active comparator (paracetamol orodispersible tablet, POT). The OOT is marketed for 
acute breakthrough pain when a rapid onset of analgesia is important. In a randomized, 
double blind, crossover study, twelve healthy volunteers received 20 mg OOT and 500 
mg POT sublingually on two separate occasions. Three pain parameters were obtained 
at regular intervals for 5 hours: Electrical pain threshold (EPTh), electrical pain tolerance 
(EPTol) and pressure pain threshold (PPT). Time-response data were analyzed with a 
novel mathematical (pharmacodynamic) model of analgesia evolution that bears some 
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similarities with the models described in Chapters 2 to 4; no pharmacokinetic data were 
obtained in this study. Important observations were that paracetamol displayed 14% 
of the analgesic efficacy of oxycodone. For the OOT the population analysis revealed a 
30% increase from baseline response at t = 15 min and t = 41 min (after drug intake) 
for EPTol and EPTh, respectively. For pressure pain a 30% increase from baseline was 
found at t = 18 min. We argue that the 30% increase in pain parameter values (onset 
of action) bears clinical significance albeit further studies are needed to validate this 
statement. The observed onset times ranging from 15 to 41 min do suggest a rather 
similar antinociceptive profile of OOT compared to conventional oral oxycodone. How 
OOT compares to other rapidly acting opioids such as intranasal fentanyl requires further 
study. 
Another relatively new approach is the application of dynamic psychophysical tests 
as predictor of drug efficacy and to better understand the analgesic mechanism. One 
such test is Conditioned Pain Modulation (CPM), a biomarker of descending inhibition. 
CPM reduces the perception of pain from a primary test stimulus during application 
of a secondary stimulus, ie. the conditioning stimulus, according to the concept “pain 
inhibits pain”. Previous studies showed that chronic pain patients who are unable to 
activate CPM benefit most from medication that interacts with the endogenous pain 
modulatory system such as duloxetine and vice versa patients that have an active CPM 
have little analgesic benefit from these drugs. In Chapter 6 the effects of the analgesics 
tapentadol (100 mg immediate release tablet), a combined mu-opioid receptor agonist 
and noradrenaline reuptake inhibitor, and morphine (40 mg immediate release tablet), 
a strong mu-opioid receptor agonist, were tested on CPM in a randomized, double-blind, 
placebo-controlled crossover trial in 12 healthy pain-free volunteers, to understand 
possible differences in mechanism of action between these opioids. CPM was detectable 
after treatment with placebo and tapentadol (peak pain ratings reduced by 20-30% 
after application of the conditioning stimulus) but not after morphine. Compared to 
placebo morphine displayed significantly less CPM. This indicates that in volunteers 
morphine negatively affects CPM, while tapentadol was without effect despite identical 
experimental conditions. These data confirm that tapentadol’s main mechanism of 
action is distinct from that of morphine and likely relates to the effect of adrenergic 





In chapter 3 we proposed the use of PD mixture models to identify response groups 
and separate the heterogeneous neuropathic pain population into responders and non-
responders. Four distinct response groups were found for the DPN population (chapter 
3), whereas five response groups were recognized in PHN patients (chapter 4). Subgroup 
4 (a group of PHN patients showing partial analgesic effect with a reduction in NPRS 
of 25-30% at week 12) was lacking in DPN patients. In fact, the response to capsaicin 
treatment as observed at the end the trial in patients with DPN was dichotomous, with 
patients showing either no effect of treatment (subgroup 2 and 3) or a full analgesic 
effect (subgroup 4). These differences may relate to differences in the underlying disease 
process. DPN is regarded as a classical denervation neuropathy (long-term dying back of 
nerve fibers) whereas PHN is considered an inflammatory mediated ‘dynamic’ denervation 
neuropathy (consisting of partial nerve injury, post-nerve repair, denervation and nerve 
sprouting).1 Since our findings (and those of others) suggest that, in contrast to patients 
with fully damaged peripheral nerves, patients with diseased  but (partly) intact nerve 
fibers are likely responders to active treatment, questionnaires and quantitative sensory 
testing may hold predictive power as they are able to detect specific symptoms (such as 
the occurrence of allodynia or burning pain) related to the state of nerve damage.2 Future 
studies should address this issue, focusing on the integrity of sensory nerve endings by 
means of immuno-histochemical analyses.3,4 
Published subgroup analyses have been restricted so far to DPN, PHN (treated with 
capsaicin, Chapters 3 and 4) and complex regional pain syndrome type 1 (CRPS 1, treated 
with ketamine, Chapter 2).  In terms of the numbers the response groups in CRPS 1 
patients were similar to those observed in DPN patients. In contrast to the comparison 
of DPN versus PHN, both treated with capsaicin (see above), comparison of DPN treated 
with capsaicin versus CRPS 1 treated with ketamine is difficult due to the use of two 
very distinct drugs (capsaicin acting at TRPV1 receptors versus ketamine acting at NMDA 
receptors) in two distinct chronic illnesses. Hence predictors of effect will differ between 
treatment of DPN with capsaicin and treatment of CRPS 1 with ketamine. I have to 
conclude that the use of treatment predictors in clinical practice is still rather premature. 
Treatment of one pain syndrome (e.g. DPN) with drugs with distinct mechanisms of 
action (e.g. opioids versus capsaicin versus ketamine versus GABAergic medication versus 
SSRI’s versus ……) in large randomized trials will allow detection of predictors of a specific 
drug-related treatment response (e.g. super-response). For example, it might well be that 
such an analysis would find that the presence of burning pain predicts a high probability 
of falling into a super-responder group when being treated with capsaicin but not with 
Chapter 7  |  GeneralDiscussion,SummaryandConclusions
128
opioids. Alternatively, it might be that the presence of wind-up in the QST will result in a 
good response to ketamine. Evidently, further research on this topic is required. Possibly, 
data mining strategies in data sets from existing (published and non-published) clinical 
trials will allow such comparisons. 
We defined the response groups by the course of the onset and offset of the 
pharmacodynamic response and observed presence of 4 to 5 subgroups in our analyses. 
However, the number of true response groups may be much larger and may not have 
been captured by our analysis in relatively small populations. Additionally, pain in chronic 
pain patients is not constant and this variability was not included in our analysis. Also 
the quality of the pain sensation and perception might differ over time with variations 
is symptomatology. Examples are patients that present with nightly allodynia and 
daytime burning pain (or the reverse) versus patients that have a constant tingling or 
electrical pain sensation. This is not readily caught in numerical ratings but may be 
addressed in questionnaires. The above suggests that variability in the pain response as 
pharmacodynamic end-point may yet be another item that deserves further study and 
that possibly will further improve the prediction of treatment effect.
Finally, it is important to realize that the response group analysis as performed in 
Chapters 3 and 4 is only possible when data points are collected over time (such as at 
1 week intervals). Using just the end-of-study data point (one measurement at week 12) 
does not allow the pharmacodynamic or time-series analyses that were performed in 
chapters 2, 3 and 4. Consequently, when using just end-of-study data, only responders 
and non-responders are detected. This indicates that a proper study design with 
multiple measurement points during and following treatment is essential for the full 
understanding of the effect of a drug treatment in the study population; this regards 
detection of subgroups and predictors. 
THE PLACEBO RESPONSE
As indicated above, the relative large confounding placebo response in randomized 
controlled trials is responsible for the lack of success of many studies in observing an effect 
of active treatment greater than placebo. Many studies have focused on understanding 
the large placebo response. Predictors include long treatment duration,5 type of 
neuropathic pain condition (DPN trials consistently show a higher placebo response 
compared to PHN trials),6 high variability in baseline pain scores,7 trials involving opioids 




of these factors clearly enhance patients expectation (e.g. treatment duration, face-to-
face visits). These findings relate to the example I gave earlier in this chapter. It is possible 
that any of these factors may have caused a large placebo response in this one “non-
informative” center mentioned above. It is our understanding that increasing experience 
in performing pain trials and training of personnel will be highly effective in reducing 
the placebo response.
Clearly, the general term “placebo response” should be separated into a more genuine 
psychosocial and physiological “placebo effect” and “placebo related behaviors” such 
as spontaneous remission of disease, regression to the mean and natural waxing and 
waning of an illness.9-11 A means to do so is to introduce a no-treatment control (NTC) arm 
in RCT design.12 An NTC arm (also referred to as the “waiting list”) is defined as an arm 
of a RCT in which randomly allocated subjects receive no treatment or intervention and 
in which subjects are only observed during the time of the trial. By doing so, predictive 
factors for the true placebo effect and mechanistic pathways that mediate the placebo 
(or nocebo, an occurrence that is opposite to placebo) effect may be identified. Current 
known pathways of placebo effect in chronic pain conditions include endogenous 
analgesic mechanisms with endogenous opioid and dopaminergic involvement.12-15 
Mechanisms for the nocebo effect include activation of cholecystokinin and deactivation 
of dopamine pathways.16-18
It is important to realize that the data presented in Chapter 4 were obtained from more 
than 160 recruitment centers. Some of these centers may be more informative than 
others, i.e. some centers effectively separate placebo response from active treatment 
response, while other find large placebo effects often not very different from the response 
to active treatment. Merlo-Pich et al.19,20 reviewed data from multicenter trials on the 
efficacy of antidepressants in patients with major depressive disorder. They applied a 
post-hoc enrichment filter that reduced between-center heterogeneity by excluding 
those centers that have a placebo response that equals or exceeds the response to active 
treatment. Such a filter could easily be applied to the current data set, not to inflate the 
response to active treatment but rather to assess which predictors are specific to placebo 
or to active treatment response efficacy. I speculate that baseline pain variability is a 
predictor of a large placebo response but not of a large response to active treatment. 
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FUTURE PERSPECTIVES: WHAT TO MEASURE, HOW TO MEASURE
The pharmacological effect of analgesics is dependent on various complex and interacting 
factors. These factors can be subdivided into substance, subject and disease related. 
Examples of substance related factors include pharmacokinetic-associated variables 
such as equilibrium delay between plasma and biophase concentrations, receptor 
association/dissociation kinetics and delay between receptor occupancy and onset of 
subsequent analgesic effect.  Subject related factors may consist of age, sex, weight, 
duration of disease, severity of pain symptoms and comorbidity.  We already know from 
clinical practice that some individuals do not respond to opioid treatment. We confirmed 
this in Chapter 5 showing that 20% of subjects did not respond to oxycodone in several 
nociceptive models. We relate the later to pharmacogenetic factors, probably due to 
reduced activity of the CYP2D6 enzyme, which causes less production of oxycodone’s 
active metabolite oxymorphone. Indeed inter-individual variability in pharmacokinetics 
is a well-known phenomenon.21,22 However, also variability in pharmacodynamics should 
be considered.23-25 Population-based PK-PD models in conjunction with pharmacogenetics 
(PG) are important tools to describe and predict the analgesic effect and the interaction 
of specific pharmacological agents within the often complex disease states. Future 
developments may make the use PK-PD-PG analyses easier to apply in pain trials and 
possibly even in clinical pain patients.  
In the near future various advances in pain measurement and evaluation of therapy are 
foreseen. The use of questionnaires, such as the ‘Patient Reported Outcomes’ (PRO) or 
painDETECT questionnaires, 26 allows detection and quantification of sensory neuropathic 
symptoms. The association between pain symptoms and treatment response may 
be used to further elucidate pathophysiological mechanisms of disease and identify 
novel drug targets. Moreover, QST enables the mapping of different sensory patterns in 
neuropathic pain syndromes. Analysis of these profiles may allow a distinction between 
responders and non-responders to specific treatments. Additionally, the application of 
dynamic psychophysical tests, such as Conditioned Pain Modulation (CPM) or Offset 
Analgesia (OA), may predict which patients benefit most from medication that interacts 
with the endogenous pain modulatory system (chapter 6). Until recently, large and 
complex experimental devices were needed to test CPM and OA. Recently, new devices 




in the clinical setting. One example is Medoc’s Qsense CPM device, a mobile system built 
to test CPM and additionally allows assessment of a large part of the QST battery. The 
use of such systems by pain clinicians in the ambulatory setting will allow a choice of 
medication based on the presence or absence of CPM. For example in chapter 1 I showed 
that DPN patients with inactive CPM benefit from tapentadol (a combined opioid and 
noradrenaline reuptake inhibitor, see chapter 6) while patients with active CPM do not. 
Finally, novel techniques such as cornea confocal microscopy, 27, 28 identifying small fiber 
disease in the cornea and point-of-care sural nerve conduction test,29 identifying large 
nerve disease, hold promises for the detection of painful neuropathic disease and its 
resolve during treatment. 
CONCLUSIONS
From the data presented in this thesis several conclusions can be formulated:
1. Longitudinal pharmacodynamic modeling can be used to describe the antinociceptive/
analgesic time course of analgesic medication. This approach yields more information 
than traditional assessment of treatment effect at specific endpoints at preset times. 
2. Mixture modeling analysis allows separation of a heterogeneous pain population into 
homogenous subgroups with distinct behaviors in response to analgesic treatment. 
3. Covariate analysis within different distinct response subgroups may identify 
important predictors of treatment effect. This will eventually allow optimization of 
individual pain therapy with specific predictors linked to specific pharmacotherapies. 
4. The onset of action of an analgesic compound may be quantified by a longitudinal 
pharmacodynamic model from sparse data sets without the need of PK sampling. 
5. In future, the application of dynamic psychophysical tests, such as Conditioned Pain 
Modulation – a marker of descending pain inhibition – may be used as a predictor of 
drug efficacy.
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Het ontwikkelen van nieuwe, effectieve en veilige pijnstillers voor de behandeling van 
chronische pijn is een uitdagend, tijdrovend en kostbaar proces. Onderzoekers zijn 
aangewezen op grote multicenter studies, aangezien er een grote variatie bestaat in 
farmacologische respons op behandeling. Zowel de intra- als inter-subject variabiliteit 
is groot, waarbij deze kan verschillen tussen de behandelcentra. Deze variatie is niet 
alleen van toepassing op het effect van het nieuw te ontwikkelen actieve middel, maar 
ook op de placebo behandeling. Veel fase III studies, zelfs de grotere, slagen er niet in 
een voordeel van nieuwe pijnstillers aan te tonen door de grootte van dit placebo effect. 
Een voorbeeld hiervan betreft een recente studie die zowel in onze instelling als in een 
ander centrum is uitgevoerd (ongepubliceerde data). Het pijnstillend vermogen van een 
nieuw medicijn werd getest in chronische pijnpatiënten door gebruik te maken van een 
placebo gecontroleerd, dubbelblind, gerandomiseerd design. Gemiddeld genomen had 
het nieuwe middel een pijnstillend effect, maar niet meer dan in de placebo groep. Er 
was echter een opvallend verschil in behandeleffect van het actieve middel en de placebo 
pijnstiller tussen de beide centra. Het ene centrum had een laag placebo effect en groot 
actief behandeleffect (dit centrum werd geclassificeerd als informatief centrum), terwijl 
het omgekeerde het geval was voor het andere centrum (een non-informatief centrum). 
Een verklaring voor dit verschil kan liggen in de ervaring met het doen van pijnonderzoek 
en de training van de medewerkers, maar er was nog een belangrijke bevinding. De 
patiënten in het non-informatieve centrum hadden allen een verhoogde body mass 
index (BMI), wat zowel de farmacokinetiek als de farmacodynamiek kan hebben 
beïnvloed. Daarnaast is aangetoond dat kleine perifere zenuwen in obese patiënten 
minder actief zijn dan in de normale populatie met een hogere prikkel detectiegraad 
en hogere pijndrempel. Dit kan van belang zijn voor studies die de functie van intacte 
zenuwen bestuderen door gebruik te maken van quantative sensory testing (QST), een 
testbatterij van 7 testen met 13 variabelen. Afgezien van de onderliggende oorzaak voor 
het verschil in behandeluitkomst, illustreert dit voorbeeld goed hoe lastig pijnonderzoek 
in het algemeen  - en multicenter pijnonderzoek in het bijzonder - kan zijn. Hoewel de 
nadere grondoorzaken nog onderzocht moeten worden, zal behalve patiënt gerelateerde 
factoren ook zeker de onderzoekskwaliteit van de instelling een mogelijke rol hebben 
gespeeld. Toekomstige oplossingen liggen in het standaardiseren van patiënten (bv. 
alleen patiënten met een normaal tot licht verhoogd BMI includeren), het toepassen van 
verrijkingstechnieken (waarbij placebo responders worden geëxcludeerd) en gebruik 
maken van informatieve of ‘high quality’ centra. Dit zal zeker het behandeleffect van het 
actieve middel in fase III studies ten goede komen. Echter, in het werkelijke leven zijn deze 
exclusies niet toegestaan. Patiënten en artsen in de behandelkamer profiteren niet van 




de voorgestelde behandeling gunstig zal reageren. Daarom is het van belang deze fase 
III studies te gebruiken om voorspellende factoren te destilleren voor behandeluitkomst 
van zowel het actieve als het placebo middel. Dit was ook het doel van het onderzoek 
zoals beschreven in dit proefschrift waarbij nieuwe analyse technieken zijn toegepast 
om niet alleen de grootte van het behandeleffect te beschrijven maar ook te voorspellen. 
Er is zowel gebruik gemaakt van bestaande datasets (hoofdstuk 3 en 4) als van nieuwe 
data verkregen uit studies in ons eigen pijnlaboratorium naar opiaten en experimentele 
pijntesten in gezonde vrijwilligers (hoofdstuk 5 en 6). De drie belangrijkste bevindingen 
van mijn proefschrift zijn dat: i) er meerdere responder subgroepen bestaan in 
pijnstillend effect in plaats van alleen responders en non-responders, ii) het belangrijk is 
om meerdere data punten van pijnstilling in de tijd te verzamelen in plaats van alleen na 
een vooraf gedefinieerde einddatum (bv. na 12 weken) en iii) voorspellers van pijnstilling 
(en placebo) verschillen in de responsgroepen en studiecentra. De bevindingen zouden 
moeten leiden tot een verrijkingstechniek voor toekomstige fase III studies. Momenteel 
wordt deze techniek zoals voorgesteld in hoofdstuk 4 al door diverse internationale 
regulerende instanties toegepast. 
In dit laatste hoofdstuk wordt een samenvatting gegeven van de observaties uit de 
eerder gepresenteerde studies. Daarna volgt een discussie over de belangrijkste thema’s 
van dit proefschrift: responsgroep analyse en placeborespons. Tot slot worden mogelijke 
toekomstperspectieven geschetst en conclusies geformuleerd. 
SAMENVATTING
In hoofdstuk 2 wordt een overzicht gegeven van de recente literatuur over farmacokinetisch 
(FK) en farmacodynamisch (FD) onderzoek in acute en chronische pijn. In deze review 
worden nieuwe bevindingen over opiaten, NSAIDs, epiduraal analgesie, ketamine en 
medicijnen aangrijpend op de GABA receptor toegelicht. Verschillende wiskundige 
modellen worden behandeld die het dynamische tijdsverloop van een pijnstiller 
kunnen beschrijven en/of voorspellen en een brug slaan tussen FK en FD. Populatie FK-
FD modellen maken het mogelijk om – naast het kwantificeren van de zogeheten fixed 
effects (de vaste FK-FD model parameter waarden) ook een inschatting te geven van de 
zogeheten random effects: de intra- en interindividuele variabiliteit. Effect compartiment 
en mechanistische biophase distributie modellen passen medicamenteuze associatie en 
dissociatie kinetiek toe en geven hiermee inzicht in de snelheid beperkende factoren in 
medicatie effect, zoals verdelingssnelheid en receptor kinetiek. Het is een gebruikelijke 
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techniek om de complexe eigenschappen van sommige middelen te doorgronden, met 
name het optreden en behandelen van bijwerkingen. Een andere toepassing in chronische 
pijn studies is het gebruik van mixture modellen. Mixture modellen maken het mogelijk 
om specifieke subgroepen te identificeren. Wanneer mixture en FK-FD modellen worden 
gecombineerd, kan dit een sterke verbetering geven van het huidige therapeutische 
arsenaal op het gebied van doseringsschema, effectiviteit, het mechanisme achter het 
effect van pijnstillers binnen bekende complexe chronische pijnsyndromen en kan dit 
nieuw pijnonderzoek stimuleren. Een voorbeeld hiervan is het effect van een 100-uur 
durende infusie van ketamine voor patiënten met het Complex Regionaal Pijn Syndroom 
type 1 (CRPS type 1). Met behulp van mixture modellering werden 4 onafhankelijke 
responsgroepen geïdentificeerd, variërend van non-responders tot super-responders. Dit 
is een belangrijke bevinding en onderstreept het belang van subgroep analyse en het 
dikwijls relatief grote placebo effect, zoals verder wordt behandeld in hoofdstuk 4 en 5.
In hoofdstuk 3 werd een farmacodynamisch model opgesteld om de mate van pijnstilling 
en snelheid van in- en uitwerken te bepalen van een capsaïcine 8% pleister voor de 
behandeling van diabetische perifere neuropathie (DPN) in 91 patiënten. Daarnaast 
werd een mixture model toegepast om subgroepen te onderscheiden. Vier specifieke 
subgroepen werden onderscheiden: (1) 3.3% van de patiënten vertoonde verergering 
van pijnklachten; (2) 31% had geen verandering van pijnklachten; (3) 32% toonde een 
snelle afname van pijnklachten met een maximale afname na drie weken waarna de 
pijn terugkeerde naar uitgangsniveau (16 ± 6% pijnafname in week 12); (4) 34% had een 
snelle afname van pijnklachten die aanhield (70 ± 5% afname in week 12). De inwerk 
halfwaardetijd was zodanig dat iedere week de pijnscores afnamen met 50% ten opzichte 
van de week ervoor (t1/2≈ 1 week). De uitwerk halfwaardetijd was ongeveer 8 weken (op 
basis van respons profielen van patiënten in groepen 2-4). Deze modelmatige aanpak 
biedt extra voordelen ten opzichte van de reguliere analyses (zoals bv. afname van 30% 
of 50% van de pijnklachten ten opzichte van uitgangsniveau) en kan de behandelduur 
en interval tussen behandelingen optimaliseren voor de verschillende subgroepen. Door 
de relatief kleine onderzoekspopulatie was het niet mogelijk voorspellende covariaten te 
onderscheiden. Deze covariaten analyse wordt verder uitgediept in hoofdstuk 4. 
In hoofdstuk 4 wordt dieper ingegaan op subgroep analyse (door gebruik te maken 
van farmacodynamische en mixture modellen) en voorspellende factoren voor 
behandeleffect. Longitudinale pijndata van vier dubbelblinde, gerandomiseerde, placebo 
gecontroleerde studies naar het effect van capsaicine 8% (Qutenza, n = 722) en actief 




patiënten geïncludeerd die 15.547 pijnscores gedurende 12 weken aanleverden. Vijf 
verschillende respons subgroepen werden onderscheiden: 1) een groep met pijntoename 
(1,5% Qutenza, 0.8% actief placebo); 2) een groep van non-responders (22.7% Qutenza, 
39.1% actief placebo); 3) een groep met initieel een pijnafname met geleidelijk 
terugkeer naar uitgangsniveau (24.7% Qutenza, 17.6% actief placebo); 4) een groep met 
gedeeltelijke pijnafname tot 25-30% in week 12 (14.5% Qutenza, 14.3% actief placebo) 
en 5) super-responders met een groot pijnstillend effect van 67-70% in week 12 (36.6% 
Qutenza, 28.2% actief placebo). Actief placebo en Qutenza toonden vergelijkbare respons 
profielen maar de verdeling over deze profielen was in het voordeel van Qutenza met 
40% minder non-responders en 25% meer super-responders. In de Qutenza super-
responder groep waren belangrijke voorspellers van behandeling: leeftijd, ziekteduur, 
gelijktijdig gebruik van opiaten, uitgangsvariabiliteit in pijnscores, uitgangspijnscore en 
effectiviteit van voorbehandeling met lidocaïne. Deze studieopzet maakt het mogelijk 
voorspellende factoren per subgroep te identificeren in plaats van alleen in responders in 
de totale studiepopulatie. Daarnaast laten de resultaten van één behandeling (Qutenza), 
in één aandoening (post-herpetische neuralgie) met waarschijnlijk één onderliggend 
ziekteproces zien dat pijnmechanismes kunnen verschillen tussen patiënten en dat 
mogelijk verschillende behandelstrategieën noodzakelijk zijn. Tot slot was er sprake van 
een groot placebo effect wat ook zichtbaar was in de actieve behandeling groep. 
Hoofdstuk 5 en 6 tonen data uit ons eigen pijnlaboratorium naar het effect van opiaten 
op experimentele pijnmodellen in gezonde vrijwilligers. Hoofdstuk 5 beschrijft het 
anti-nociceptieve profiel van oxycodon zuigtablet (OZT) in vergelijking met een actief 
placebo (paracetamol zuigtablet, PZT). OZT is geregistreerd voor de behandeling van 
acute doorbraakpijn wanneer een snelle intrede van pijnstilling noodzakelijk is. In een 
gerandomiseerde, dubbelblinde, cross-over studie kregen 12 gezonde vrijwilligers 20 
mg OZT en 500 mg PZT toegediend. Drie verschillende pijntesten werden gedurende 
5 uur op vaste tijden verricht: elektrische pijndrempel (EPD), elektrische pijntolerantie 
(EPT) en drukpijndrempel (DPD). Beloop van pijnstilling in de tijd werd geanalyseerd met 
een nieuw wiskundig (farmacodynamisch) model wat enige gelijkenis vertoont met de 
modellen zoals gebruikt in hoofdstuk 2 t/m 4. Er werden geen farmacokinetische data 
gebruikt. Belangrijke uitkomsten waren dat paracetamol 14% van het analgetisch effect 
van oxycodon bezit. OZT liet een 30% toename in EPD en EPT zien op respectievelijk t 
= 15 min en t = 41 min na inname. Voor DPD werd 18 min na inname een 30% toename 
gevonden. Een 30% toename wordt als mogelijk klinisch significant beschouwd, hoewel 
toekomstige studies dit verder moeten valideren. Met een inwerktijd van 15 tot 41 min lijkt 
OZT een vergelijkbaar analgetisch profiel te vertonen als conventionele orale oxycodon. 
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Hoe OZT zich verhoudt tot andere snelwerkende opiaten zoals intranasale toediening 
van fentanyl dient toekomstig onderzoek uit te wijzen. 
Relatief nieuw in de pijngeneeskunde is het toepassen van experimentele pijntesten als 
voorspeller van pijnstillend effect en om het onderliggend analgetisch mechanisme beter 
te doorgronden. Een voorbeeld van een dergelijke test is Conditioned Pain Modulation 
(CPM), een maat voor endogene inhibitie van afferente input. CPM vermindert de 
pijnervaring van een primaire test stimulus gedurende de toepassing van een secundaire 
stimulus, de zogeheten conditionele stimulus, volgens het concept ‘pijn vermindert pijn’. 
Eerdere studies toonden aan dat chronische pijnpatiënten met een inactieve CPM het 
meest profiteren van medicatie die het endogene modulatoire pijnsysteem activeert zoals 
duloxetine. Het omgekeerde is waar voor patiënten die reeds een actieve CPM hebben. 
In hoofdstuk 6 worden het effect van tapentadol (100 mg immediate release tablet, een 
gecombineerde mu-opiaat receptor agonist en noradrenaline reuptake inhibitor) en 
morfine (40 mg immediate release tablet) op CPM onderzocht in een gerandomiseerde, 
dubbelblinde, placebo gecontroleerde studie in 12 gezonde proefpersonen om een 
verschil in werkingsmechanisme tussen beide opiaten vast te stellen. CPM kon worden 
vastgesteld na behandeling met placebo en tapentadol (piek pijnscores waren 20-
30% lager na toediening van de conditionele stimulus), maar niet na behandeling met 
morfine. Vergeleken met placebo gaf morfine significant minder CPM. Dit toont aan dat 
in vrijwilligers morfine CPM vermindert, terwijl tapentadol onder gelijke condities dit 
effect niet laat zien. Deze data bevestigt dat het belangrijkste werkingsmechanisme 
van tapentadol verschilt van morfine en zeer waarschijnlijk gerelateerd is aan het 
noradrenerge effect op endogene inhibitie van pijnstimuli.
RESPONSGROEPEN
In hoofdstuk 3 toonden wij aan dat met behulp van FD mixture modellen het mogelijk is 
responsgroepen te identificeren in een heterogene neuropathische pijnpopulatie en zo 
responders van non-responders te scheiden. Vier verschillende responsgroepen werden 
gevonden voor de DPN populatie (hoofdstuk 3) en vijf groepen voor PHN patiënten 
(hoofdstuk 4). Subgroep 4 (een groep van PHN patiënten met een partieel pijnstillend 
effect van 25-30% afname ten opzichte van de uitgangssituatie) ontbrak in de DPN 
populatie. De respons op capsaïcine behandeling in DPN patiënten was min of meer 
dichotoom, met ofwel geen effect van behandeling (subgroep 2 en 3), danwel een groot 




ziekteproces. DPN wordt beschouwd als een klassieke denervatie neuropathie (waarbij 
zenuwen gedurende een lange periode langzaam afsterven), terwijl PHN valt onder 
inflammatie gemedieerde ‘dynamische’ denervatie neuropathieën (met gedeeltelijke 
schade en partieel herstel van zenuwen, terugtrekken van oude en aangroei van nieuwe 
zenuwvezels).1 Aangezien onze bevindingen (en die van anderen) suggereren dat patiënten 
met gedeeltelijke zenuwschade in tegenstelling tot patiënten met volledig aangedane 
zenuwen het meest profiteren van behandeling met capsaïcine, kunnen vragenlijsten 
en QST een voorspellend vermogen voor behandeleffect bezitten, aangezien hiermee 
specifieke symptomen voor zenuwschade kunnen worden aangetoond (zoals allodynie 
en brandende pijn).2 Toekomstige studies moeten dit verder onderzoeken, waarbij met 
name aandacht besteed dient te worden aan de integriteit van de zenuwuiteinden door 
middel van immunohistochemische analyses.3,4
Reeds gepubliceerde subgroep analyses zijn tot op heden verricht in DPN, PHN (behandeld 
met capsaïcine, hoofdstuk 3 en 4) en CRPS type 1 (behandeld met ketamine, hoofdstuk 2). 
Voor wat betreft de aantallen lijken de responsgroepen in CRPS type 1 sterk op die in DPN. 
In tegenstelling tot de vergelijking tussen DPN en PHN, die beide behandeld zijn met 
capsaïcine, is het vergelijken van DPN (behandeld met capsaïcine werkend op de TRPV1 
receptor) met CRPS 1 (behandeld met ketamine aangrijpend op de NMDA receptor) lastig 
aangezien het om twee verschillende middelen in twee verschillende aandoeningen 
gaat. Daardoor zullen voorspellers van effect verschillen tussen beide behandelingen. 
Tot slot moet worden opgemerkt dat het gebruik van voorspellers van effect nog erg 
ongebruikelijk is in de klinische praktijk. Grote gerandomiseerde studies zullen moeten 
aantonen of de behandeling van een pijnsyndroom (bv. DPN) met verschillende 
werkzame medicijnen (zoals opiaten, capsaïcine, ketamine, GABA-agonisten, SSRI’s, etc.) 
een middel-afhankelijke voorspeller van effect (bv. met relatief veel super-responders) 
kan opleveren. Het kan bijvoorbeeld zijn dat de aanwezigheid van brandende pijn een 
voorspeller is van een succesvolle respons op behandeling met capsaïcine maar niet 
met opiaten. Of dat de aanwezigheid van het wind-up fenomeen in de QST een goede 
respons op ketamine voorspelt. Meer onderzoek hiernaar is noodzakelijk, bijvoorbeeld 
door gebruik te maken van patroonanalyse in datasets van bestaande (gepubliceerde en 
niet-gepubliceerde), grote klinische studies. 
Responsgroepen werden door ons gedefinieerd op basis van het inwerk- en 
uitwerkpatroon van de farmacodynamische respons. Hiermee werden 4 tot 5 subgroepen 
aangetoond. Het kan echter zijn dat de werkelijke hoeveelheid subgroepen veel groter is 
en nog onontdekt is in onze relatief kleine onderzoekspopulatie. Daarnaast is de mate 
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van pijn in chronische pijnpatiënten niet constant in de tijd en deze natuurlijke variatie 
is niet meegenomen in onze analyses. Voorbeelden hiervan zijn patiënten die nachtelijke 
allodynie vertonen en overdag brandende pijn (of andersom) of patiënten die continu 
wisselend een tintelend of elektrisch prikkelend gevoel ervaren. Deze variabiliteit en 
kwalitatieve beschrijving van pijn komt niet goed tot uitdrukking in numerieke waarden 
maar kan beter door middel van vragenlijsten worden gescoord. De mate van variabiliteit 
kan een mogelijke voorspeller van behandeleffect zijn en verdient verdere aandacht in 
toekomstige farmacodynamische studies. 
Tot slot moet worden opgemerkt dat responsgroep analyse (zoals beschreven in 
hoofdstuk 3 en 4) alleen mogelijk is wanneer meerdere datapunten in de tijd verzameld 
worden (zoals pijnscores met wekelijkse intervallen). Wanneer alleen de scores aan het 
eind van de behandeling worden meegenomen (1 meting aan het eind van de 12 weken 
behandelperiode), is farmacodynamische analyse zoals beschreven in hoofdstuk 2, 3 en 
4 niet mogelijk. Met een dergelijke studieopzet is het alleen mogelijk om te spreken 
over algemene responders en non-responders. Een studieopzet daarentegen met 
longitudinale data is essentieel om het werkelijke behandeleffect in de gehele populatie 
te doorgronden, inclusief subgroepen en voorpellers van effect.
DE PLACEBO RESPONS
Zoals eerder beschreven is de relatief grote bijdrage van het placebo effect in veel 
gerandomiseerde studies verantwoordelijk voor het niet kunnen aantonen van een 
voordeel van actieve behandeling boven placebo. Veel studies probeerden een verklaring 
te geven voor deze grote placebo respons. Voorspellers zijn onder andere lange 
behandelduur,5 type neuropathische pijnaandoening (DPN studies laten aanzienlijk vaker 
een grote placebo respons zien dan PHN studies),6 hoge variabiliteit in uitgangspijnscore,7 
studies naar opiaten,8 veel contactmomenten en randomisatie verhouding (hoe meer 
patiënten in de actieve behandelgroep ten opzichte van placebo, hoe kleiner de placebo 
respons).8 Sommige van deze factoren beïnvloeden het verwachtingspatroon (zoals 
behandelduur en contactmomenten). Mogelijk hebben een of meerdere van deze 
factoren een rol gespeeld bij het eerder genoemde onderzoek met informatieve en non-
informatieve centra. Wij zijn van mening dat een grondige training van medewerkers en 
ruime ervaring in het doen van pijnonderzoek hoogst effectief zijn in het verminderen 




De algemene term ‘placebo respons’ zou gescheiden moeten worden in een psychosociaal 
en fysiologisch ‘placebo effect’ en ‘placebo gerelateerd gedrag’ zoals regressie naar het 
gemiddelde en het natuurlijk fluctuerend beloop en spontaan herstel van ziekte.9-11 
Een methode om dit bereiken is het introduceren van een no-treatment controle (NTC) 
groep in gerandomiseerde placebo gecontroleerde studies. Een NTC groep (ook wel de 
‘wachtgroep’ genoemd) is gedefinieerd als een groep waarin willekeurig toegewezen 
proefpersonen geen behandeling of interventie krijgen en waarin personen alleen worden 
geobserveerd in de tijd. Hierdoor kunnen voorspellende factoren voor het werkelijke 
placebo effect en mechanismen achter het placebo (of nocebo, het tegenovergestelde 
van placebo) effect worden vastgesteld. Huidige bekende mechanismen van het 
placebo effect in chronische pijnaandoeningen zijn endogene pijnstillers met opioïde 
en dopaminerge betrokkenheid.12-15 Mechanismen achter het nocebo effect zijn activatie 
van cholecystokinines en deactivatie van dopaminerge aangrijpingspunten.16-18
Het is belangrijk om te beseffen dat de data uit hoofdstuk 4 is verkregen uit meer 
dan 160 onderzoekscentra. Sommige van deze centra zijn informatiever dan andere. 
Sommige centra zijn in staat de placebo respons te scheiden van actieve behandeling, 
terwijl andere een relatief grote bijdrage van de placebo behandeling vinden welke niet 
significant verschilt van actieve behandeling. Merlo-Pich et al. hebben data geanalyseerd 
van multicenter studies over de effectiviteit van antidepressiva bij mensen met ernstige 
depressies.19,20 Zij hebben post-hoc een verrijkingsfilter toegepast waarbij centra werden 
geëxcludeerd met een placebo effect dat groter of gelijk aan behandeleffect was. Een 
dergelijk filter zou gemakkelijk kunnen worden toegepast op de huidige dataset, niet 
om het behandeleffect te vergroten maar om voorspellers van effect van placebo en van 
actieve behandeling aan te wijzen. Het zou goed kunnen zijn dat sommige van de eerder 
gevonden variabelen, zoals uitgangsvariabiliteit in pijnscore, meer een voorspeller is van 
placebo dan van actieve behandeling. 
TOEKOMSTPERSPECTIEVEN: WAT TE METEN, HOE TE METEN?
Het farmacologische effect van pijnstillers is afhankelijk van verschillende complexe 
en samenhangende factoren. Deze factoren kunnen worden onderverdeeld in middel, 
patiënt en ziekte gerelateerd. Voorbeelden van middel gerelateerde factoren zijn 
farmacokinetische variabelen, zoals de tijd om een evenwicht in te stellen tussen 
plasma en plaats het middel werkzaam is, receptor kinetiek en tijd na receptorbinding 
tot daadwerkelijk pijnstillend effect. Patiëntgebonden factoren zijn bijvoorbeeld leeftijd, 
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geslacht, gewicht, ziekteduur, ernst van de pijnklachten en comorbiditeit. Vanuit de 
kliniek is bekend dat sommige personen niet op behandeling met opiaten reageren. Dit 
werd herbevestigd in hoofdstuk 6 waarbij 20% van de proefpersonen geen reactie op 
oxycodon liet zien in verschillende pijnmodellen. Wij denken dat dit veroorzaakt wordt 
door farmacogenetische (FG) eigenschappen, zoals verminderde activiteit van het CYP2D6 
enzym wat minder productie geeft van oxycodon’s actieve metaboliet oxymorfon. Grote 
inter-individuele variabiliteit in farmacokinetiek is een bekend fenomeen.21,22 Echter, ook 
de variabiliteit in farmacodynamiek moet in ogenschouw worden genomen.23-25 Populatie 
FK-FD modellen in combinatie met farmacogenetica zijn belangrijke middelen om het 
effect en de interactie van medicijnen binnen complexe ziektebeelden te beschrijven 
en te voorspellen. Toekomstige ontwikkelingen maken wellicht het gebruik van FK-FD-
FG analyses gemakkelijker toe te passen in pijnstudies en misschien zelfs in klinische 
pijnpatiënten. 
In de nabije toekomst is vooruitgang te verwachten op het gebied van pijnmetingen en 
beoordelen van pijntherapie. Het gebruik van vragenlijsten zoals de ‘Patient Reported 
Outcomes’ (PRO) of de painDETECT maken het mogelijk op grote schaal neuropathische 
pijnsymptomen te identificeren en kwalitatief te beschrijven.26 De relatie tussen 
pijnsymptomen en behandelrespons kan gebruikt worden om pathofysiologische 
mechanismen bloot te leggen en aangrijpingspunten voor nieuwe medicijnen te 
introduceren. Daarnaast zal het gebruik van QST het mogelijk maken patronen in 
pijnsymptomen in diverse chronische pijnaandoeningen te herkennen. Met behulp van 
deze patronen kan een eerste aanzet gegeven worden responders van non-responders 
te voorspellen. Daarnaast kan het toepassen van psychofysische testen zoals CPM en 
offset analgesia (OA) mogelijk voorspellen welke patiënten het meest profiteren van 
medicatie die aangrijpt op het endogene modulatoire pijnsysteem (hoofdstuk 6). Tot vrij 
recent waren grote en logge apparaten nodig om CPM en OA te testen. Tegenwoordig 
zijn kleinere apparaten op de markt verschenen die snel en betrouwbaar in de klinische 
setting CPM en OA kunnen beoordelen. Een voorbeeld hiervan is Medoc’s Qsense CPM, 
een mobiel systeem wat naast CPM ook een groot deel van de QST batterij kan testen. 
Het gebruik van een dergelijk apparaat op de pijnpoli maakt een keuze mogelijk tussen 
verschillende medicatie afhankelijk van de aan- of afwezigheid van CPM. Bijvoorbeeld, in 
hoofdstuk 1 werd aangetoond dat DPN patiënten met een inactieve CPM baat hebben van 
tapentadol (een gecombineerde opiaat en noradrenaline reuptake inhibitor, zie hoofdstuk 
6), terwijl dit niet het geval is bij een actieve CPM. Tot slot zijn nieuwe diagnostische 
technieken, zoals cornea confocal microscopy, 27, 28 die kleine zenuwvezel aandoeningen 




aandoeningen aantoont, veelbelovend voor het aantonen van zenuwaandoeningen en 
voor het vervolgen gedurende behandeling. 
CONCLUSIES
Uit de data gepresenteerd in dit proefschrift kunnen de volgende conclusies worden 
getrokken:
1. Longitudinale farmacodynamische modellen kunnen worden gebruikt om het anti-
nociceptieve/analgetisch tijdbeloop van pijnstillers te beschrijven. Deze aanpak geeft 
meer informatie dan de tot nu toe gebruikelijke beoordeling van behandeleffect op 
een tevoren vastgesteld moment in de tijd.
2. Mixture modellen maken het mogelijk een heterogene pijnpopulatie te scheiden in 
homogene subgroepen met elk een eigen respons op pijnbehandeling.
3. Covariaten analyse binnen de verschillende subgroepen maakt het mogelijk 
voorspellers van behandeling te identificeren. Dit kan uiteindelijk een geoptimaliseerd 
individueel behandelprofiel opleveren met voorspellers voor iedere medicamenteuze 
therapie.
4. De snelheid van inwerken van een pijnstiller kan worden beschreven middels een 
longitudinaal farmacodynamisch model met beperkte datapunten zonder de 
noodzaak van FK samplen.
5. In de toekomst kan het toepassen van experimentele pijntesten, zoals CPM, als maat 
voor endogene inhibitie van afferente input, gebruikt worden om medicatie effect te 
voorspellen.
Chapter 8  |  Algemene discussie, samenvatting en conclusies
148
REFERENTIES
1. Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and 
mechanisms of action of the new high-concentration capsaicin 8% patch. BJA 2011; 
107: 490-502.
2. Gustorff B, Poole C, Kloimstein H, Hacker N, Likar R. Treatment of neuropathic pain 
with the capsaicin 8% patch: Quantative sensory testing (QST) in a prospective 
observational study identifies potential predictors of response to capsaicin 8% patch 
treatment. Scan J of Pain 2013; 4: 138-145.
3. Polydefkis M, Hauer P, Sheth S, Sirdofsky M, Griffin JW, McArthur JC. The time course 
of epidermal nerve fiber regeneration: studies in normal controls and in people with 
diabetes, with and without neuropathy. Brain 2004; 127: 1606-15.
4. Kennedy WR. Opportunities afforded by the study of unmyelinated nerves in skin and 
other organs. Muscle Nerve 2004; 29: 756-67.
5. Quessy SN, Rowbothan MC. Placebo response in neuropathic pain trials. Pain 2008; 
138:479-83.
6. Dworkin RH, Turk DC, Peirce-Sandner S, McDermott MP, Farrar JT, Hertz S, Katz NP, Raja 
SN, Rappaport BA. Placebo and treatment group responses in postherpetic neuralgia 
versus painful diabetic peripheral neuropathy clinical trials in the REPORT database. 
Pain 2010; 150: 12-16.
7. Farrar JT, Troxel AB, Haynes K, Gilron I, Kerns RD, Katz NP, Rappaport BA, Rowbotham 
MC, Tierney AM, Turk DC, Dworkin RH. Effect of variability in the 7-day baseline pain 
diary on the assay sensitivity of neuropathic pain randomized clinical trials: an 
ACTTION study. Pain 2014; 155: 1622-31.
8. Vase L, Vollert J, Finnerup NB, Miao X, Atkinson G, Marshall S, Nemeth R, Lange B, Liss C, 
Price DD, Maier C, Jensen TS, Segerdahl M. Predictors of the placebo analgesia response 
in randomized controlled trials of chronic pain: A meta-analysis of the individual data 
from nine industrially sponsored trials. Pain 2015; [Epub ahead of print]
9. Benedetti F. Placebo Effects: Understanding The Mechanisms In Health And Disease, 
Oxford University Press, 2009.
10. Finniss DG, Benedetti F. Mechanisms of the placebo response and their impact on 
clinical trials and clinical practice. Pain 2006; 114: 3–6.
11. Wechsler ME, Kelley JM, Boyd IO, Dutile S, Marigowda G, Kirsch I, Israel E, Kaptchuk TJ. 
Active albuterol or placebo, sham acupuncture, or no intervention in asthma. NEJM 
2011; 365: 119–126.
12. Hall KT, Loscalzo J, Kaptchuk TJ. Genetics and the placebo effect: the placebome. 




13. Finniss DG, Kaptchuk TJ, Miller F, Benedetti F. Biological, clinical, and ethical advances 
of placebo effects. Lancet 2010; 375: 686-95.
14. Levine JD, Gordon NC, Fields HL. The mechanism of placebo analgesia. Lancet 1978; 2: 
654-7.
15. Rief W, Bingel U, Schedlowski M, Enck P. Mechanisms involved in placebo and nocebo 
responses and implications for drug trials. Clin Pharmacol Ther 2011; 90: 722-6.
16. Benedetti F, Amanzio M, Casadio C, Oliaro A, Maggi G. Blockade of nocebo hyperalgesia 
by the cholecystokinin antagonist proglumide. Pain 1997; 71: 135–40.
17. Benedetti F, Amanzio M, Vighetti S, et al. The biochemical and neuroendocrine bases 
of the hyperalgesic nocebo effect. J Neurosci 2006; 26: 12014–22.
18. Scott DJ, Stohler CS, Egnatuk CM, Wang H, Koeppe RA, Zubieta JK. Placebo and nocebo 
effects are defined by opposite opioid and dopaminergic responses. Arch Gen 
Psychiatry 2008; 65: 220–31.
19. Merlo-Pich E, Alexander RC, Fava M, Gomeni R. A new population-enrichment strategy 
to improve efficiency of placebo-controlled clinical trials of antidepressant drugs. Clin 
Pharmacol Ther 2010; 88: 634–42.
20. Merlo-Pich E, Gomeni R. Model-based approach and signal detection theory to 
evaluate the performance of recruitment centers in clinical trials with antidepressant 
drugs. Clin Pharmacol Ther 2008; 84: 378–84. 
21. Viberg A, Lannergard A, Larsson A, Cars O, Karlsson MO, Sandstrom M. A population 
pharmacokinetic model for cefuroxime using cystatin C as a marker of renal function. 
Br J Clin Pharmacol 2006; 62: 297-303.
22. Li C, Kuti JL, Nightingale CH, Nicolau DP. Population pharmacokinetic analysis and 
dosing regimen optimization of meropenem in adult patients. J Clin Pharmacol 2006; 
46: 1171-1178.
23. Romberg R, Olofsen E, Sarton E, den Hartigh J, Taschner PE, Dahan A. Pharmacokinetic-
pharmacodynamic modeling of morphine-6-glucuronide-induced analgesia in 
healthy volunteers: absence of sex differences. Anesthesiology 2004; 100: 120-33.
24. Lack NA, Green B, Dale DC, Calandra GB, Lee H, MacFarland RT, Badel K, Liles WC, Bridger 
G. A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ 
hematopoietic progenitor cells by AMD3100. Clin Pharmacol Ther 2005; 77: 427-36.
25. Levy G. Impact of pharmacodynamic variability on drug delivery(1). Adv Drug Deliv 
Rev 1998; 33: 201-206.
26. Freynhagen R, Baron R, Gockel U, Tolle TR. painDETECT: a new screening questionnaire 
to identify neuropathic components in patients with back pain. Curr Med Res Opin 
2006; 22: 1911-20.
27. Brines M, Swartjes M, Tannemaat MR, Dunne A, van Velzen M, Proto P, Hoitsma 
Chapter 8  |  Algemene discussie, samenvatting en conclusies
150
E, Petropoulos I, Chen X, Niesters M, Dahan A, Malik R, Cerami A. Corneal nerve 
quantification predicts the severity of symptoms in sarcoidosis patients with painful 
neuropathy. Technology 2013; 1: 20-26.
28. Dahan A, Dunne A, Swartjes M, Proto PL, Heij L, Vogels O, van Velzen M, Sarton E, 
Niesters M, Tannemaat MR, Cerami A, Brines M. ARA 290 improves symptoms in 
patients with sarcoidosis-associated small nerve fiber loss and increases corneal 
nerve fiber density. Mol Med 2013; 19: 334-45.
29. Lee JA, Halpern EM, Lovblom LE, Yeung E, Bril V, Perkins BA. Reliability and validity of a 
point-of-care sural nerve conduction device for identification of diabetic neuropathy. 








Addenda  |  Curriculum Vitae
154
CURRICULUM VITAE
Christian Martini was born on the 13th of January 1980 in Rotterdam, the Netherlands. He 
attended the Stedelijk Gymnasium Leiden and obtained his VWO degree in June 1998 
(cum laude). He was immediately admitted to University College Utrecht (international 
Honours College of Utrecht University) for one year following a pre-medical major 
program. One year later he started his medical studies at the Leiden University Medical 
Center (LUMC), during which he deployed several extra-curricular activities. 
In 2000 he participated in the setup of an exchange program for undergraduate students 
with the Karolinska Institutet, Stockholm, Sweden. One year later he became member of 
the board of the medical students association (M.F.L.S.), where he was involved in finance 
and sponsor acquisition. He led a curriculum exploration at Harvard Medical School, 
Boston, USA (2002) and in the same year he attended the Honours Class programme of 
the LUMC “Marktwerking en gezondheidszorg”. In 2003 he was elected for a position in 
the students council and worked as assistant co-ordinator at the International Office for 
undergraduate students.
During his studies he performed a research project at the department of Clinical 
Epidemiology, LUMC, (Prof. dr. F.R. Rosendaal) on the role of genetic variants in the TAFI 
gene on the development of venous thrombosis. As a result he was accepted as a research 
fellow at the Hemophilia and Thrombosis Center Angelo Bianchi Bonomi, University of 
Milan, Italy, (Prof. dr. P.M. Mannucci) to perform a subanalysis of prothrombotic genes on 
myocardial infarction in young adults without cardiovascular risk factors. Moreover, he 
studied the effects of factor VII gene polymorphisms on the risk of myocardial infarction 
in young women.
After his return from Italy he graduated from Medical School in August 2006. In October 
2006 he was appointed at the department of Anesthesiology, LUMC, combining both 
residency (Prof. dr. L.P.H.J. Aarts) and research (Prof. dr. A. Dahan) for which he received 
a grant from the Netherlands Organisation for Health Research and Development 
(Agikobeurs ZonMw, 2007). Since October 2013 he is a staff member of the department of 
Anesthesiology, LUMC. He is currently involved in many ongoing research projects, in Crew 





Addenda  |  List of publications
LIST OF PUBLICATIONS
1. Martini CH, Doggen CJ, Cavallini C, Rosendaal FR, Mannucci PM. No effect of 
polymorphisms in prothrombotic genes on the risk of myocardial infarction in young 
adults without cardiovascular risk factors. J Thromb Haemost 2005; 3: 177-9.
2. Peyvandi F, Bernardinelli L, Martini CH, Celli P, Mannucci PM. Factor VII gene 
polymorphisms are not associated with myocardial infarction in young women. J 
Thromb Haemost 2005; 3: 803-4.
3. Martini CH, Brandts A, de Bruijne EL, van Hylckama Vlieg A, Leebeek FW, Lisman T, 
Rosendaal FR. The effect of genetic variants in the thrombin activatable fibrinolysis 
inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous 
thrombosis. Br J Haematol 2006; 134: 92-4.
4. Martini C, Olofsen E, Yassen A, Aarts L, Dahan A. Pharmacokinetic-pharmacodynamic 
modeling in acute and chronic pain: an overview of the recent literature. Expert Rev 
Clin Pharmacol 2011; 4: 719-28.
5. Martini C, Yassen A, Olofsen E, Passier P, Stoker M, Dahan A. Pharmacodynamic analysis 
of the analgesic effect of capsaicin 8% patch (Qutenza™) in diabetic neuropathic pain 
patients: detection of distinct response groups. J Pain Res 2012; 5: 51-9.
6. Niesters M, Khalili-Mahani N, Martini C, Aarts L, van Gerven J, van Buchem MA, 
Dahan A, Rombouts S. Effect of subanesthetic ketamine on intrinsic functional brain 
connectivity: a placebo-controlled functional magnetic resonance imaging study in 
healthy male volunteers. Anesthesiology 2012; 117: 868-77.
7. Niesters M, Martini C, Dahan A. Ketamine for Chronic Pain: Risks and Benefits. Br J Clin 
Pharmacol. 2014; 77: 357-67. 
8. Boon M, Martini CH, Aarts LP, Bevers RF, Dahan A. Effect of variations in depth 
of neuromuscular blockade on rating of surgical conditions by surgeon and 
anesthesiologist in patients undergoing laparoscopic renal or prostatic surgery (BLISS 
trial): study protocol for a randomized controlled trial. Trials 2013; 14: 63.
157
Addenda
9. Martini C, Yassen A, Olofsen E, Dahan A. A novel approach to identify responder 
subgroups and predictors of response to low- and high-dose capsaicin patch in 
postherpetic neuralgia. Eur J Pain 2013; 17: 1491-501.
10. Martini CH, Boon M, Bevers RF, Aarts LP, Dahan A. Evaluation of surgical conditions 
during laparoscopic surgery in patients with moderate vs deep neuromuscular block. 
Br J Anaesth 2014; 112: 498-505.
11. Martini CH, Proto P, Olofsen E, van Velzen M, Aarts L, Dahan A, Niesters M. A randomized 
controlled trial and novel mathematical analysis of the analgesic effect of oxycodone 
versus paracetamol orodispersible tablets. Eur J Pain 2015; 19: 295-304.
12. Khalili-Mahani N, Martini CH, Olofsen E, Dahan A, Niesters M. Effect of subanaesthetic 
ketamine on plasma and saliva cortisol secretion. Br J Anaesth 2015; 115: 68-75.
13. Martini C, van Velzen M, Drewes A, Aarts L, Dahan A, Niesters M. A Randomized 
Controlled Trial on the Effect of Tapentadol and Morphine on Conditioned Pain 
Modulation in Healthy Volunteers. PLoS One 2015; [Epub ahead of print]
14. Martini CH, Boon M, Broens SJ, Hekkelman EF, Oudhoff LA, Buddeke AW, Dahan A. 
Ability of the Nociception Level, a Multiparameter Composite of Autonomic Signals, 
to Detect Noxious Stimuli during Propofol-Remifentanil Anesthesia. Anesthesiology 
2015; [Epub ahead of print]
158
159
160
